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ABSTRACT	Locomotion	and	turning	are	complex	movement	patterns	essential	to	activities	of	daily	living.	Individuals	with	Parkinson’s	disease	(PD)	report	difficulties	turning,	often	coupled	with	impaired	balance	and	increased	fear	of	falling.	The	purpose	of	this	within-subject	study	was	to	determine	if	orthotics,	with	and	without	a	textured	top	cover,	can	improve	gait	stability	and	turning	performance	within	Parkinson’s	participants.	Seven	participants	with	a	diagnosis	of	idiopathic	Parkinson’s	disease,	aged	55-80	years	old,	participated	in	the	study.	Participants	completed	three	testing	sessions;	baseline,	4	weeks	post-baseline,	and	5	weeks	post-baseline.	The	‘footwear	only’	and	‘footwear	+	non-textured	orthotic’	conditions	were	tested	at	baseline,	‘footwear	+	non-textured	orthotic’	and	‘footwear	+	textured	orthotic’	conditions	were	testing	at	4-weeks,	and	the	‘footwear	+	textured	orthotic’	condition	was	repeated	at	5	weeks.	Kinematic,	kinetic,	electromyographical,	and	video	data	was	collected	during	a	turning	task.	The	turn	task	consisted	of	walking	towards	a	pre-determined	turn	area,	and	then	completing	a	180°	to	static	stance.	Variables	of	interest	were	categorized	into	three	main	areas:	dynamic	stability	(COM/BOS	ML	maximum,	minimum,	and	range),	turning	performance	(turn	strategy,	step	count,	step	length,	step	width,	and	average	walking	velocity),	and	average	muscle	activity	of	lower	limb	musculature	(tibialis	anterior,	medial	gastrocnemius,	and	peroneus	longus).	Results	were	further	subdivided	between	acute	and	long-term	changes	associated	with	both	non-textured	and	textured	orthotics.	Long-term	orthotic	wear	and	the	addition	of	texture	appears	to	significantly	improve	dynamic	stability,	characterized	by	an	increase	in	the	ML	maximum	and	ML	range	COM/BOS	relationship.	Significant	increases	in	averaged	muscle	activity	of	the	ipsilateral	tibialis	anterior	and	medial	gastrocnemius	were	noted	in	the	textured	orthotic	condition,	along	with	significant	decreases	in	ipsilateral	peroneus	longus.	These	study	results	provide	two	potential	treatment	options,	foot	orthotics	and	textured	orthotics,	for	rehabilitation	professionals	treating	Parkinson’s	disease	individuals.	
Keywords:	 Parkinson’s	disease,	orthotics,	somatosensory,	mechanoreceptors,	balance,	turns,	falls	
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GLOSSARY	OF	TERMS		Analysis	of	Variance	(ANOVA)	
• inferential	statistical	analysis	method	used	in	analyzing	the	difference	between	group	means	Balance	
• the	body’s	ability	to	resist	linear	and	angular	accelerations	(Hamill,	Knutzen,	&	Derrick,	2015a)	Base	of	Support	(BOS)	
• specifically	during	gait,	the	BOS	is	defined	by	the	lateral	border	of	one,	or	both	feet,	in	contact	with	the	ground	surface	Biomechanics	
• study	of	motion	and	the	effect	of	forces	on	biological	systems	(Hamill	et	al.,	2015a)	Center	of	Mass	(COM)	
• the	point	about	which	the	distribution	of	mass	sums	to	zero	(Hamill	et	al.,	2015a)	Center	of	Pressure	(COP)	
• the	point	about	which	the	distribution	of	pressure	sums	to	zero	(Hamill	et	al.,	2015a)	COM-BOS	Stability	Margin	
• the	degree	to	which	the	COM	approached	the	limits	of	stability	defined	by	the	BOS,	a	larger	distance	suggests	increased	stability	(Perry,	Radtke,	McIlroy,	Fernie,	&	Maki,	2008)	Cutaneous	Mechanoreceptors	
• receptors	located	in	the	skin	of	hands	and	feet,	responsible	for	tactile	sensation	(Gardner	&	Johnson,	2013b)	Force	Platform	
• an	instrument	used	to	sense	and	record	the	dynamic	ground	reaction	forces	(Hamill	et	al.,	2015a)	Functional	Gait	Assessment	(FGA)	
		 12	
• assessment	tool	derived	from	the	Dynamic	Gait	Index,	used	to	assess	postural	stability	in	individuals	with	PD	during	various	walking	tasks		Gait	
• basic	reference	to	human	locomotion.	One	full	gait	cycle	consists	of	the	period	of	time	between	successive	ipsilateral	heel	strikes	(Michaud,	1997)	Gastrocnemius	
• superficial	muscle	of	the	posterior	calf,	has	two	prominent	bellies	(medial	and	lateral),	plantar	flexes	when	the	knee	is	extended	and	flexes	the	knee	when	the	foot	is	dorsiflexed	(Marieb,	Mallatt,	&	Wilhelm,	2005)	Ground	Reaction	Force	(GRF)	
• a	single	equivalent	force	equal	to	the	sum	of	a	distribution	of	forces	applied	to	a	surface	(Robertson,	Caldwell,	Hamill,	Kamen,	&	Whittlesey,	2014)	Hoehn	and	Yahr	(HY)	
• most	widely	used	and	universally	accepted	staging	system	for	overall	functional	disability	in	Parkinson’s	disease	(Hoehn	&	Yahr,	1967)	Kinematics	
• area	of	study	that	examines	the	spatial	and	temporal	components	of	motion	(position,	velocity,	and	acceleration)	(Hamill	et	al.,	2015a)	Kinetic	
• study	of	forces	that	act	on	a	system	(Hamill	et	al.,	2015a)	Meissner’s	Corpuscles	
• RA1	cutaneous	mechanoreceptor,	responds	to	lateral	motion	and	lies	close	to	skin	surface	(dermal	papillae)	(Gardner	&	Johnson,	2013b)	Merkel	Cells	
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• SA1	cutaneous	mechanoreceptor,	responds	to	edges	and	points,	and	lies	on	the	tips	of	epidermal	sweat	ridges	(Gardner	&	Johnson,	2013b)	Monofilament	
• Instrument	used	to	test	an	individual’s	sensation	on	the	skin,	in	this	experiment,	used	on	the	plantar	sole	of	the	foot	Orthotics	
• An	orthopaedic	appliance	placed	in	footwear	to	correct,	align,	or	cushion	the	foot	or	lower	leg	Pacinian	Corpuscles	
• RA2	cutaneous	mechanoreceptor,	responds	to	vibration	and	lies	in	deep	dermal	tissue	(Gardner	&	Johnson,	2013b)	Parkinson’s	Disease	
• Neurodegenerative	disorder	involving	the	degeneration	of	dopamine-producing	cells	in	the	substantia	nigra	(Anderson,	2015)	Peroneus	Longus	
• Superficial	lateral	muscle,	plantar	flexes	and	everts	the	foot	(Marieb	et	al.,	2005)	Postural	Control	
• Our	body’s	equilibrium,	or	balance,	involving	active	resistance	to	external	forces	acting	on	the	body	(Macpherson	&	Horak,	2013)	Postural	Sway	
• The	medio-lateral	or	antero-posterior	movement	of	the	body	to	remain	in	a	state	of	equilibrium	Ruffini	Endings	
• SA2	cutaneous	mechanoreceptor,	responds	to	skin	stretch	and	lies	in	the	dermis	(Gardner	&	Johnson,	2013b)	Single	Stance	
• portion	of	the	gait	cycle	whereby	the	body	is	supported	by	a	single	limb		
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Somatosensory	
• bodily	system	serving	three	functions:	1)	proprioception:	sense	of	oneself,	2)	exteroception:	sense	of	direct	interaction	with	the	external	world,	and	3)	interoception:	sense	of	internal	state	of	bodily	organs	(E.P.	&	Johnson,	2013)	Spin	Turn	
• a	change	in	walking	direction	by	spinning	the	body	around	the	stance	foot	(Hase	&	Stein,	1999)	Stability	
• refers	to	a	state	of	balance	or	the	ability	of	a	joint	to	resist	dislocation	(Hamill	et	al.,	2015a)	Step	Turn	
• a	change	in	walking	direction	by	shifting	body	weight	from	one	foot	to	the	other	to	complete	the	direction	change	(Hase	&	Stein,	1999)	Texture	
• tactile	surface	characteristics.	In	this	experiment,	texture	is	referenced	to	the	material	selection	on	the	top	cover	of	the	orthotics	Tibialis	Anterior		
• superficial	muscle	of	the	anterior	lower	leg,	prime	mover	of	dorsiflexion	(Marieb	et	al.,	2005)	Timed	Up	and	Go	(TUG)	
• a	clinical	performance-based	screening	tool,	validated	for	Parkinson’s	Disease	populations,	to	evaluate	lower	extremity	function,	mobility,	and	fall	risk	(Herman,	Giladi,	&	Hausdorff,	2011)	Unified	Parkinson’s	Disease	Rating	Scale	(UPDRS)	
• most	widely	used	scale	to	assess	impairment	and	disability	in	PD	populations	(Fahn	&	Elton,	1987)	Velocity	
• vector	quantity	defined	as	the	time	rate	of	change	of	position	(Hamill,	Knutzen,	&	Derrick,	2015b)			 	
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CHAPTER	1:	INTRODUCTION	
	Parkinson’s	disease	(PD)	is	a	neurodegenerative	disorder,	characterized	by	the	substantia	nigra	producing	insufficient	amounts	of	dopamine	(Przedborski,	2015).	This	neurotransmitter	has	a	critical	role	in	muscle	activation,	whereby	loss	of	dopamine	results	in	increased	abnormal	neuron	firing	patterns,	and	impaired	control	of	purposeful	movements	(Przedborski,	2015).	Clinically,	impairments	to	gait	and	balance	are	among	the	most	common	debilitating	symptoms,	increasing	the	fear	of	falling,	and	largely	decreasing	these	patient’s	quality	of	life	(Lindholm,	Hagell,	Hansson,	&	Nilsson,	2014).	PD	gait	characteristics	are	important	in	understanding	the	pathophysiological	changes	within	this	demographic;	however,	they	provide	minimal	information	on	intervention	strategies.	Understanding	these	underlying	mechanisms	of	impaired	gait	can	translate	into	improved	treatment	options	for	clinicians,	and	consequently,	have	a	direct	impact	on	improving	quality	of	life.	The	relationship	between	PD	gait	changes,	impaired	balance,	and	fear	of	falling	has	been	minimally	researched	(Lindholm	et	al.,	2014).	Furthermore,	there	is	a	lack	of	treatment	options	specifically	targeting	Parkinsonian	gait	characteristics.	Consequently,	this	thesis	study	aims	to	increase	both	research	and	clinical	knowledge	for	this	demographic.	This	study	aims	to	increase	plantar	foot	sole	mechanoreceptor	activation,	with	the	addition	of	orthotics	and	texture	under	the	entire	length	of	the	plantar	sole	of	the	foot,	as	a	potential	treatment	option	for	individuals	with	Parkinson’s	disease.		Parkinson’s	disease	(PD)	is	the	second	most	common	neurodegenerative	disorder	following	Alzheimer’s	disease	(Hirtz,	Thurman,	Mohamed,	Chaudhuri,	&	Zalutsky,	2007).	Statistics	Canada	reports	Canadian	disease	prevalence	at	an	estimated	55,000	adults	living	in	private	households	and	12,500	residing	in	long-term	residential	institutions.	Gait	impairment	is	the	most	common	motor	characteristic	associated	with	the	condition,	further	complicated	by	freezing	of	gait,	experienced	in	30-60%	of	PD	patients	(Nanhoe-Mahabier	et	al.,	2011).	The	2014	Canadian	Seniors’	Falls	Report	lists	balance	and	gait	deficits,	neurological	disorders,	and	reduced	physical	fitness,	as	the	main	risk	factors	contributing	to	increased	falls.	This	same	report	suggests	that	“each	year,	fall-related	hospitalizations	account	for	about	
		 17	
85%	of	injury	hospitalizations	for	seniors”	(Wong,	Gilmour,	&	Ramage-Morin,	2014).	Risk	factors	include	Parkinson’s	disease,	lack	of	muscle	strength,	and	fear	of	falling	(FOF).	Consequently,	continued	research	progress	in	Parkinson’s	disease,	balance,	and	gait	disorders	has	important	implication	in	clinical	rehabilitation.	It	is	quite	evident	that	falls	create	a	large	economic	burden	to	our	health	care	system,	and	have	large	personal	consequences	to	PD	individual’s	quality	of	life.	If	we	can	increase	our	understanding	of	the	gait	and	balance	impairments	that	increase	falls,	and	couple	this	understanding	with	the	task-specific	activities	that	increase	risk	factors	to	falls,	we	can	translate	this	knowledge	towards	targeted	intervention	strategies	preventing	falls.	Since	walking	and	turning	are	self-reported	activities	increasing	the	risk	of	falls	in	PD	(Ashburn,	Stack,	Ballinger,	Fazakarley,	&	Fitton,	2008),	this	thesis	has	a	focus	on	turning	behavior.	Sensory	augmentation,	via	foot	orthotics	with	and	without	texture,	are	two	proposed	intervention	strategies	to	decrease	fall	risks	in	individuals	with	Parkinson’s	disease.			
Parkinson’s	Disease	and	Motor	Symptoms			 The	clinical	phase	of	Parkinson’s	disease	is	defined	by	the	onset	of	motor	symptoms.	Tremors,	bradykinesia,	rigidity,	and	balance	problems	are	among	the	most	common	symptoms	of	the	condition.	PD	medications	offer	some	symptomatic	relief;	however,	the	normalization	of	motor	symptoms	is	stage	dependent.	For	example,	Levadopa,	one	of	the	most	effective	medications	for	Parkinson’s	disease,	has	a	wearing-off	period	prior	to	a	secondary	dose.	This	diminishing	effect	is	most	commonly	experienced	during	the	mid	to	late	stages	of	the	disease,	where	motor	symptoms	re-emerge	before	the	body	receives	additional	medication.	Furthermore,	as	PD	progresses,	the	development	of	postural	instabilities,	freezing	of	gait,	loss	of	balance,	and	frequent	falls	increase	ambulatory	impairments	(National	Institute	of	Neurological	Disorders,	2015).	These	secondary	complications	are	drug-resistant,	highlighting	a	need	for	greater	understanding	of	causes	and	treatment	availability.		
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Gait	Characteristics	The	axial	impairments	of	a	Parkinsonian	gait	include	a	stooped	posture,	shuffling	feet,	postural	imbalances,	and	freezing	(Carpenter	&	Bloem,	2011).	In	comparison	to	normal	walking	patterns,	a	PD	gait	includes	decreased	stride	length	and	velocity,	with	increased	cadence,	and	duration	in	double	limb	support	time	(Morris,	Iansek,	Matyas,	&	Summers,	1998).	PD	patients	experiencing	walking	patterns	with	freezing	of	gait	(FOG)	tend	to	have	additional	impairments;	including	increased	stride	length	variability	(Hausdorff	et	al.,	2003),	larger	asymmetries	between	lower	leg	swing	times	(Plotnik,	Giladi,	Balash,	Peretz,	&	Hausdorff,	2005),	and	increased	irregularity	of	inter-limb	coordination	(Nanhoe-Mahabier	et	al.,	2011).	Plantar	force	research	has	demonstrated	altered	force	distribution	patterns	within	the	PD	demographic.	A	slower	load	acceptance	at	heel	strike,	an	earlier	forefoot	load,	reduced	amplitude	at	toe-off	(Nieuwboer	&	De	Weerdt,	1998),	decreased	peak	ground	reaction	forces	(GRFs)	at	initial	contact	and	toe-off,	and	lower	peak	power	production	of	lower	limb	joints	(Morris,	Huxham,	McGinley,	Dodd,	&	Iansek,	2001)	have	all	been	previously	observed.		
Balance	and	Fear	of	Falling	Approximately	75%	of	PD	patients	are	affected	by	impaired	balance,	greatly	increasing	their	fall	risks	in	comparison	to	healthy	individuals	of	the	same	age	(Nilsson,	Hariz,	Iwarsson,	&	Hagell,	2012).	Balance	in	the	PD	literature	is	commonly	reported	by	functional	performance	tests	(example:	Timed	Up	and	Go)	and	postural	sway.	Nilsson	et	al.	(2012)	reported	balance	impairments	resulting	from	postal	survey	results.	Participant	responses	to	the	Swedish	‘Walk-12G’	questionnaire,	determined	that	self-reported	balance	deficits	are	the	largest	walking	difficulty	contributing	to	fear	of	falling.	Lindholm	et	al.	(2014)	replicated	these	results,	highlighting	functional	balance,	dual-task	difficulties,	and	gait	speed	as	the	strongest	factors	increasing	fear	of	falling	in	PD	patients.	Ambulatory	tasks	seem	to	be	the	largest	contributor	to	increased	falls,	including	abnormal	posture	and	poor	balance	(Latt,	Lord,	Morris,	&	Fung,	2009).	Balance	in	these	previously	reported	studies	(Ashburn	et	al.,	2008;	Lindholm	et	al.,	2014;	Nilsson	et	
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al.,	2012)	was	defined	from	results	of	self-reported	questionnaires,	diary	logs,	and	performance-based	instruments.		 The	measure	of	balance,	and	the	mechanisms	by	which	a	researcher	defines	balance	improvements,	varies	study	by	study.	Within	the	PD	literature,	balance	impairment	is	commonly	quantified	by	force	plate	posturography;	the	measurement	of	postural	sway,	through	the	analysis	of	center	of	mass	(COM)	motion,	in	relation	to	the	center	of	pressure	(COP)	and	base	of	support	(BOS)	(Stylianou,	McVey,	Lyons,	Pahwa,	&	Luchies,	2011).	Studies	in	the	early	1990’s	fail	to	consider	the	effects	of	medication	and	disease	severity	when	reporting	the	effect	of	PD	on	quiet	standing	postural	sway.	Consequently,	early	documentation	of	postural	sway	analysis	revealed	mixed	results.	Current	research	attempts	to	quantify	the	postural	movement	strategies	of	PD	patients	during	static	and	dynamic	conditions,	while	considering	the	effects	of	Levadopa	and	disease	severity,	in	eyes	open	and	closed	conditions.	During	static	stance,	in	mild	to	moderate	PD	(Hoehn-Yahr	scale	stages	1-3),	both	the	medio-lateral	(ML)	sway	path	length	and	range	appear	to	increase	(Stylianou	et	al.,	2011).	This	sway	path	direction	has	been	further	linked	to	increased	fall	risk,	an	important	consideration	for	the	PD	community	(Maki	&	McIlroy,	1996).	The	presence	of	visual	input	has	a	greater	effect	on	postural	sway	in	the	antero-posterior	(AP)	sway	path	length,	area,	and	range	(Stylianou	et	al.,	2011),	compared	to	the	ML	direction.	AP	sway	is	also	greater	in	PD	patients	compared	to	healthy	age	matched	controls.	It	is	important	to	note	these	results	are	observed	when	PD	patients	are	on	their	medications,	and	it	remains	unclear	if	force	plate	posturography	is	an	appropriate	measure	of	static	balance	in	studies	conducted	when	patients	are	off	their	medication.	In	the	assessment	of	static	balance	using	an	inclinometric	device,	Matinolli	et	al.	(2007)	recorded	postural	sway	data	for	60	seconds	during	normal	static	standing,	in	both	eyes	open	and	closed	conditions	(Matinolli	et	al.,	2007).	Disease	duration	and	severity,	medication,	recent	fall	history,	and	use	of	walking	aids,	were	all	associated	with	larger	postural	sway.		Additional	Parkinson’s	disease	research	is	investigating	gait	and	balance	by	classifying	PD	into	disease	subtypes	(postural	instability	gait	difficulty	[PIGD]	vs.	tremor	dominant	[TD])	(Herman,	Weiss,	
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Brozgol,	Giladi,	&	Hausdorff,	2014),	evaluating	the	influence	of	freezing	of	gait	(Bloem,	Hausdorff,	Visser,	&	Giladi,	2004),	and	attempting	to	gain	a	larger	understanding	of	the	influence	of	the	on	and	off	cycle	of	Levadopa	medication	(Curtze,	Nutt,	Carlson-Kuhta,	Mancini,	&	Horak,	2015;	Morris	et	al.,	2001).		As	researchers	develop	a	greater	understanding	of	the	contributing	factors	influencing	PD	patients’	falls	and	impaired	balance,	this	increased	knowledge	generation	is	slowly	transferring	into	clinical	practice.	There	is	a	gap	within	current	literature	to	further	understand	dynamic	stability	and	the	potential	treatment	interventions	to	facilitate	balance	improvements.	Furthermore,	there	is	a	failure	to	consider	balance	during	specific	times	within	the	gait	cycle,	most	importantly,	when	the	body	is	at	a	greatest	threat	to	its	state	of	equilibrium.	Balance	analysis	during	static	stance	is	an	important	first	step	in	evaluating	the	neural	complexities	of	equilibrium,	however	isolates	the	experimental	results	to	static	stance	conditions.		A	body	is	considered	balanced	when	the	COM	falls	within	the	base	of	support,	as	defined	by	the	individual’s	area	of	contact	on	the	ground	surface.	An	individual	is	most	vulnerable	to	balance	disturbances	during	the	single	support	phase	of	gait,	when	only	one	foot	is	in	contact	with	the	ground.	The	displacement	of	the	COM	within	the	base	of	support,	during	this	time	of	the	gait	cycle,	is	a	strong	indicator	of	stability	during	dynamic	movement	(Perry	et	al.,	2008).	As	the	COM	approaches	the	lateral	base	of	support,	resulting	in	a	smaller	stability	margin,	small	threats	to	the	balance	system	can	result	in	a	fall.	If	the	stability	margin	is	greater,	a	larger	threat	is	required	to	increase	fall	risks.	Consequently,	an	individual	is	considered	more	stable,	and	thus	less	vulnerable	to	balance	loses,	with	a	larger	stability	margin	(See	Figure	1)	(Perry	et	al.,	2008).	Fall	mechanisms	are	more	complex	then	single	stance	isolation,	however	a	greater	understanding	of	this	stability	margin	variability	in	PD	can	further	our	knowledge	of	balance	strategies	during	dynamic	movement.		
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Figure	1:	The	COM/BOS	and	lateral	stability	margin.	Larger	stability	margins	(left	figure)	result	in	increased	stability	and	less	vulnerability	to	balance	impairments.	Smaller	stability	margins	(right	figure)	are	less	stable	and	vulnerable	to	balance	impairments.		Adapted	from	Perry	et	al.,	2008.	
	
	
Turning	Performance:	A	Comparison	Between	Typical	and	PD	Turning	Behavior	
Typical	Turning	Strategies	
	 There	are	two	main	turning	strategies	commonly	adopted	during	human	locomotion:	a	turn	step	and	a	spin	step.	By	definition,	a	turn	involves	that	an	individual	decelerate	forward	motion,	rotate	the	body,	and	step	out	towards	the	new	direction	(Hase	&	Stein,	1999).	Two	factors	influencing	turn	strategy	adoption	include	the	location	or	side	of	the	braking	foot	(the	last	foot	on	ground	contact	prior	to	initiating	the	turn)	and	turn	direction.	During	a	spin	turn,	the	ball	of	the	foot	serves	as	a	turning	axis	whereby	the	body	spins	around	on	the	stance	foot.	This	strategy	is	less	stable	than	a	step	turn	as	the	deceleration	of	forward	momentum	and	change	in	turn	direction	occurs	almost	simultaneously.	Secondly,	the	complete	change	of	direction	occurs	in	single	stance.	Spin	turns	are	commonly	adopted	when	the	braking	foot	side	and	turn	direction	are	the	same	(example:	right	braking	foot	and	right	turn	direction).	The	step	turn	utilizes	both	feet	to	change	direction,	each	serving	as	an	axis	for	part	of	the	turn.	Step	turns	are	more	common	when	the	braking	foot	side	and	turn	direction	oppose	each	other	(example:	right	braking	foot	and	
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left	turn	direction).	Step	turns	have	a	wider	base	of	support	than	spin	turns,	resulting	in	a	more	stable	turning	strategy	(Hase	&	Stein,	1999).	A	visual	representation	of	turning	strategies	is	shown	in	Figure	2.	This	thesis	adopts	the	spin	and	step	turn	definitions	described	above.	Recent	literature	(Conradsson,	Paquette,	&	Lo,	2017)	has	adopted	a	slightly	different	definition	between	turns,	an	important	consideration	when	comparing	results	between	authors.	
																								 	
Figure	2:	Spin	and	step	strategies.		Adapted	from	Hase	&	Stein,	1999.	
Parkinson’s	Disease	and	Turning	Performance	
	 Previous	turning	performance	literature	has	focused	on	the	changes	in	postural	characteristics,	axial	trunk	rotation,	and	electromyography	in	patients	with	PD.	During	functional	tasks,	such	as	making	tea	in	one’s	kitchen,	PD	subjects	with	self-reported	difficulties	completing	turns	require	more	steps	to	complete	the	movement	compared	to	PD	subjects	without	self-reported	difficulties	(Stack,	Ashburn,	&	Jupp,	2006).	Trunk	rotation	has	been	evaluated	under	various	turning	conditions;	including	velocity	changes,	cued	turning,	and	dual	task	performance.	Within	each	turning	condition,	longer	turn	times	and	a	decrease	in	yaw	(vertical	axis)	and	roll	(longitudinal	axis)	angular	velocity	is	observed	in	PD	subjects	compared	to	healthy	controls	(Visser	et	al.,	2007).	Crenna	et	al.	(2007)	observed	similar	results	when	PD	subjects	were	
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required	to	turn	90	degrees	and	continue	ambulation.	PD	subjects	required	more	steps	to	complete	the	turn,	decreased	velocity	approaching	the	turn,	had	a	prolonged	mean	duration	of	turn	step,	and	abnormal	timing	of	head-trunk	rotation	(Crenna	et	al.,	2007).	When	turning	180	degrees	on	the	spot,	PD	subjects	have	simultaneous	movement	of	the	head,	trunk,	and	pelvis,	and	an	increased	number	of	steps	and	turn	time.	Interestingly,	the	absence	of	a	craniocaudal	turning	strategy	was	not	accompanied	by	changes	in	lower	limb	muscle	activation	patterns	(Hong,	Perlmutter,	&	Earhart,	2009).	It	is	difficult	to	make	further	comparisons	between	these	studies	as	turning	characteristics	are	all	unique	to	each	testing	condition.	The	ambulatory	movements	preceding	a	turn	will	have	effects	on	performance	ability.		Secondly,	this	literature	combines	testing	on	PD	subjects	during	both	on	and	off	medication	times,	an	important	consideration	when	interpreting	these	results.	A	recent	study	by	Conradsson	and	associates	(2017)	investigated	PD	subjects	turning	performance	both	on	and	off	dopaminergic	medication.	Medicinal	intake	had	no	effects	on	turn	strategy	adoption	and	PD	participants’	turning	impairments	remained	following	dopaminergic	medication.	Conradsson	et	al.	(2017)	concluded	that	the	regulation	of	step	width	was	the	most	crucial	difference	between	PD	participants	and	healthy	controls.	PD	participants	took	narrower	steps,	increased	crossover	steps	during	turns,	and	compromised	their	ML	stability	(Conradsson	et	al.,	2017).	In	this	thesis	study,	the	turning	variables	of	interest	include	turn	strategy,	step	count,	and	velocity	changes	between	experimental	conditions.	All	subjects	were	tested	during	on	times	of	dopaminergic	medication.	
	
Balance	and	Somatosensory	Response	The	visual,	vestibular,	and	somatosensory	systems	all	contribute	to	the	body’s	movement	control	(Eils	et	al.,	2002).	Somatosensory	receptors,	located	throughout	the	body,	provide	the	afferent	feedback	to	the	central	nervous	system	required	for	the	performance	of	human	movement.	There	are	four	types	of	receptors	responsible	for	somatic	sensation	response:	1)	cutaneous	and	subcutaneous	mechanoreceptors;	2)	thermoreceptors;	3)	nociceptors,	and	4)	muscle	and	skeletal	proprioceptors.	In	balance	control,	proprioceptors	and	mechanoreceptors	are	most	important,	responding	to	muscle	length	and	force	changes,	
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joint	angle	changes,	and	skin	deformation	(Gardner	&	Johnson,	2013a).		The	mechanoreceptors	in	the	feet,	and	the	proprioceptors	located	in	our	muscles	and	joints	have	important	roles	in	the	response	to	postural	changes.	These	specialized	receptors	play	a	large	role	in	the	neural	mechanisms	responsible	for	controlling	center	of	mass	motion.	When	the	body	experiences	an	unpredicted	disturbance	to	its	state	of	equilibrium,	automatic	postural	adjustments	and	muscle	activation	produce	direction-specific	forces	to	maintain	balance	control	(Macpherson	&	Horak,	2013).	Further	details	on	the	somatosensory	system	and	its	receptors	can	be	found	in	Appendix	A.		In	attempts	to	better	understand	the	role	of	the	somatosensory	system	in	balance	control,	studies	have	explored	various	manipulations	at	the	plantar	sole	of	the	foot.	These	studies	focus	on	manipulating	plantar	cutaneous	mechanoreceptor	activity,	through	either	sensory	augmentation	or	down-regulation	of	their	cutaneous	response.	Down-regulation	of	plantar	foot	sole	mechanoreceptor	activity	is	experimentally	manipulated	by	placing	ice	under	the	foot.	When	exposed	to	these	conditions,	participant’s	adopt	a	more	cautious	walking	pattern	and	observe	longer	contact	times	during	all	phases	of	gait	(Eils	et	al.,	2002).	This	diminished	cutaneous	sensation	alters	plantar	pressure	distribution	patterns,	with	significant	reductions	noted	under	the	calcaneus	and	metatarsals.	This	decreased	calcaneal	and	forefoot	pressure	suggests	a	more	cautious	walking	pattern	at	initial	contact	and	toe-off.		Secondly,	during	single	leg	stance,	load	is	shifted	to	the	forefoot	earlier	under	iced	conditions.		In	comparison	to	normal	conditions,	there	is	a	larger	contact	area	between	foot	and	ground,	consequently	increasing	contact	time	and	load	distribution	across	the	foot	(Eils	et	al.,	2002).	Perry	et	al.	(2000)	explored	the	specific	roles	of	plantar	mechanoreceptors	to	better	understand	their	role	in	compensatory	stepping	reactions.	Plantar	mechanoreceptors	provide	important	spatial	and	temporal	information	to	the	body.	With	diminished	plantar	cutaneous	sensation,	participants’	stepping	patterns	changed	in	instances	of	unpredictable	postural	perturbations.	Compensatory	stepping	patterns	appear	to	be	both	direction	specific	and	step	phase	dependent	(Perry,	McIlroy,	&	Maki,	2000).	These	results	suggest	that	the	role	of	plantar	mechanoreceptors	contribute	to	the	relationship	between	the	body’s	base	of	support	and	stability	limits.	Changes	in	gait	kinematics	have	also	been	observed,	with	
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significant	differences	in	the	hip,	knee,	and	ankle	joint	angles	when	plantar	cutaneous	feedback	is	down-regulated.	Electromyography	(EMG)	analysis	revealed	decreases	in	muscle	activity	of	key	lower	limb	muscles,	including	the	tibialis	anterior,	peroneus	longus,	and	gastrocnemius	(Eils	et	al.,	2004).		In	PD	patients,	the	pathogenesis	of	peripheral	neuropathy	and	the	mechanisms	inducing	peripheral	nerve	damage	remain	unclear	(Nolano	et	al.,	2008).	Secondly,	this	neuropathy	tends	to	mirror	limb	asymmetry	and	PD	motor	symptomology.	Clinically,	PD	patients	demonstrate	decreased	sensitivity	of	the	plantar	sole	of	the	foot	and	higher	monofilament	testing	thresholds	for	touch	and	vibration.	The	motor	and	somatosensory	system	changes	in	PD	patients	appear	to	be	correlated,	with	increased	motor	impairment	resulting	in	increased	plantar	sole	sensitivity	thresholds	(Prätorius,	Kimmeskamp,	&	Milani,	2003).	Consequently,	reduced	somatosensory	response	may	be	a	contributing	factor	to	impaired	balance	control.		If	standing	conditions	are	altered,	such	as	standing	on	a	declining	hill,	PD	patients	have	difficulties	estimating	the	magnitude	of	balance	adjustments	required	for	the	appropriate	postural	adjustments.	Postural	adaptation	and	learning	can	occur	following	the	trial,	however	PD	patients	commonly	over-respond	to	the	required	counterbalancing	adjustments	(Macpherson	&	Horak,	2013),	threatening	their	state	of	equilibrium,	and	consequently	increasing	their	fall	risks.	The	age-related	loss	of	plantar	mechanoreceptors,	accompanied	by	PD	induced	changes	in	sensory	nerve	conduction,	highlights	the	need	for	a	greater	understanding	of	the	mechanisms	available	to	increase	plantar	somatosensory	feedback.	This	thesis	focuses	on	the	muscle	activity	of	the	tibialis	anterior,	peroneus	longus,	and	medial	gastrocnemius	due	to	the	two	above	mentioned	rationales:	the	knowledge	of	decreased	amplitudes	of	these	specific	muscles	during	diminished	cutaneous	feedback	(Eils	et	al.,	2004),	and	the	decreased	plantar	foot	sole	sensitivity	in	PD	individuals.	To	manipulate	the	plantar	foot-sole	interface,	two	intervention	strategies	were	proposed:	non-textured	orthotics	and	textured	orthotics.	An	increase	in	muscle	activity,	specifically	during	initial	contact	and	toe-off,	is	suggestive	of	improvements	to	walking	confidence	in	the	single	stance	phase	of	gait.	If	these	significant	increases	in	muscle	activity	are	noted	during	the	appropriate	times	of	
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single	stance	(initial	contact	and	push-off	phases	respectively),	this	increased	amplitude	could	be	attributed	to	the	increase	in	sensory	facilitation.		
	
Interventions	Strategies	
Foot	Orthoses	Minimal	research	has	focused	on	using	orthotics,	over-the-counter	or	custom	devices,	to	increase	balance	through	increased	somatosensory	response.	It	is	important	to	note	that	the	terminology	surrounding	foot	orthoses	can	be	confusing	throughout	the	literature.	A	recent	systematic	review	by	Aboutorabi	et	al.	(2016)	is	a	perfect	example,	whereby	the	summarized	foot	orthotic	research	includes	all	variations	of	foot-ground	manipulations.	Of	the	22	articles	reviewed,	only	1	article	examined	a	true	custom	orthotic	(Gross,	Mercer,	&	Lin,	2012).	Footwear	characteristics,	manipulations,	insole	design	changes,	over-the-counter	orthotics,	and	custom	devices,	are	routinely	grouped	together	under	the	keyword	“foot	orthoses”.		Foot	orthoses	can	be	a	valuable	clinical	tool	in	treatment	options	aimed	at	improving	balance.		Foot	orthoses	function	by	improving	lower	limb	alignment	and	correcting	abnormal	motion	during	the	gait	cycle	(Michaud,	1997).	Furthermore,	foot	orthoses	increase	the	surface	contact	of	the	plantar	sole	of	the	foot	to	the	orthotic	top	cover.	This	increased	surface	contact,	consequently	increased	mechanoreceptor	activation,	has	been	linked	to	postural	sway	changes	improving	dynamic	balance	task	scores	for	individuals	suffering	from	chronic	ankle	instability	(Sesma,	Mattacola,	Uhl,	Nitz,	&	McKeon,	2008).	The	use	of	custom	foot	orthoses	on	static	and	dynamic	balance	was	evaluated	in	children	with	flexible	flat	feet.	There	was	a	significant	improvement	in	balance	with	long	term	(3	months)	wear	of	the	custom	orthotics.	Balance	was	defined	as	decreased	center	of	gravity	(COG)	velocity,	during	static	stance,	with	one	eye	closed	(Lee,	Lim,	&	Yoo,	2015).	More	recently,	Shin	et	al.	(2016)	compared	three	different	contact	heights	between	orthotic	and	the	plantar	sole	of	the	foot.	Closer	foot	contact,	between	the	plantar	foot	sole	and	the	top	of	the	
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orthotic,	resulted	in	larger	improvements	in	static	balance.	These	improvements	were	characterized	by	a	decrease	in	ML	COP,	total	AP	distance,	and	ML	velocity	(Shin,	Ryu,	&	Yi,	2016).	Additional	research	is	necessary	to	further	understand	the	relationship	between	orthotics	and	postural	sway,	and	more	specifically,	during	dynamic	movement.	
Textured	Insoles	One	method	of	increasing	the	cutaneous	receptors’	sensory	response	is	with	the	addition	of	texture	between	the	plantar	sole	of	the	foot	and	walking	surface.	This	interface	manipulation	has	been	shown	to	alter	static	double-limb	balance	(Hatton,	Dixon,	Rome,	&	Martin,	2011),	improve	postural	control	in	the	elderly	(Palluel,	Olivier,	&	Nougier,	2009),	and	have	injury	specific	implications	for	rehabilitation	professionals	(Mckeon,	Stein,	Ingersoll,	&	Hertel,	2012).	Perry	et	al.	(2008)	investigated	the	effects	of	a	balance-enhancing	insole,	demonstrating	how	changes	in	insole	design	can	influence	balance	control	in	older	adults.	This	facilitative	insole	has	also	proven	effective	in	increasing	single-limb	support	time	and	normalizing	muscle	activation	patterns	of	the	tibialis	anterior	muscle	in	Parkinson’s	patients	(Jenkins	et	al.,	2009).	The	facilitative	insole	helped	PD	patients	approach	a	normal	heel-to-toe	walking	pattern,	suggesting	that	increased	plantar	cutaneous	sensation	can	alter	gait	parameters	and	muscle	activation	patterns.	The	use	of	textured	insoles	had	been	further	explored	in	special	populations,	including	multiple	sclerosis	(Kalron,	Pasitselsky,	Greenberg-Abrahami,	&	Achiron,	2015;	Kelleher,	Spence,	Solomonidis,	&	Apatsidis,	2010),	and	Charcot-Marie-Tooth	disease	(Wegener,	Wegener,	Smith,	Schott,	&	Burns,	2016).	In	respect	to	Parkinson’s	disease,	Qiu	et	al.	(2013)	reported	an	improvement	in	static	postural	stability	when	wearing	a	textured	insole	(Qiu	et	al.,	2013).	Further	PD-specific	research	is	needed	to	gain	a	better	understanding	of	the	relationship	between	enhanced	cutaneous	sensation	and	PD	walking	kinematics.		
	
Summary	of	The	Literature	and	Research	Implications		 To	summarize,	individuals	with	Parkinson’s	disease	have	altered	gait	and	turning	performance	characteristics	compared	to	non-pathological	populations.	Postural	instabilities	and	balance	impairments	
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are	among	the	largest	contributing	factors	increasing	fall	risks.	The	somatosensory	system	plays	a	large	role	in	balance	control,	and	manipulations	at	the	plantar	sole	of	the	foot	has	proven	effective	in	facilitating	sensory	response.	The	aim	of	this	study	is	to	combine	the	physiological	benefits	of	increasing	sensory	augmentation	and	orthotics	in	Parkinson’s	patients.	In	this	study,	we	aim	to	increase	plantar	foot	sole	mechanoreceptor	activity	with	the	addition	of	orthotics	and	texture	under	the	plantar	sole	of	the	foot,	as	a	potential	treatment	option	for	the	gait	deficits	in	individuals	with	Parkinson’s	disease.	To	date,	no	research	has	combined	orthotics	and	added	texture,	towards	the	improvement	of	balance	parameters,	in	either	a	non-pathological	or	pathological	population.	From	a	research	perspective,	this	study	will	advance	PD	literature	and	gain	a	better	understanding	of	the	relationship	between	plantar	sensory	information	and	orthotics	within	this	special	population.	Clinically,	this	research	study	has	large-scale	implications	for	rehabilitation	professionals.	Results	may	provide	a	cost-effective	treatment	option	for	PD	patients,	by	improving	gait,	balance,	and	decreasing	fear	of	falling,	and	consequently	improving	PD	patient’s	quality	of	life.		
Research	Questions		 The	purpose	of	this	research	is	to	answer	the	following	research	questions.	In	individuals	with	Parkinson’s	disease,	when	completing	a	180°	turn	to	static	stance:		1) Will	the	use	of	foot	orthotics	increase	stability	(defined	as	an	increase	in	the	distance	between	the	COM	and	the	lateral	border	of	the	BOS	in	the	braking	step)	compared	to	footwear	without	foot	orthotics?	Does	stability	further	increase	with	long-term	wear?	Does	stability	increase	with	the	addition	of	texture	to	the	orthotics?	2) Will	the	use	of	foot	orthotics,	with	and	without	texture,	alter	walking	and	turn	performance	in	the	steps	preceding	and	initiating	a	180°	turn?		3) Do	the	use	of	foot	orthotics,	with	and	without	texture,	alter	the	total	activation	magnitude	of	key	lower	limb	muscles	during	single	stance?	
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Purpose	and	Hypotheses	The	purpose	of	this	study	was	to	evaluate	turning	behavior	in	PD	participants	between	three	different	conditions:	footwear	only	(F),	non-textured	orthotics	(FO),	and	textured	orthotics	(FOT),	and	further	subdivide	these	results	between	acute	and	long-term	turning	behavior.	The	variables	of	interest	were	divided	into	three	classifications:	gait	stability,	walking	and	turn	performance,	and	muscle	activation	patterns.			 It	was	hypothesized	that	gait	stability	would	gradually	increase	between	each	condition,	with	greater	increases	noted	with	prolonged	orthotic	wear	and	the	addition	of	texture.	Increased	stability	was	characterized	by	an	increased	distance	between	the	COM	and	the	lateral	border	of	the	BOS.	It	was	hypothesized	that	walking	and	turn	performance	would	improve	with	prolonged	orthotic	wear	and	the	addition	of	texture.	Improvements	in	turning	performance	are	characterized	by	increased	step	length,	width	and	velocity,	and	a	decrease	in	step	count.	It	was	further	hypothesized	that	the	total	magnitude	of	lower	limb	muscles	activity	during	static	stance	(tibialis	anterior,	peroneus	longus,	and	medial	gastrocnemius)	would	change	between	the	experimental	conditions.	More	specifically,	the	largest	changes	in	total	muscle	magnitude	were	expected	in	the	textured	orthotic	conditions	(both	acute	and	long-term).			 	
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CHAPTER	2:	METHODOLOGY	
Participant	Recruitment,	Pre-Screening,	and	Attrition	All	study	procedures	were	reviewed	and	approved	by	the	Wilfrid	Laurier	Research	Ethics	board	(REB#5082).	A	convenience	sample	of	14	participants	was	originally	recruited	for	the	study.	Male	and	female	candidates,	aged	55-75,	with	a	diagnosis	of	idiopathic	Parkinson’s	disease	were	eligible	for	participation.	Recruitment	occurred	throughout	Southwestern	Ontario’s	PD	support	groups	(Kitchener,	Cambridge,	Brantford,	Woodstock,	Stratford,	Goderich,	and	London),	the	Parkinson’s	Society	of	Southwestern	Ontario,	and	advertisements	within	the	general	population.	Recruitment	posters	were	placed	on	bulletin	boards	and	common	advertising	locations	of	local	communities	and	churches	(See	Appendix	B).	The	study	was	further	advertised	electronically	when	churches	noted	email	as	their	preferred	method	of	communication.		All	interested	candidates	completed	a	‘Pre-Screening	Questionnaire’.	This	questionnaire	was	administered	over	the	telephone	to	all	study	candidates.	The	questionnaire	was	designed	to	ensure	all	prospective	participants	met	the	study’s	general	inclusion	criteria	(See	Appendix	C).	All	other	criteria	were	exclusionary.	The	pre-screening	questionnaire	immediately	excluded	any	candidate	with	a	history	of	peripheral	neuropathy,	vestibular	concerns,	cognitive	impairment,	or	other	conflicting	medical	conditions.	Individuals	who	had	undergone	deep	brain	stimulation,	previously	(within	the	past	two	years)/or	currently	wearing	orthotics,	or	had	an	awareness	of	decreased	sensation	on	the	plantar	surface	of	their	feet,	were	also	excluded.	Candidates	suffering	from	severe	arthritic	conditions	or	large	amounts	of	pain	in	the	low	back,	pelvic	region,	legs,	or	feet	were	not	immediately	excluded	from	the	study;	however,	they	were	evaluated	based	on	severity	of	the	condition,	and	their	ability	to	participate	in	the	testing	sessions.	Participants	were	required	to	walk	10	meters	unassisted.	Walking	sticks,	canes,	and/or	other	assistive	devices	were	accepted,	on	condition	that	participants	could	ambulate	short	distances	without	such	devices.		The	pre-screening	questionnaire	determined	exclusion	based	on	frequency	of	use	and	confidence	to	walk	without	these	devices.	Assistive	devices	were	not	permitted	for	use	during	the	testing	trials;	however,	they	
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were	encouraged	for	assistance	between	testing	sessions,	and	to	ambulate	to	and	from	the	biomechanics	lab.	One	male	candidate	was	excluded	from	the	study	as	he	was	currently	wearing	orthotics.		Following	successful	completion	of	the	questionnaire,	the	seven	participants	were	scheduled	for	an	initial	screening	assessment	at	Wilfrid	Laurier’s	neuromechanics	lab.	Participants	were	provided	verbal	and/or	emailed	instructions,	details	on	assessment	expectations,	and	directions	to	the	Bricker	Academic	Building.	Participants	were	compensated	for	all	parking	fees	when	visiting	the	campus	(screening	appointment	and	each	testing	session).	The	screening	appointment	initiated	with	three	exclusionary	evaluations:	1)	a	footwear	evaluation	2)	the	Montreal	Cognitive	Assessment	(MoCA),	and	3)	Semmes	Weinstein	monofilament	testing.	As	footwear	plays	a	vital	role	in	orthotic	treatment	success,	participant’s	footwear	was	the	first	exclusionary	evaluation.	There	was	an	expectation	that	all	participants	wore	appropriate	footwear	throughout	the	duration	of	the	study	(Further	details	provided	under	the	‘screening	appointment’	section).	One	participant	was	asked	to	purchase	new	footwear,	whereas	all	other	candidates	had	an	appropriate	footwear	option.	Details	pertaining	to	the	footwear	evaluation,	MoCA	assessment,	and	monofilament	testing	are	described	under	the	‘screening	appointment’	section.	Two	male	candidates	were	excluded	during	these	evaluations.	Eleven	participants	remained	in	the	study.	All	participants	were	asked	to	sign	the	informed	consent,	as	approved	by	the	Wilfrid	Laurier’s	research	ethics	board.	This	consent	briefly	outlined	the	purpose	of	the	study,	participant	expectations,	study	procedures,	risks	and	benefits,	and	confidentiality.	See	Appendix	D	for	the	informed	consent	statement	signed	by	all	participants.	Between	the	screening	appointment	and	initial	testing	session,	two	female	participants	withdrew	from	the	study.	One	participant	withdrew	due	to	travel	concerns	throughout	the	winter	weather,	and	one	participant	was	no	longer	interested	in	study	participation.	Two	participants	withdrew	from	the	study	between	baseline	and	week	5	testing.	See	Figure	3	for	a	flowchart	outlining	participant	attrition.	Consequently,	seven	participants	completed	all	three	testing	sessions.	Demographic	information	for	these	participants	is	presented	in	Table	1.		
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Figure	3:	Summary	of	participant	attrition	throughout	the	study.	
	
Table	1.	Participant	demographics	and	baseline	scores	
Participant	 Gender	 Age		 Weight		
(kg)	
Height	
(cm)	
PD	Dx	
(yrs)	
MoCA	 HY	 UPDRS-
III	
S&E	
(%)	1	 F	 72	 82.10	 161.2	 10	 29	 3	 7	 80	4	 M	 76	 92.53	 177.8	 6	 26	 3	 10	 80	7	 M	 59	 70.31	 175.26	 12	 29	 2	 6	 100	8	 M	 77	 88.45	 175.26	 14	 28	 2	 5	 90	9	 F	 62	 63.50	 157.48	 1	 27	 2	 6	 70	11	 M	 82	 72.57	 177.8	 18	 26	 3	 15	 60	12	 M	 70	 92.99	 175.26	 1	 26	 2	 6	 90	
Mean	 --	 71.54	 80.35	 171.44	 8.86	 27.29	 2.43	 7.86	 81.43	
SD	 --	 8.25	 11.71	 8.41	 6.49	 1.38	 0.53	 3.53	 13.45	
*Note:	PD	Dx	=	years	since	Parkinson’s	disease	diagnosis;	HY	=	Hoehn	and	Yahr;	S&E	=	Schwab	and	England	Activities	of	Daily	Living	
scale	scores		
Screening	Appointment	The	screening	appointment	initiated	with	an	evaluation	of	participant’s	footwear	using	the	‘Footwear	Assessment	Form’.	A	comfortable	walking	shoe	(athletic	or	casual	dress)	was	required	for	study	participation.	As	footwear	was	not	standardized	across	all	participants,	footwear	option	restrictions	were	very	specific	during	the	length	of	study	participation.	Secondly,	participants	were	required	to	wear	the	
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n=14
Screening	Appointment
n=13
Week	0	(Baseline)
n=9
Week	4
n=8
Week	5
n=7	(2	females,	5	males)
1	Male
(currently	wearing	orthotics)
2 Males
(MoCA scores	did	not	meet	inclusion	
criteria)
2 Females
(winter	travel	concerns,	no	longer	
interested	in	participating)
1	Male
(injury)
1	Female
(no	longer	interested	in	
participating)
Study	Attrition
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same	footwear,	indoors	and	outdoors,	throughout	the	entire	five	weeks.		Participant’s	footwear	required	components	of	adjustability,	torsion	strength,	a	strong	heel	counter,	a	wide	base	of	support,	and	a	heel	drop	between	8-12mm.	Participant’s	footwear	was	evaluated	for	a	proper	fit	in	length	and	width.	Footwear	with	excessive	wear	patterns,	inside	or	outside	of	the	shoe,	including	the	soling	and/or	upper	forefoot	were	considered	unacceptable.	All	footwear	was	loosely	evaluated	based	on	the	Menz	and	Sherrington’s	(2000)	‘Footwear	Evaluation	Form’	(included	in	the	Pedorthic	assessment	form,	see	appendix	G);	however,	components	of	footwear	comfort	and	practicality	to	participants	were	also	considered.	If	the	participant’s	current	footwear	met	all	requirements,	it	was	considered	acceptable	for	the	study.	There	are	strengths	and	drawbacks	to	standardizing	participant’s	footwear.	Allowing	each	participant	to	wear	their	own	footwear	removed	the	need	of	an	adjustment	period	to	any	new	footwear	prior	to	the	orthotic	interventions.	On	the	contrary,	the	between-participant	variability	of	footwear	is	an	important	consideration	in	evaluating	study	results.	The	MoCA	assessment	(Appendix	E)	was	used	as	a	screening	tool	to	evaluate	participants’	cognitive	impairment.	The	screening	domains	included	attention,	concentration,	executive	functions,	memory,	abstraction,	calculation,	orientation,	and	visuospatial	abilities	(Julayanont,	Phillips,	Chertkow,	&	Nasreddine,	2012).	The	test	took	approximately	10	minutes	to	complete,	and	was	scored	out	of	30.	A	score	of	26,	which	indicated	an	absence	of	cognitive	impairment	was	required	for	study	participation.			The	UPDRS	is	a	Parkinson’s	disease	clinical	rating	scale	evaluating	motor	and	non-motor	experiences	of	daily	living.	The	scale	is	divided	into	four	parts,	including:	1)	mentation,	behavior,	and	mood,	2)	activities	of	daily	living,	3)	motor	examination,	and	4)	complications.	Both	the	‘Hoehn	and	Yahr	Staging’	(HY),	and	the	‘Schwab	and	England	Activities	of	Daily	Living’	scales	often	accompany	the	UPDRS	(Goetz,	2012).	In	this	study,	the	UPDRS	was	used	to	quantify	disease	severity,	specifically	related	to	participants’	motor	impairments.	Subsection	III	is	directly	related	to	motor	difficulties;	therefore,	for	the	purposes	of	this	thesis,	and	to	remain	consistent	with	previous	motor	related	PD	research,	this	was	the	only	section	of	the	UPDRS	completed	during	the	screening	assessment,	along	with	the	HY	and	the	‘Schwab	and	England	
		 34	
Activities	of	Daily	Living’.	These	sections	took	approximately	5	to	15	minutes	to	complete.	See	Appendix	F	for	a	copy	of	these	three	assessment	tools.	Plantar	sole	sensation	was	evaluated	according	to	the	Semmes	Weinstein	(North	Coast	Medical,	Inc.,	Morgan	Hill,	CA)	monofilament	examination.	Testing	procedures	were	explained	to	all	participants	prior	to	commencing.	Participants	were	asked	to	remove	their	socks	and	sit	comfortably	in	a	chair.	With	their	eyes	closed,	participants	were	asked	to	respond	‘yes’	if	they	felt	the	monofilament	touch	the	plantar	sole	of	their	foot.	Each	monofilament	was	pressed	at	a	90degree	angle	to	four	locations	on	the	bottom	of	the	foot:	the	hallux,	1st	and	5th	metatarsals,	and	the	calcaneus.	Each	location	was	tested	at	random.	Testing	started	with	the	1.65	monofilament.	If	this	monofilament	was	felt	on	all	sites	bilaterally,	the	testing	was	complete.	When	participants	did	not	respond	‘yes’	to	feeling	this	monofilament,	testing	continued	with	a	larger	monofilament.	The	5.07	monofilament,	exerting	a	10g	force	on	the	plantar	surface	of	the	foot,	was	the	plantar	sole	sensation	threshold	required	to	participate	in	the	study.	Two	participants	did	not	meet	this	sensation	threshold	(the	same	two	participants	who	did	not	meet	the	MoCA	exclusionary	criteria),	and	were	excluded	from	the	study.	Following	the	questionnaires	and	monofilament	testing,	a	basic	pedorthic	assessment	included	static	and	dynamic	observations,	and	range	of	motion	testing.	See	Appendix	G	for	a	copy	of	the	pedorthic	assessment,	FPI,	and	footwear	evaluation	forms.	Participants	were	asked	to	stand	for	approximately	2-5	minutes	and	perform	basic	movement	tasks.	Areas	of	observation	included	the	hip/pelvis	area,	knee,	tibia	(lower	leg	alignment),	and	subtalar	joint	alignment.	The	Foot	Posture	Index	(FPI)	was	used	to	evaluate	static	foot	posture.	The	FPI	is	a	6-item	clinical	tool	used	to	categorize	static	foot	posture.	It	requires	observation	and	palpation	of	the	rearfoot	and	forefoot	during	static	stance.	FPI	normative	values	range	between	0	to	+5,	with	an	average	of	approximately	+4	(slightly	pronated)	in	healthy	older	adults	(Redmond,	Crane,	&	Menz,	2008).	Physical	testing	included	torso	rotation,	a	double	heel	raise,	and	a	double	limb	squat.	These	tests	ensured	the	function	of	the	tibialis	posterior	muscle,	ensured	no	osseous	block	of	the	ankle	joint,	and	provided	confirmation	of	inversion/eversion	movement	of	the	subtalar	joint.	If	
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required,	balance	assistance	was	provided	for	all	physical	tests.	In	the	presence	of	anxiety,	discomfort,	or	pain,	participants	had	the	option	to	terminate	any	performance	of	exercises.	None	of	the	participants	experienced	discomfort.	Participants	were	asked	to	walk	for	approximately	2	minutes.	Visual	observations	of	each	participant’s	gait	and	balance	were	noted,	specifically	related	to	initial	contact,	midstance,	toe-off,	and	swing	phases	bilaterally.	The	gait	cycle	was	video	recorded	for	all	participants,	and	used	as	future	reference	when	required.	Lastly,	participants	were	asked	to	sit	in	a	chair	for	range	of	motion	testing.	Passive	and	active	range	of	motion	testing	(ROM)	was	performed	non-weight-bearing.	The	ROM	assessment	was	difficult	and	highly	inaccurate	in	this	study’s	population,	specifically	when	participants	experienced	tremors	at	the	end	ranges	of	joint	motion.	These	measurements	were	complete	in	approximately	5-10	minutes.			It	is	important	to	note	that	there	was	a	large	amount	of	information	collected	during	this	pedorthic	assessment,	not	all	of	which	was	utilized	during	the	remainder	of	the	thesis.	For	the	completion	of	this	thesis	document,	I	have	elected	to	note	all	details	surrounding	participant	involvement;	however,	pedorthic	related	details,	specifically	the	FPI	results,	were	collected	for	future	analysis.			Following	these	ROM	assessments,	study	protocol	and	testing	day	expectations	were	explained.	The	rationale	behind	participant	postcards	were	explained,	noting	the	importance	of	communicating	pertinent	details	surrounding	medicine	changes	and	the	occurrence	of	falls	during	study	participation.	The	total	duration	of	participant	involvement,	from	the	completion	of	the	initial	screening	appointment	to	the	last	testing	day,	was	approximately	6-weeks.	Screening	appointments	were	approximately	1	hour	and	30	minutes.	Testing	sessions	occurred	at	baseline	(week	0),	4-weeks	post-baseline,	and	5-weeks	post-baseline.	Baseline	and	week	4	testing	sessions	were	between	1-2	hours,	and	the	5-week	testing	session	was	approximately	1	hour	in	length.	All	participant	questions	and/or	concerns	were	answered,	and	most	shared	their	personal	stories	surrounding	their	Parkinson’s	disease	diagnosis,	and	discussed	current	ambulation	difficulties	during	their	activities	of	daily	living.		
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Testing	Sessions	Testing	was	complete	1	-	2	hours	following	the	participant’s	ingestion	of	medication	or	during	their	self-reported	“on”	time	during	the	day.	Participants	were	instructed	to	arrive	at	each	testing	session	immediately	prior	to	their	‘on’	medicine	times,	and	to	take	their	medication	at	approximately	the	same	time	prior	to	each	testing	session.	For	example,	if	testing	was	scheduled	at	11am,	the	participant	would	take	their	dose	of	medication	around	10:15am.	The	participant’s	self-determined	‘on’	time	may	not	occur	until	11:30am,	however	this	provided	an	important	window	for	instrumentation	set-up,	synching	the	start	of	testing	with	the	participant’s	‘on’	time.	All	three	testing	sessions,	for	each	participant,	were	scheduled	at	the	same	time	of	the	day.	At	baseline	testing	(week	0),	monofilament	testing	was	repeated	to	ensure	the	sensation	threshold	for	study	inclusion	was	still	met	by	all	participants	(see	Table	2	for	week	4	results).	Orthotic	break-in	instructions	were	provided	when	dispensing	the	orthotics	and	socks	were	provided	to	all	participants.	Throughout	the	5-week	testing	period,	participants	were	encouraged	to	wear	their	socks	daily.	One	participant	(participant	#12)	provided	valid	medical	reason	to	refrain	from	wearing	the	socks	(he	required	daily	compression	therapy);	however,	all	other	participants	wore	the	dispensed	socks.			
Table	2.		Week	4	-	Monofilament	Results	
 Plantar Surface Location 
1st MTP Head 5th MTP Head Calcaneus 
Participant Right Left Right Left Right Left 
1 4.08 3.84 3.84 3.22 4.87 3.22 
4 4.17 4.31 4.56 4.56 3.84 4.56 
7 4.17 4.17 4.17 4.31 4.17 4.31 
8 4.56 4.08 4.74 4.31 4.31 4.31 
9 2.83 3.61 3.84 3.61 3.84 2.83 
11 4.74 4.56 4.31 4.31 4.17 4.56 
12 4.31 4.56 4.17 4.17 4.17 4.93 
Mean 
SD 
4.123 
0.617 
4.161 
0.354 
4.233 
0.338 
4.070 
0.476 
4.196 
0.347 
4.103 
0.773 
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Equipment		To	collect	all	research	variables	of	interest	(discussed	later	in	this	thesis	document),	three	apparatuses	were	used	for	data	collection:	three	force	plates,	the	Optotrak	motion	capture	system,	and	electromyography	collection	system	(EMG).	The	three	force	plates	(AMTI	OR6-5-2000;	Watertown,	Massachusetts,	United	States	of	America)	were	embedded	in	the	ground	of	the	participant	walkway	(see	figure	10),	and	were	used	to	collect	ground	reaction	forces	(GRF)	of	each	participant’s	braking	and	turning	steps.	The	vertical	GRF	allowed	for	the	extrapolation	of	timing	of	the	single	stance	phase	of	the	gait	cycle.	The	cameras	and	IRED	markers	of	the	Optotrak	motion	capture	system	(Optotrak3020;	Norther	Digital	Inc.,	Waterloo,	Ontario)	were	used	to	collect	3D	kinematic	data.	Twelve	IRED	markers	were	placed	on	the	following	anatomical	landmarks:	bilateral	3rd	metatarsals,	ankle,	knee,	hip,	shoulder,	forehead,	and	xyphoid	process	(see	Figure	4).	Optotrak	data	was	used	to	calculate	the	transverse	plane	center	of	mass	(COM)	location	and	the	location	of	the	lateral	border	of	the	base	of	support	(BOS)	required	for	COM-BOS	relationship	analysis.	
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Figure	4:	The	location	of	12	IRED	markers	placed	on	participant’s	anatomical	locations,	used	during	data	collection	to	collect	3D	kinematic	data.		 Electromyography	(AMT-8	Octopus,	Bortec,	Calgary,	AB)	was	recorded	from	the	tibialis	anterior,	peroneus	longus,	and	gastrocnemius	muscles	bilaterally.	See	Figure	5	for	electrode	placement.	Electrodes	on	the	peroneus	longus	muscles	were	located	by	initially	palpating	the	fibular	head,	and	placed	side	by	side,	along	the	muscle	fibers,	with	three	fingers	below	the	fibular	head	(directed	towards	the	lateral	aspect	of	the	fibula).	To	ensure	adequate	placement	of	the	electrodes,	the	participant	was	asked	to	plantarflex	and	evert	the	foot.	Initially	locating	the	tibial	tuberosity,	and	placing	four	fingers	below	this	bony	prominence,	and	one	finger	laterally,	determined	the	location	of	the	tibialis	anterior.	Participants	were	asked	to	dorsiflex	the	foot	to	ensure	adequate	placement	on	the	muscle	belly.	The	medial	head	of	the	gastrocnemius	was	located	with	one	hand	inferior	to	the	popliteal	crease,	on	the	medial	aspect	of	the	calf	muscle	belly.	To	test	proper	placement,	the	participant	was	asked	to	plantarflex	the	foot	with	an	extended	knee.	A	reference	electrode	
During Data Collection: 
To ensure data is being saved: explorer Æ ndigital Æ collections 
- in session summary, can R click last file that’s been recorded & overwrite prev. file 
 
In stripchart view: R click, under dataset, check marker 9 (zyphoid), analogue channels 4, 10, 16 (force plates) & 
20 (R-Tib. Ant). 
 
   
 
EMG Channels (on patient unit) 
Green cord (Channel  1) Æ from patient unit channel 1 to ground electrode (R – tibial tuberosity) 
Yellow cord Æ to back of amplifier – runs through stress release cable (hook on belt) 
Red Æ to battery pack 
 
Channel  1: Right - Tibialis Anterior  Channel  4: Left - Tibialis Anterior  
Channel  2: Right – Med. Gastrochs  Channel  5: Left – Med. Gastrochs 
Channel  3: Right – Peroneus Longus  Channel  6: Left – Peroneus Longus 
 
*looking for 1V of EMG activity on ocscilloscope* 
- on amplifier, move between channels to view EMG on oscilloscope 
- gain needs to be recorded for eac  muscle prior t  each testing d y 
 
ON PARTICIPANTS BELT: 2 battery packs, EMG patient unit & strobber  
ON PARTICIPANT: 6 EMG sites (with two electrodes/site) + 1 ground electrode AND  12 markers 
		 39	
was	placed	on	the	right	tibial	tuberosity.	This	protocol	remained	consistent	for	each	participant	and	each	testing	session	throughout	the	length	of	the	study.	All	data	was	collected	at	a	frequency	of	1000Hz.		
	
Figure	5:	The	bi-polar	electrode	placement	on	three	lower	limb	muscles;	tibialis	anterior,	medial	gastrocnemius,	and	peroneus	longus	(Adapted	from	Pearson	Education	Inc.,	2009).		All	testing	sessions	were	recorded	using	a	video	camera.	These	videos	were	used	to	ensure	accurate	foot	placement	on	the	force	plates	and	provided	the	opportunity	to	review	testing	sessions	as	required.	These	videos	were	reviewed	on	two	occasions:	to	review	step	count	and	participant’s	turning	strategies.	
Socks,	FO	and	FOT	All	participants	were	provided	identical	socks	(ATW3202-014/M/TO2/P10/S04,	Athletic	Works,	Wal-Mart	Canada	Corp.)	to	wear	during	the	length	of	the	experiment.	As	previously	mentioned,	only	one	participant	was	unable	to	wear	them	due	to	medical	reasons.	These	socks	were	a	thin	material	with	minimal	seams,	and	provided	to	participants	based	on	their	self-determined	footwear	size.	Socks	were	made	of	76%	polyester,	22%	olefine,	and	2%	rubber.		
Peroneus	Longus
Tibialis	Anterior
Medial	
Gastrocnemius
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The	Sole	‘thin	sport’	orthotic	(D609561,	Sole	Thin	Sport	Footbeds,	Edge	Marketing	Corp;	Calgary,	AB,	Canada)	was	used	for	both	FO	and	FOT	conditions.	Sole	orthotics	are	a	heat-moldable,	over-the-counter	orthotic.	These	are	not	custom-made	orthotics,	and	consequently,	they	are	not	individually	fabricated	for	each	participant.	A	sizing	ring	was	used	to	best	match	the	orthotic	size	to	the	arch	length	of	participant’s	feet.	Each	orthotic	was	heated	prior	to	participant	wear,	which	provided	the	best	contoured	fit	between	plantar	foot	sole	and	the	orthotic.		The	textured	orthotics	were	prepared	prior	to	participant’s	week	4	testing	session.	Grooved	plates	(Gilad	Shoham,	Medonyx,	Inc,	Toronto,	ON)	were	custom	made	to	manufacture	the	desired	top	cover	design	(which	was	grooved	into	the	plates)	and	thickness	(Figure	6).	Silicone	rubber	(Smooth-Sil	950	Series)	was	prepared	based	on	the	manufacturer’s	instructions	(Smooth-ON,	Inc.),	and	immediately	poured	into	the	grooved	plates	to	cure	for	24hrs.	A	thin	layer	(1.0mm)	of	black	synthetic	suede	was	placed	over	the	wet	silicone	while	it	dried.	Following	the	curing	process,	the	silicone	top	cover	was	heat	molded	and	glued	to	the	‘Thin	Sport’	Sole	orthotic.	The	‘Thin	Sport’	orthotic	alone	weighed	53.2g,	whereas	the	‘Thin	Sport’	orthotic	with	added	textured	weighed	184.6g.	See	Figures	7	&	8	for	both	orthotics	used	in	the	study.	
	
Figure	6:	The	custom	made	grooved	plates	used	during	the	manufacturing	process	of	the	textured	top	cover	design.		
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Figure	7:	The	Sole	'thin	sport'	(D609561,	Sole	Thin	Sport	Footbeds)	over	the	counter	orthotic,	used	as	the	"footwear+non-textured"	orthotic	condition	throughout	the	study		
	
Figure	8:	The	Sole	'thin	sport'	(D609561,	Sole	Thin	Sport	Footbeds)	over	the	counter	orthotic,	with	added	texture,	used	as	the	"footwear+textured"	orthotic	condition	throughout	the	study				 There	were	many	considerations	throughout	the	development	process	of	the	textured	orthotics.	First	and	foremost,	the	goal	of	retaining	the	benefits	of	orthotics,	and	simply	add	the	addition	of	texture.	The	most	important	aspect	was	to	maintain	contact	between	the	entire	length	of	the	plantar	sole	of	the	foot	and	the	textured	material.	Consequently,	this	required	a	flexible	material	to	mold	around	the	orthotic	device	(acting	as	a	top	cover	to	the	orthotic),	especially	around	the	contours	of	the	heel	and	medial	longitudinal	arch.	Secondly,	the	material	required	a	sufficient	durometer	(material	hardness)	to	retain	its	
IntroductionParkinson’s	disease	(PD)	is	a	neurodegenerative	disorder,	characterized	by	the	substantia	nigra producing	insufficient	amounts	of	dopamine	in	the	body.	The	relationship	between	PD	gait	changes,	impaired	balance,	and	fear	of	falling	has	been	minimally	researched	[1].	The	purpose	of	the	study	is	to	increase	clinical	knowledge	of	the	relationship	between	increased	plantar	foot	sole	sensation	and	balance,	with	the	use	of	orthotics	and	a	textured	insole	in	a	Parkinsonian	gait.	
AimThe	objectives	of	the	study	are	to	determine	if	orthotics,	with	and	without	a	textured	top	cover,	can	alter	muscle	activation,	gait	parameters,	balance,	and	functional	mobility,	as	well	as	decrease	fall	risks	in	Parkinson’s	participants.
MethodologyParticipants:	Ten	participants	with	a	diagnosis	of	idiopathic	Parkinson’s	disease,	aged	55-80	years	old,	will	participate	in	the	study.	Testing: Participants	will	complete	three	testing	sessions;	baseline,	4	weeks	post-baseline,	and	5	weeks	post-baseline.	Study	duration	is	6	weeks.	Two	conditions	will	be	tested	at	baseline;	footwear	only	and	footwear	+	non-textured	orthotics,	two	conditions	at	week	4	testing;	footwear	+	non-textured	orthotics	and	footwear	+	textured	orthotics,	and	1	condition	at	week	5;	footwear	+	textured	orthotic.	Four	assessments	will	be	performed	at	each	testing	session:	1)	static	balance,	double	limb	stance,	with	eyes	closed,	2)	Timed	Up	and	Go	(TUG),	3)	Functional	Gait	Assessment	(FGA),	and	4)	Walking	trials	(with	dominant	&	non-dominant	turning).	
Figure	1:	Non-Textured	Orthotic
Figure	2:	Textured	Orthotic
Outcome	MeasuresGait	parameters,	functional	mobility,	muscle	activation	patterns	and	balance	are	the	main	outcomes	of	the	study.	Gait	parameters	(stride	length,	width,	time	in	single	limb	stance,	gait	velocity)	and	the	COM/COP	and	BOS	relationship	during	static	and	dynamic	stance	will	be	measured	by	force	plates	and	the	OptoTrak Motion	Capture	System	(Northern	Digital	Inc.,	Waterloo,	ON,	Canada).	EMG	(AMT-8	Octopus,	Bortec,	Calgary,	AB,	Canada)	of	the	length	timing	(onset/offset)	and	magnitude	of	the	tibialis	anterior,	peroneus	longus,	and	gastrocnemius	muscles	will	be	recorded.
Orthotics	and	Parkinson’s	Disease:	The	Acute	and	Long-Term	
Effects	of	Increased	Somatosensory	Feedback
Kelly	A.	Robb1,	Stephen	D.	Perry1
1Kinesiology	and	Physical	Education,	Wilfrid Laurier	University,	Waterloo,	ON
Expected	ResultsIt	is	hypothesized	that	participants	in	the	footwear	+	textured	orthotic	condition	will	experience	improvement	in	gait	parameters;	including	increased	walking	velocity,	decreased	stride	width,	increased	stride	length	and	single	limb	support	time.	Increased	balance	is	expected,	defined	as	a	decrease	in	COM	trajectory	and	AP	sway	velocity	while	remaining	within	the	BOS	stability	margin.	During	ambulation,	increased	stability	is	anticipated	with	a	COM	lowering	to	the	BOS,	and	increased	normalization	of	tibialis	anterior,	peroneus	longus,	and	gastrocnemius	muscle	activation	patterns.	Improved	scores	on	the	TUG,	and	FGA	are	also	anticipated,	however	it	is	unclear	if	these	clinical	assessment	tools	are	sensitive	enough	to	detect	minimally	significant	improvements.	
Preliminary	Results
Walking	Trials	+ Dominant	Turn
ImplicationsIncreased	knowledge	of	the	relationship	between	increasing	plantar	foot	sole	sensation	and	orthotics,	can	assist	in	the	development	of	cost-effective	treatment	options	for	Parkinson’s	Disease	patients.	Improvement	to	gait	and	balance	impairments	can	decrease	fear	of	falling,	and	consequently	improve	PD	patient’s	quality	of	life.
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[1]	Lindholm et	al.	(2014).	Factors	associated	with	fear	of	falling	in	people	with	Parkinson’s	disease.	BMC	
Neurology,	14(19);	p.	1-7.
This	study	was	supported	by	NSERC,	CIHR,	CFI,	OIT	and	Sole,	Canada
	
	
	
	
	
	
0
200
400
600
800
1000
1200
2 3 4 5 6 7 8 9 10
Ve
rt
ica
l	F
or
ce
	(N
)
Time	(s)
Baseline	- Footwear	Only
FP1
FP2
FP3
0
200
400
600
800
1000
1200
2 3 4 5 6 7 8 9 10
Ve
rt
ica
l	F
or
ce
	(N
)
Time	(s)
Baseline:	Non-Textured	Orthotic
FP1
FP2
FP3
0
200
400
600
800
1000
1200
2 3 4 5 6 7 8 9 10
Ve
rt
ica
l	F
or
ce
	(N
)
Time	(s)
4-Week	Testing:	Non-Textured	Orthotic
FP1
FP2
FP3
0
200
400
600
800
1000
1200
2 3 4 5 6 7 8 9 10
Ve
rt
ica
l	F
or
ce
	(N
)
Time	(s)
4-Week	Testing:	Textured	Orthotic
FP1
FP2
FP3
IntroductionParkinson’s	disease	(PD)	is	a	neurodegenerative	disorder,	characterized	by	the	substantia	nigra producing	insufficient	amounts	of	dopamine	in	the	body.	The	relationship	between	PD	gait	changes,	impaired	balance,	and	fear	of	falling	has	been	minimally	researched	[1].	The	purpose	of	the	study	is	to	increase	clinical	knowledge	of	the	relationship	between	increased	plantar	foot	sole	sensation	and	balance,	with	the	use	of	orthotics	and	a	textured	insole	in	a	Parkinsonian	gait.	
AimThe	objectives	of	the	study	are	to	determine	if	orthotics,	with	and	without	a	textured	top	cover,	can	alter	muscle	activation,	gait	parameters,	balance,	and	functional	mobility,	as	well	as	decrease	fall	risks	in	Parkinson’s	participants.
Meth dologyParticipants:	Ten	participants	with	a	diagnosis	of	idiopathic	Parkinson’s	disease,	aged	55-80	years	old,	will	participate	in	the	study.	Testing: Participants	will	complete	three	testing	sessions;	baseline,	4	weeks	post-baseline,	and	5	weeks	post-baseline.	Study	duration	is	6	weeks.	Two	conditions	will	be	tested	at	baseline;	footwear	only	and	footwear	+	non-textured	orthotics,	two	conditions	at	week	4	testing;	footwear	+	non-textured	orthotics	and	footwear	+	textured	orthotics,	and	1	condition	at	week	5;	footwear	+	textured	orthotic.	Four	assessments	will	be	performed	at	each	testing	session:	1)	static	balance,	double	limb	stance,	with	eyes	closed,	2)	Timed	Up	and	Go	(TUG),	3)	Functional	Gait	Assessment	(FGA),	and	4)	Walking	trials	(with	dominant	&	non-dominant	turning).	
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Figure	2:	Textured	Orthotic
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Expected	ResultsIt	is	hypothesized	that	participants	in	the	footwear	+	textured	orthotic	condition	will	experience	improvement	in	gait	parameters;	including	increased	walking	velocity,	decreased	stride	width,	increased	stride	length	and	single	limb	support	time.	Increased	balance	is	expected,	defined	as	a	decrease	in	COM	trajectory	and	AP	sway	velocity	while	remaining	within	the	BOS	stability	margin.	During	ambulation,	increased	stability	is	anticipated	with	a	COM	lowering	to	the	BOS,	and	increased	normalization	of	tibialis	anterior,	peroneus	longus,	and	gastrocnemius	muscle	activation	patterns.	Improved	scores	on	the	TUG,	and	FGA	are	also	anticipated,	however	it	is	unclear	if	these	clinical	assessment	tools	are	sen itive	enough	to	detect	mi imally	significant	improvements.	
Preliminary	Results
Walking	Trials	+ Dominant	Turn
ImplicationsIncreased	knowledge	of	the	relationship	between	increasing	plantar	foot	sole	sensation	and	orthotics,	can	assist	in	the	development	of	cost- ffective	treatment	options	for	Parkinson’s	Disease	patients.	Improvement	to	gait	and	balance	impairments	can	decrease	fear	of	falling,	and	consequently	improve	PD	patient’s	quality	of	life.
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shape	during	weight-bearing.	If	the	material	compressed	with	prolonged	wear,	this	would	both	confound	study	results	and	minimize	sensory	effects.	During	the	initial	attempts	to	glue	the	textured	material	to	the	Sole	orthotic,	the	dry	silicone	was	not	adhering	to	the	top	cover	of	the	orthotic.	This	was	corrected	by	adding	synthetic	suede	between	both	layers.	The	suede	was	applied	to	the	silicone	while	still	wet,	dried	during	the	silicone	curing	process,	then	adhered	to	the	Sole	orthotic.	The	final	consideration	was	related	to	the	textured	design.	Based	on	previous	textured	insole	literature,	insoles	with	cupped	heels	and	harder	materials	provide	the	largest	benefits	to	static	and	dynamic	balance	(Iglesias,	Vallejo,	&	Peña,	2012;	Qu,	2015).	Horizontal	ridges	were	selected	to	oppose	the	direction	of	participant’s	walking.	This	opposition,	coupled	with	the	allocated	space	between	each	ridge,	enhanced	the	continuous	stimulation	of	cutaneous	mechanoreceptors,	while	minimizing	the	likelihood	of	habituation.			 The	manufacturing	company’s	(Sole)	fitting	instructions	were	followed	for	each	participant.	At	the	time	of	orthotic	dispensing,	a	heat	gun	was	used	on	the	orthotics	for	2mins,	at	200	degrees	Fahrenheit.	The	orthotics	were	placed	in	participant’s	footwear	and	they	were	asked	to	walk	around	the	biomechanics	lab	for	two	minutes	prior	to	continuing	testing.	This	molding	process	occurred	at	baseline	testing	for	the	FO	condition,	and	at	week	4	for	the	FOT	condition.		
Protocol	This	experiment	was	a	within-subject	study	design,	whereby	all	participants	were	exposed	to	every	experimental	condition,	and	each	testing	session.	From	study	inclusion	to	the	final	testing	day,	the	experiment	took	approximately	6	weeks	per	participant	to	complete.		Each	testing	session	(0,	4	and	5	weeks)	consisted	of	four	assessments,	each	administered	per	condition:	1)	Static	balance,	double	limb	stance,	with	eyes	closed	2)	Timed	Up	and	Go	(TUG),	3)	Functional	Gait	Assessment	(FGA),	and	4)	Walking	+	180°	turn.	Three	conditions	were	tested	throughout	the	study:	1)	footwear	only	(F);	2)	footwear	+	non-textured	orthotic	(FO);	and,	3)	footwear	+	textured	orthotic	(FOT).	It	
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is	important	to	note	that	all	three	conditions	were	not	tested	at	each	session.	Conditions	F	and	FO	were	tested	at	baseline,	conditions	FO	and	FOT	at	week	4,	and	only	FOT	at	week	5.	At	baseline	testing	(week	0),	monofilament	testing	was	repeated	to	ensure	the	sensation	threshold	for	study	inclusion	was	still	met	by	all	participants.	Immediately	following	the	baseline	testing	session,	participants	were	required	to	wear	the	FO	for	4	weeks	until	the	next	testing	session.	Participants	were	required	to	wear	the	FOT	for	1	week,	between	weeks	4	and	5	testing.	See	Figure	9.	At	baseline	and	over	the	next	4	weeks,	participants	were	instructed	to	wear	the	FO’s	during	95%	of	their	weight-bearing	activities	(including	indoor	and	outdoor	activities).	The	same	instructions	were	provided	for	the	FOT	between	the	4-week	and	5-week	testing	sessions.		All	participants	were	asked	to	complete	weekly	postcards	to	track	changes	in	medicinal	doses,	their	perceived	level	of	comfort	while	wearing	the	orthotics,	duration	of	wear	time,	and	report	of	any	falls.	These	postcards	were	mainly	used	to	continue	communication	with	participants	during	the	off-testing	weeks,	and	to	ensure	no	major	changes	took	place	in	their	everyday	activities.	Participants	were	instructed	to	wear	the	orthotics	‘as	much	as	possible’	throughout	the	length	of	the	study.	They	were	informed	that	the	orthotics	should	‘not	cause	pain’,	however	participants	may	feel	minor	aches	and	discomfort	while	acclimatizing	to	the	devices.	If	the	orthotics	could	not	be	tolerated	by	the	participant,	they	were	advised	to	communicate	with	the	biomechanics	lab.	All	participants	tolerated	the	orthotics	during	the	testing	period.	Three	participants	noted	discomfort	with	the	textured	orthotics,	however	this	was	not	communicated	until	their	week	5	testing	session.	This	discomfort	has	no	effect	on	the	time	of	wear	in	the	textured	orthotics.	A	follow	up	call	was	scheduled	in	circumstances	where	a	participant	experienced	a	fall	between	experimental	sessions.	One	subject	reported	a	fall;	however,	occurred	during	the	hours	of	night,	and	was	unrelated	to	study	participation.			
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Figure	9:	A	flow	chart	graphically	displaying	the	experimental	conditions	at	each	testing	session.	
Testing	Sessions	All	participant	questions	were	answered	prior	to	starting	the	experimental	setup.	The	EMG	electrodes	and	IRED	markers	were	placed	on	participants	as	previously	discussed.	Maximum	voluntary	contractions	(MVCs)	were	performed	for	each	muscle	of	interest	in	the	study,	at	each	testing	session.	Testing	began	with	static	double	limb	stance	with	eyes	closed.	Participants	were	asked	to	stand	as	still	as	possible	with	their	eyes	closed	for	1	minute.	At	baseline	testing,	tracing	paper	was	used	to	identify	the	exact	foot	position	on	the	force	plates.	This	same	tracing	paper	was	used	to	ensure	accuracy	of	foot	position	during	each	participant’s	static	stance	testing.	The	TUG	and	FGA	were	administered	conforming	to	the	instructional	protocols	for	these	two	assessment	tools.	Prior	to	the	completion	of	the	“Timed	Up	and	Go”	(TUG)	test,	participants	were	asked	to	start	the	test	sitting	back	comfortably	in	a	chair,	with	both	arms	resting	on	their	lap.	On	the	command	“go”,	participants	stood	from	the	chair,	walked	a	clearly	marked	3m	distance	on	the	floor,	turned	around,	and	returned	to	their	chair,	with	their	back	resting	against	the	chair.	The	timer	started	when	the	participant	initiated	movement	from	the	chair,	and	stopped	when	they	had	returned	to	their	original	position.	A	practice	trial	was	offered	to	all	participants.	The	FGA	required	participants	to	perform	various	walking	tasks,	including	turns,	stepping	over	objects,	walking	backwards,	and	walking	with	a	narrowed	base	of	support	(Appendix	H).	Note	that	the	static	stance,	TUG,	and	FGA	assessments	are	not	analyzed	for	this	thesis.	They	are	described	here	as	they	were	part	of	each	participant’s	testing	experience,	however	they	are	only	being	analyzed	in	future	statistical	analysis.	
Week	0
Week	4
Week	5
Condition	1:	Footwear	only	(F)
Condition	2:	non-textured	orthotics	(FO)
Condition	2:	non-textured	orthotics	(FO)
Condition	3:	textured	orthotics	(FOT)
Condition	3:	textured	orthotics	(FOT)
*	Wore	FO	for	4	weeks
*	Wore	FOT	for	1	week
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Walking	Trials	+	180°	Turn	For	each	experimental	condition,	participants	completed	ten	walking	trials	+	180°	turn.	A	demonstration	was	provided	to	each	participant	prior	to	starting.	Participants	walked	towards	the	force	plates	at	a	self-selected	walking	speed.	When	they	arrived,	they	turned	180°	on	the	force	plate,	and	stopped	with	one	foot	on	each	plate.	They	remained	in	static	stance	until	the	10seconds	of	data	collection	was	complete	(Figure	10).	For	the	first	trial,	participants	turned	in	their	direction	of	choice.	This	choice	of	direction	was	determined	to	be	their	‘dominant’,	or	‘preferred’	turn	direction,	which	remained	consistent	throughout	the	rest	of	the	testing	conditions	and	sessions.	Following	the	first	trial,	participants	were	told	which	direction	to	turn	prior	to	initiating	the	trial.	In	three	of	ten	trials,	participants	were	asked	to	turn	in	their	‘non-dominant’	direction.	These	walking	trials	+	180°	turn	were	completed	twice	on	week	0	(F	and	FO	conditions),	twice	on	week	4	(FO	and	FOT	conditions),	and	once	on	week	5	(FOT	condition	only).	A	sample	data	collection	sheet	can	be	found	in	Appendix	I.	
	
	
Figure	10:	A	graphical	representation	of	the	force	plates	and	turn	location	when	participants	completed	the	walking	trials	+	180	degree	turns.	
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Variables	of	Interest	All	variables	of	interest	were	divided	into	three	main	categories:	dynamic	stability,	turning	performance,	and	average	muscle	activity.	Outcome	variables	were	isolated	into	two	different	analysis	windows.	The	COM/BOS,	average	velocity,	and	average	muscle	activity,	were	isolated	to	the	single	stance	phase	of	the	braking	step	(refer	to	Figure	2).	This	braking	foot	was	defined	as	the	last	step	prior	to	the	initiation	of	turning	movement	(torso	or	forefoot	deviation	towards	the	direction	of	the	turn).	Step	length	and	step	width	were	isolated	to	the	step	immediately	following	this	braking	step.	The	start	of	single	stance	was	defined	as	the	moment	the	contralateral	limb	was	non-weight	bearing,	initiating	the	swing	phase	of	gait,	and	cessation	was	defined	as	the	moment	the	contralateral	limb	returned	to	ground	contact.	Consequently,	the	analysis	window	was	the	specific	time	in	gait	when	only	one	foot	was	weight	bearing.	The	variables	of	interest	in	determining	dynamic	stability	were	the	maximum,	minimum,	and	range	of	the	COM/BOS	relationship.	Kinematic	data	was	used	to	calculate	the	locations	of	the	transverse	plane	COM	and	the	lateral	border	of	BOS.	Based	on	each	participant’s	anthropometric	measures	and	foot	width,	the	BOS	was	determined	from	the	ankle	and	3rd	metatarsal	IRED	markers.	This	distance	was	translated	to	the	lateral	border	of	the	BOS.	The	final	values	for	COM/BOS	maximum,	minimum,	and	range	were	calculated	from	a	custom	visual	basic	program.	Turning	performance	variables	included	step	length,	step	width,	average	walking	velocity,	step	count,	and	turning	strategy.	The	average	muscle	activity	during	single	stance	was	measured	for	the	tibialis	anterior,	peroneus	longus,	and	medial	gastrocnemius	muscles,	bilaterally.	The	EMG	signals	were	processed	with	an	antialiasing	low	pass	filter,	using	a	cut	off	frequency	of	40Hz.	Muscle	activity	was	synchronized	with	force	plate	data	to	ensure	accuracy	of	the	onset	and	offset	timing	of	single	stance.	The	EMG	signal	was	normalized	to	the	peak	muscle	activity,	allowing	comparisons	between	EMG	data	collected	between	participants,	and	across	different	testing	sessions.	EMG	data	was	further	corrected	for	which	limb,	the	ipsilateral	or	contralateral	limb,	was	used	during	the	braking	step.	Results	are	expressed	as	a	percentage	of	the	average	muscle	activity	that	occurred	during	single	stance	of	the	braking	step.	
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Data	Processing		Three	software	programs	were	used	in	data	processing.	‘Optofix’,	a	custom	visual	basic	software	program,	was	used	to	clean	the	data.	A	cubic	spline	interpolation	was	selected	to	join	data	gaps	where	marker	values	provided	missing	data.	The	“fixed”	files	were	processes	through	a	‘COM-12’	custom	program,	which	approximates	the	COM	values	from	the	optotrak	markers.	Lastly,	the	final	visual	basic	software	was	customized	for	this	experiment.	Final	processing	synched	ankle	marker	velocities	and	force	plate	GRF’s,	allowing	for	the	extrapolation	of	the	single	stance	analysis	windows.		
	
Statistical	Analysis		 Initially,	a	total	of	fifty-two	one-way	repeated	measures	analysis	of	variance	(ANOVA)	statistical	tests	were	performed.	These	fifty-two	ANOVA’s	were	broken	down	into	sixteen	statistical	tests	per	dependent	variable;	maximum	ML	COM/BOS,	minimum	ML	COM/BOS,	ML	range	COM/BOS,	step	count,	step	width,	step	length,	average	velocity,	and	EMG	of	3	lower	limb	muscles,	bilaterally.	Subsequent	analysis	included	twelve	ANOVA’s,	discussed	further	in	the	discussion	section	of	this	document.	SAS	university	edition,	version	9.2,	was	used	for	all	statistical	analysis.	The	following	four	conditions	were	analyzed:	acute	and	long-term	non-textured	orthotic	wear,	and	acute	and	long-term	textured	orthotic	wear.	The	acute	non-textured	orthotic	results	compared	the	variables	of	interest	between	week	0	F	and	FO	conditions,	whereas	the	acute	textured	orthotic	results	compared	the	variables	between	week	4	FO	and	FOT.		The	long-term	non-textured	orthotic	results	compared	week	0	FO	to	week	4	FO,	and	the	long-term	textured	orthotic	results	compared	week	4	FOT	to	week	5	FOT.	Consequently,	these	long-term	results	differ	between	comparisons:	the	non-textured	orthotic	results	compare	4	weeks	of	FO	wear,	whereas	the	textured	orthotic	results	compared	1	week	of	FOT	wear.	An	alpha	of	0.05	was	set	a	priori.	All	data	was	inspected	for	outliers,	and	a	rank-transformation	was	performed	when	the	data	did	not	meet	the	assumption	of	normality.	Potential	outliers	were	identified	at	two	standard	deviations	from	the	means.	No	outliers	were	removed	from	the	data	set.	Upon	inspection	of	all	potential	outliers,	these	values	were	determined	to	be	
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representative	of	the	variability	between	participants,	rather	than	indicating	an	error	within	the	data	set.	Consequently,	this	variability	was	considered	important	to	retain	in	study	results.	When	the	differences	between	group	means	were	statistically	significant,	a	Tukey’s	post	hoc	procedure	confirmed	direction	and	significance.		 All	data	analysis	utilized	a	statistical	model	incorporating	both	inter-subject	variability	and	between	trial	variability,	for	each	factor.	The	reported	error	terms	for	the	degrees	of	freedom	(df)	expressed	in	this	document	range	from	83	to	126.	These	high	values	reflect	a	df	error	term	that	included	each	subject	(7	participants	in	this	study),	each	factor	(footwear	or	week),	and	10	walking	trials	per	factor,	providing	a	maximum	df	error	term	of	140.		This	ANOVA	design	was	adopted	to	acknowledge	the	importance	of	considering	both	participant	and	walking	trial	variability,	an	important	consideration	in	neurological	populations	such	as	PD.		 	
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CHAPTER	3:	RESULTS	
Postcards	As	previously	stated,	the	weekly	postcards	were	used	to	continue	communication	with	participants	during	the	off-testing	weeks,	and	to	ensure	no	major	changes	took	place	in	their	everyday	activities.	All	participants	wrote	on	the	postcards,	or	discussed	during	the	testing	sessions,	the	difference	in	thickness	between	the	FO	and	FOT	conditions.	One	participant	experienced	slight	changes	to	their	Levadopa	medication,	more	specifically,	this	medication	increased	between	weeks	1-2,	and	4-5,	by	½	a	pill/dose.	The	FO’s	and	FOT’s	were	worn	by	all	participants	between	4-10	hours/day.	All	participants	were	comfortable	in	the	FO	condition;	however,	three	participants	reported	discomfort	while	wearing	the	FOT.	None	of	these	participants	decreased	their	wear	time	in	the	FOT;	however,	one	participant	reported	a	severe	progression	of	discomfort	through	to	the	final	week	of	testing.	One	participant	experienced	a	fall	during	the	study.	The	fall	occurred	during	the	evening	hours	when	the	participant	misjudged	the	location	of	the	bed.	The	participant	was	not	wearing	the	orthotics	at	the	time	of	fall	and	suffered	no	injuries	from	the	incident.	Additional	participant	feedback	includes	increased	feelings	of	arch	support	during	both	orthotic	conditions,	and	positive	family	member	comments	on	improved	walking	patterns.			Four	one-way	repeated	measures	ANOVA	were	performed	for	each	variable	(totaling	fifty-two	one-way	repeated	measures	ANOVA).	Appendix	J	includes	summary	tables	of	all	statistical	results.	Chapter	3	of	this	document	details	the	statistical	results	for	each	variable	of	interest	in	the	experimental	study.	Statistical	significance	is	denoted	by	a	star	(*)	on	the	data	figures.			
COM/BOS	ANALYSIS	
Maximum	ML	COM/BOS		 The	three	variables	of	interest	in	the	analysis	of	COM/BOS	were	maximum	ML	distance,	minimum	ML	distance,	and	ML	range.	With	the	exception	of	the	long-term	non-textured	orthotic	condition,	(Figure	
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11),	all	comparisons	were	non-significant.	In	the	non-textured	orthotic	condition,	there	was	a	statistically	significant	increase	in	maximum	ML	COM/BOS	distance	at	week	4,	F(1,89)=7.46,	p=.0076,	ETA-square=.33	(0.1298m±0.0538)	as	compared	to	week	0	(0.1069m±0.0494).	The	acute	wear	of	both	non-textured	orthotics	(week	0-F	[0.1170m±0.0478]	as	compared	to	week	0-FO	[0.1069m±SD=0.0494];	week	4-FO	[0.1298m±0.0538]	as	compared	to	week	4-FOT	[0.1239m±0.0510])	and	textured	orthotics	appear	to	slightly	decrease	maximum	ML	COM/BOS,	however	both	non-significant.	Long-term	wear	of	the	textured	orthotics	resulted	in	a	slight,	non-significant	increase	in	maximum	ML	COM/BOS	(week	4-FOT	[0.1239m±0.0510]	as	compared	to	week	5-FOT	[0.1317m±0.0556].		
	
Figure	11:	The	maximum	ML	COM/BOS	relationship	across	testing	sessions	(week	0,	4,	and	5),	and	conditions	(footwear	only	(F),	non-textured	orthotic	(FO),	and	textured	orthotic	(FOT))	during	the	stance	phase,	of	1	step	post-braking	step.	
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Minimum	ML	COM/BOS		 All	minimum	ML	COM/BOS	results	were	non-significant.	Statistical	results	for	minimum	ML	COM/BOS	revealed	small	decreases	in	both	acute	orthotic	conditions,	(week	0-F	[0.0823m±0.0426]	compared	to	week	0-FO	[0.0720m±0.0409],	and	(week	4-FO	[0.0857m±0.0492]	as	compared	to	week	4-FOT	[0.0844m±0.0485]),	and	small	increases	in	both	long-term	orthotic	conditions	(week	0-FO	[0.0720m±0.0409]	as	compared	to	week	4-FO	[0.0857m±0.0492],	and	(week	4-FOT	[0.0844m±0.0485]	as	compared	to	week	5-FOT	[0.0874m±0.0471]).		
ML	Range	COM/BOS	All	statistic	results	for	ML	range	revealed	a	slight	increase	between	experimental	conditions,	apart	from	the	acute	textured	orthotics.	There	was	a	slight	decrease	in	ML	range	between	week	4-FO	(0.0441m±0.0259)	compared	to	week	4-FOT	(0.0395m±0.0296).	All	ML	range	COM/BOS	results	were	non-significant.			
Turning	Performance	Analysis		 Turning	performance	was	evaluated	using	turning	strategy,	step	count,	step	length,	step	width,	and	average	walking	velocity	analysis.	All	participants	(100%)	performed	step	turns	for	every	trial,	at	each	testing	session,	and	under	each	experimental	condition.	There	were	a	total	of	416	braking	steps	on	the	right	leg,	and	only	15	braking	steps	on	the	left	leg.		
Step	Count	There	were	statistical	significant	decreases	in	step	count	between	week	0-F	(5.52steps±1.08)	and	week	0-FO	(5.23steps±0.87)	conditions,	F(1,108)=4.86,	p=.0296,	ETA-square=.54,	and	between	week	4-FO	(5.23steps±1.31),	and	week	4–FOT	(4.67steps±0.76)	conditions,	F(1,	126)=13.21,	p=.0004,	ETA-square=.55	(Figure	12).	Small,	non-significant,	step	count	increases	were	observed	in	both	long-term	orthotic	
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conditions,	(week	0-FO	[5.23steps±0.87]	compared	to	week	4-FO	[5.24steps±1.31])	and	(week	4-FOT	[4.67steps±0.76]	compared	to	week	5-FOT	[4.73steps±0.78]).			
		
Figure	12:	The	average	step	count	across	testing	sessions	(week	0,	4,	and	5),	and	conditions	(footwear	only	(F),	non-textured	orthotic	(FO),	and	textured	orthotic	(FOT))	during	the	stance	phase,	of	1	step	post-braking	step.	
	
Step	Length		 All	step	length	results	were	non-significant.	There	was	a	decrease	in	step	length	in	the	acute	FO	condition	(week	0-F	[0.7662m±0.4850]	as	compared	to	week	0-FO	[0.7100m±0.3888])	and	long-term	FOT	condition	(week	4-FOT	[0.8080m±0.3185]	as	compared	to	week	5-FOT	[0.7773m±0.2693]);	however	an	increase	in	step	length	between	the	long-term	FO	condition	(week	0-FO	[0.7100m±0.3888]	as	compared	to	week	4-FO	[0.7952m±0.3094]),	and	acute	FOT	condition	(week	4-FO	[0.7952m±0.3094]	as	compared	to	week	4-FOT	[0.8080m±0.3185]).		
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Step	Width	All	step	width	results	were	non-significant.	Step	width	decreased	between	all	comparisons,	except	for	a	slight	increase	between	week	4-FO	(0.1594m±0.0640)	and	week	4-FOT	(0.1597m±0.0641).		
Average	Walking	Velocity		 Average	walking	velocity	significantly	decreased	between	week	0-F	(0.9443m/s±0.1682)	and	week	0-FO	(0.8143m/s±0.2723),	F(1,111)=16.91,	p<.0001,	ETA	square=.48,	however	it	significantly	increased	between	week	0-FO	(0.8143m/s±0.2723),	and	week	4-FO	(0.9180m/s±0.2196),	F(1,116)=12.20,	p=.0007,	ETA	square=.66	(Figure	13).	Non-significant	increases	were	observed	between	both	FOT	conditions	(week	4-FO	[0.9180m/s±0.2196]	compared	to	week	4-FOT	[0.9512m/s±0.2074])	and	(week	4-FOT	[0.9512m/s±0.2074]	compared	to	week	5-FOT	[0.9524m/s±0.1858]).			
	
Figure	13:	Average	velocity	during	the	first	stance	phase	of	the	stepping	strategy.	
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EMG	Analysis	Statistical	analysis	was	performed	on	the	measurement	of	the	average	activation	magnitude	of	six	lower	leg	muscles;	the	ipsilateral	and	contralateral	tibialis	anterior,	medial	gastrocnemius,	and	peroneus	longus.	Results	of	the	average	EMG	activity	during	the	single	stance	phase	of	the	gait	cycle	were	expressed	as	a	percentage	of	the	peak	EMG	activation	that	occurred	during	the	entire	trial	of	interest	(normalized).	As	most	braking	steps	were	performed	on	the	right	foot,	the	right	limb	musculature	was	mostly	activated	during	weight-bearing	single	stance.	There	was	large	participant	variability	across	all	testing	sessions	and	experimental	conditions.	See	figure	14	for	a	sample	of	force	plate	data	and	EMG	data.	
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Figure	14:	The	timing	of	force	plate	contact	synched	with	EMG	results	(TA	=	tibialis	anterior;	MG	=	medial	gastrocnemius;	PL	=	peroneus	longus).	The	ipsilateral	and	contralateral	muscle	activity	is	demonstrating	during	single	stance	contact	on	force	plate	1	and	force	plate	2.	
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Ipsilateral	Tibialis	Anterior	Average	ipsilateral	tibialis	anterior	muscle	activity	significantly	increased	between	week	0-FO	(4.75%±2.48)	and	week	4-FO	(6.59%±3.40),	F(1,125)=17.42,	p<.0001,	ETA-square=.42	(Figure	14).	All	other	comparisons	were	non-significant.	Average	muscular	activity	for	the	ipsilateral	tibialis	anterior	decreased	in	both	acute	orthotic	conditions,	FO	(week	0-F	[6.04%±5.6]	as	compared	to	week	0-FO	[4.75%±2.48])	and	FOT	(week	4-FO	[6.59%±3.40]	as	compared	to	week	4-FOT	[6.04%±3.54]).	These	results	were	insignificant,	along	with	the	slight	increase	in	muscular	activity	observed	with	long-term	textured	orthotic	wear	(week	4-FOT	[6.04%±3.54]	compared	to	week	5-FOT	[6.84%±4.04]).			
	
Figure	15:	The	averaged	ipsilateral	tibialis	anterior	muscle	activity	during	the	first	stance	phase	of	the	stepping	strategy.		
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Ipsilateral	Medial	Gastrocnemius	Statistical	significance	was	observed	in	all	ipsilateral	medial	gastrocnemius	analyses,	apart	from	acute	FOT,	(week	4-FO	[4.39%±2.04]	as	compared	to	week	4-FOT	[4.69%±2.04]).	There	was	a	statistical	significant	increase	in	average	muscle	activity	of	the	ipsilateral	medial	gastrocnemius	between	week	0-F	(4.91%±2.24)	and	week	0-FO	(5.96%±3.48)	F(1,124)=5.75,	p=.0180,	ETA-square=.39,	and	between	week	4-FOT	(4.69%±2.04)	and	week	5-FOT	(5.97%±2.72),	F(1,126)=11.67,	p=.0009,	ETA-square=.18.	There	was	a	significant	decrease	in	average	muscle	activity	of	the	ipsilateral	medial	gastrocnemius	between	week	0-FO	(5.96%±3.48)	and	week	4-FO	(4.39%±2.04),	F(1,125)=14.52,	p=.0002,	ETA-square=.41	(Figure	15).				
	
Figure	15:	The	averaged	ipsilateral	medial	gastrocnemius	muscle	activity	during	the	first	stance	phase	of	the	stepping	strategy.	
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Ipsilateral	Peroneus	Longus	Statistical	significance	in	average	muscle	activity	of	the	ipsilateral	peroneus	longus	was	observed	in	the	same	three	comparisons	as	the	ipsilateral	medial	gastrocnemius.	There	was	a	statistically	significant	decrease	in	average	muscle	activity	of	the	ipsilateral	peroneus	longus	muscle	between	week	0-F	(8.57%±4.92)	and	week	0-FO	(7.13%±3.02),	F(1,124)=4.13,	p=.0442,	ETA-square=.20,	and	between	week	4-FOT	(8.94%±3.29)	and	week	5-FOT	(7.23%±2.50),	F(1,126)=14.37,	p=.0001,	ETA=square=.25.	There	was	a	statistically	significant	increase	in	average	muscle	activity	of	the	ipsilateral	peroneus	longus	muscle	between	week	0-F0	(7.13%±3.02)	and	week	4-FO	(8.51%±3.07),	F(1,125)=10.33,	p=.0017,	ETA-square=.26	(Figure	16).	An	insignificant	increase	in	average	muscle	activity	of	the	ipsilateral	peroneus	longus	was	observed	between	week	4-FO	(8.51%±3.07)	and	week	4-FOT	(8.94%±3.29).			
	
Figure	16:	The	averaged	ipsilateral	peroneus	longus	muscle	activity	during	the	first	stance	phase	of	the	stepping	strategy.	
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Contralateral	Tibialis	Anterior		 Statistically	significant	increases	in	average	muscle	activity	of	the	contralateral	tibialis	anterior	muscle	were	observed	in	both	FO	comparisons,	and	non-significant	decreases	in	both	FOT	comparisons.	There	was	a	statistically	significant	increase	in	average	muscle	activity	of	the	contralateral	tibialis	anterior	muscle	between	week	0-F	(5.60%±5.30)	and	week	0-FO	(6.44%±4.81),	F(1,125)=6.03,	p=.0154,	ETA-square=.60,	and	between	week	0-FO	(6.44%±4.81)	and	week	4-FO	(6.99%±3.14),	F(1,126)=5.74,	p=.0181,	ETA-square=.52	(Figure	17).	Non-significant	decreases	in	average	muscle	activity	of	the	contralateral	tibialis	anterior	muscle	was	observed	between	week	4-FO	(6.99%±3.14)	and	week	4-FOT	(6.69%±4.02),	and	between	4-FOT	(6.69%±4.02)	and	week	5-FOT	(5.60%±5.30).		
	
Figure	17:	The	averaged	contralateral	tibialis	anterior	muscle	activity	during	the	first	stance	phase	of	the	stepping	strategy.		
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Contralateral	Medial	Gastrocnemius		 All	contralateral	medial	gastrocnemius	results	were	non-significant.	Average	muscle	activity	of	the	contralateral	medial	gastrocnemius	muscle	slightly	increased	in	acute	FO	(week	0-F	[5.21%±3.51]	as	compared	to	week	0-FO	[5.39%±3.34])	and	acute	FOT	(week	4-FO	[5.04%±2.36]	as	compared	to	week	4-FOT	[5.26%±2.55])	conditions,	and	slightly	decreased	in	long-term	FO	(week	0-FO	[5.39%±3.34]	as	compared	to	week	4-FO	[5.04%±2.36])		and	FOT	(week	4-FOT	[5.26%±2.55]	as	compared	to	week	5-FOT	[4.63%±3.11])		conditions.		
Contralateral	Peroneus	Longus		 Similar	non-significant	results	were	observed	in	the	average	muscle	activity	of	the	contralateral	peroneus	muscle.	Small,	non-significant,	muscle	decreases	were	observed	in	both	acute	FO	(week	0-F	[7.53%±3.90]	as	compared	to	week	0-FO	[7.33%±3.47])	and	FOT	conditions	(week	4-FO	[7.50%±2.93]	as	compared	to	week	4-FOT	[7.35%±3.14]),	and	small,	non-significant,	muscle	increases	in	both	long-term	FO	(week	0-FO	[7.33%±3.47]	as	compared	to	week	4-FO	[7.50%±2.93])		and	FOT	conditions	(week	4-FOT	[7.35%±3.14]	as	compared	to	week	5-FOT	[8.04%±3.97]).		 	
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CHAPTER	4:	DISCUSSION	
	The	purpose	of	this	study	was	to	evaluate	turning	behavior	in	PD	participants	between	three	different	conditions:	footwear	only	(F),	non-textured	orthotics	(FO),	and	textured	orthotics	(FOT),	and	further	subdivide	these	results	between	acute	and	long-term	turning	behavior.	When	individuals	are	required	to	change	direction,	the	planning	of	direction	change	is	initiated	and	programmed	in	the	steps	preceding	the	turn	(Patla,	Prentice,	Robinson,	&	Neufeld,	1991).	Consequently,	the	analysis	of	braking	steps	prior	to	turning	movement	are	important	analysis	windows	in	understanding	turning	behavior.	From	a	clinician’s	perspective,	this	experimental	study	provides	two	different	sets	of	information.	Acute	FO	and	FOT	results	provide	a	greater	understanding	of	the	neuromuscular	changes	and	adaptation	process	that	a	bodily	system	experiences	when	initially	wearing	a	foot	orthotic.	However,	these	acute	results	were	observed	after	only	minutes	of	wearing	the	orthotics,	and	rarely	will	foot	orthotics	be	used	as	such	a	short-term	intervention	strategy.	Thus,	these	acute	changes	are	important	for	clinicians	to	appreciate	the	orthotic	adaptation	process;	however,	the	long-term	FO	and	FOT	results	provide	greater	insight	into	using	orthotics	as	a	potential	intervention	strategy	in	Parkinson’s	disease.	Consequently,	this	discussion	is	divided	into	the	acute	and	long-term	foot	orthotic	conditions.		
Acute	Non-Textured	Foot	Orthotics–Comparison	Between	Week	0-F	and	Week	0-FO	The	experimental	design	of	this	study	is	important	to	note	when	considering	the	acute	non-textured	orthotic	condition.	Study	inclusion	insisted	that	participants	had	never	worn	orthotics	previously,	suggesting	that	all	participants	were	naïve	to	orthotics	until	these	first	few	minutes	in	the	biomechanics	lab.	The	COM/BOS	analysis	revealed	slight	decreases	in	maximum	and	minimum	ML	movement,	and	an	increased	ML	range.	Although	non-significant,	these	results	suggest	a	slight	increase	in	instability	when	first	wearing	the	orthotics.	Without	statistical	significance,	it	is	important	to	acknowledge	these	result	as	speculative.	However,	in	considering	the	relationship	between	all	COM/BOS	variables,	this	interaction	
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provides	compelling	clinical	knowledge.	Turning	performance	behavior	is	consistent	with	these	findings;	when	initially	wearing	the	foot	orthotics,	participants’	walking	velocity	significantly	decreased.	It	appears	that	a	more	hesitant	walking	behavior	occurred	when	an	adaptation	to	the	orthotics	was	required.	PD	subjects	compensated	for	the	decrease	in	stability,	noted	by	the	decrease	in	stability	margin,	by	altering	gait	velocity	to	complete	the	turn	task.		Interestingly,	significant	decreases	in	step	count	suggests	that	participants	took	fewer	steps	to	complete	the	turns.	Previous	turning	performance	literature	highlights	the	importance	of	self-perceived	confidence	in	the	ability	of	individuals	with	Parkinson’s	disease	to	complete	turns.	PD	participants	with	self-reported	turning	difficulties	require	more	steps	to	successfully	perform	a	turn	(Stack	et	al.,	2006).	Consequently,	the	current	study	results	suggest	that	the	balance	disturbances	(non-significant	COM/BOS	results)	were	not	large	enough	to	effect	participant’s	self-perceived	confidence	to	complete	the	task,	however	compensatory	behaviors	occurred	to	safely	perform	the	turning	movement.			 All	EMG	was	analyzed	during	the	single	stance	phase	of	the	braking	step;	i.e.,	the	final	forward	facing	step	prior	to	initiating	the	turn.	As	most	braking	steps	were	performed	on	the	ipsilateral	foot,	the	ipsilateral	limb	musculature	was	activated	in	single	stance	weight-bearing,	whereas	the	contralateral	limb	was	in	the	swing	phase	of	the	gait	cycle.	A	small	non-significant	decrease	in	ipsilateral	tibialis	anterior	activity	was	noted;	however	more	importantly,	ipsilateral	medial	gastrocnemius	activity	significantly	increased,	whereas	ipsilateral	peroneus	longus	activity	significantly	decreased.	These	results	suggest	a	greater	magnitude	of	lower	leg	posterior	compartment	muscle	activation,	accompanied	by	a	decrease	in	lateral	compartment	activation.	When	considering	the	role	of	the	medial	gastrocnemius	in	single	stance,	we	can	hypothesize	this	increased	activity	occurred	at	toe-off.	This	is	simply	a	hypothesis,	and	cannot	be	inferred	as	a	definitive	conclusion	until	closer	analysis	of	the	muscular	activity	within	each	individual	stance	phase	period	is	examined.	This	is	important	to	note,	as	lower	limb	muscles	have	a	phase	dependency	within	single	stance,	and	their	primary	role	changes	throughout	the	gait	cycle.	The	decrease	in	peroneus	longus	activity	may	be	a	result	of	the	orthotic	causing	a	subtalar	joint	position	change	to	the	foot.	The	foot	
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orthotic	raised	the	medial	longitudinal	arch,	increased	subtalar	joint	supination,	and	consequently	decreased	the	peroneus	longus	demands	to	resist	the	supinatory	forces	generated	by	the	posterior	compartment	musculature	(Michaud,	1997).	Furthermore,	the	orthotics	have	a	mechanical	role	in	changing	the	orientation	of	foot	structures.	As	these	1%	changes	in	muscular	activity	are	expressed	as	an	average	across	participant’s	stance	phase,	these	small	numerical	percentages	may	significantly	alter	limb	movement.	A	significant	increase	in	contralateral	tibialis	anterior	muscle	activation	was	observed	in	the	swing	phase	of	the	gait	cycle.	Anterior	compartment	muscle	activity	in	the	swing	phase	of	gait	is	quite	typical,	and	tibialis	anterior	activity	in	PD	individuals	is	generally	overactive	(Dietz,	1997).	A	potential	explanation	for	this	drastic	increase	in	muscle	activity,	is	the	orthotic	providing	the	sensation	of	greater	muscle	firing	required	to	make	the	same	amount	of	ground	clearance	as	without	the	orthotic.	Non-significant	changes	were	observed	in	the	contralateral	medial	gastrocnemius	and	peroneus	longus	muscles	in	the	swing	phase	of	gait.				
Acute	Textured	Foot	Orthotics–Comparison	Between	Week	4-FO	and	Week	4-FOT	The	acute	textured	orthotics	results	compare	4	weeks	of	orthotic	wear,	to	initially	placing	the	textured	orthotics	under	participant’s	feet.	The	dynamic	balance	analysis	showed	small,	non-significant	decreases	across	all	COM/BOS	variables,	ML	maximum,	minimum,	and	ML	range.	These	results	are	consistent	with	the	COM/BOS	changes	during	the	acute	non-textured	condition,	whereby	the	balance	system	felt	a	slight	threat	to	dynamic	stability.	These	non-significant	results	can	be	interpreted	similarly	to	the	acute	non-textured	condition,	whereby	the	interaction	of	all	three	COM/BOS	variables	provide	clinical	insight	into	the	balance	system	changes	when	initially	exposed	to	texture.	Positive	outcomes	were	observed	in	turning	performance,	with	a	significant	reduction	in	step	count	and	an	increase	in	walking	velocity.	This	ambulatory	performance	suggests	an	increased	confidence	in	the	steps	preceding	turns,	an	important	consideration	in	decreasing	fear	of	falling	in	PD	individuals	(Lindholm	et	al.,	2014).	
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Furthermore,	we	can	speculate	this	acute	increase	in	somatosensory	feedback	is	a	result	of	the	added	texture	to	the	orthotic	device.	Specific	to	the	turning	performance	variables	(step	count	and	average	velocity),	the	increase	in	somatosensory	feedback	played	a	positive	role	in	the	postural	system’s	ability	to	facilitate	balance	control.		Electromyography	results	are	similar	between	acute	non-texture	and	textured	orthotic	conditions.	Slight	changes	between	average	muscle	activity	are	observed;	however,	these	could	be	equally	attributed	to	the	differences	between	participants	then	to	the	addition	of	texture	to	the	orthotics.	The	addition	of	texture	to	the	orthotics,	and	consequent	increase	in	somatosensory	feedback,	appeared	to	have	no	effect	on	motor	neuronal	output.	Minimal	changes	in	step	length	and	width	were	observed	in	both	acute	orthotic	conditions.			
Long-Term	Non-Textured	Foot	Orthotics	–	Comparison	Between	Week	0-FO	And	Week	4-FO		 All	participants	wore	the	non-textured	foot	orthotic	for	four	weeks.	In	the	analysis	of	COM/BOS,	long-term	FO	wear	resulted	in	a	significant	increase	in	maximum	ML,	and	small	non-significant	increases	in	minimum	ML	and	COM/BOS	ML	range.	In	returning	to	the	adopted	definition	of	stability,	a	body	is	considered	balanced	when	the	COM	falls	within	the	BOS.	More	specifically,	a	body	is	considered	more	stable	when	the	distance	between	the	COM	and	the	lateral	base	of	support	increases,	consequently	increasing	the	stability	margin		(Perry	et	al.,	2008).	Study	results	indicate	larger	maximum	ML	COM/BOS	values	in	the	long-term	FO	condition,	suggesting	that	participants	experienced	increased	stability	with	prolonged	orthotic	wear.	It	is	important	to	note,	that	these	results	are	being	compared	to	the	acute	FO	condition,	which	experienced	a	slight	decrease	in	maximum	ML	data.	Improvements	in	COM/BOS	are	also	observed	when	compared	to	the	Week	0-F	condition.	Turning	performance	results	reflect	a	similar	interpretation.	Step	count	between	acute	and	long-term	orthotic	wear	are	very	similar;	however	significantly	less	steps	were	used	to	complete	turns	compared	to	the	footwear	only	condition.	Consistent	with	acute	findings,	no	changes	were	noted	in	step	length	and	width.	
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The	observed	changes	in	walking	velocity	are	quite	interesting.	Long-term	orthotic	wear	(week	4-FO)	revealed	significant	increases	in	walking	velocity	compared	to	the	acute	orthotic	condition	(week	0-FO).	However,	the	average	velocity	in	the	week	4-FO	condition	is	still	slower	than	the	week	0-F	condition.	These	results	suggest	that	participant’s	walking	speed	was	faster	with	long-term	orthotic	wear	compared	to	short-term	wear;	however,	speed	had	yet	to	return	to	their	normal	walking	velocity	in	the	footwear-only	condition.	Participants	were	still	adopting	a	more	cautious	walking	pattern	4	weeks	after	wearing	the	orthotics.		 EMG	analysis	in	the	long-term	orthotic	condition	revealed	significant	increases	in	ipsilateral	tibialis	anterior	and	ipsilateral	peroneus	longus	average	muscle	activation,	accompanied	by	significant	decreases	in	ipsilateral	medial	gastrocnemius	activity.	During	typical	static	stance	perturbations,	the	gastrocnemius	has	a	strong	compensatory	reaction,	followed	by	increased	tibialis	anterior	activation.	In	Parkinson’s	disease	individuals,	this	secondary	tibialis	anterior	activation	is	stronger	than	in	healthy	age-matched	controls	(Dietz,	Zijlstra,	Assaiante,	Trippet,	&	Berger,	1993).	Decreased	medial	gastrocnemius	activity	is	a	positive	suggestion	that	muscular	response	is	not	compensatory	in	nature;	however,	without	isolating	results	to	the	specific	phases	of	static	stance,	this	interpretation	is	speculative	in	nature.	If	this	interpretation	is	accurate,	the	increased	tibialis	anterior	activity	can	be	attributed	to	the	increased	sensory	response	between	the	plantar	foot	sole	and	orthotic	device.	A	possible	explanation	for	this	muscle	activity	behavior,	is	the	increased	demand	of	tibialis	anterior	in	decelerating	the	forefoot	to	the	ground.	As	previously	explained,	the	foot	orthotic	places	the	subtalar	joint	in	a	more	supinated	position,	and	the	peroneus	longus	may	partially	resist	this	supinatory	action.	In	comparing	week	0-FO	to	week	4-FO,	significant	increases	in	peroneus	longus	activity	are	noted.	However,	when	comparing	these	mean	values	to	week	0-F,	peroneus	longus	activity	has	simply	returned	to	baseline	values	(footwear	only	condition),	suggesting	adaptation	throughout	the	4-weeks	of	orthotic	wear.		
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Long-Term	Textured	Foot	Orthotics	–	Comparison	Between	Week	4-FOT	and	Week	5-FOT	All	dynamic	balance	variables,	including	maximum,	minimum,	and	ML	range,	progressively	improved	throughout	each	orthotic	condition	in	the	study	(See	COM/BOS	results	in	tables	3,	4,	and	5).	Significant	difference	between	acute	FOT	and	long-term	FOT	conditions	were	not	observed,	however	I	would	argue	that	clinically	important	changes	are	observed	between	both	long-term	FO/FOT	and	footwear-only	conditions.	Consistent	with	previous	research,	this	continued	improvement	suggests	that	postural	control	progressively	improved	with	long-term	orthotic	wear,	and	with	the	addition	of	texture	(Jenkins	et	al.,	2009).	I	would	encourage	the	consideration	of	a	participant’s	foot	width	in	evaluating	the	COM/BOS	results.	Two-centimeter	changes	are	being	observed	between	COM/BOS	variables.	It	remains	at	the	discretion	of	clinicians	to	determine	if	these	differences	are	clinically	significant,	and	if	there	is	practical	application	in	patient	treatment.	A	continued	decrease	in	step	count	was	progressively	observed	throughout	the	study;	however	minimal	changes	were	noted	between	acute	and	long-term	FOT	conditions.	The	1	week	of	FOT	wear	had	minimal	effect	on	step	count;	however	there	remained	approximately	1	step	less	in	turn	completion	compared	to	the	footwear	only	condition.	A	small	progressive	decrease	in	step	width	is	observed,	along	with	minimal,	non-significant	changes	to	step	length.	In	this	final	testing	week,	participant’s	average	walking	velocity	resulted	in	small	increases	in	speed	compared	to	acute	FOT,	and	returned	to	similar	values	as	the	footwear-only	condition.	Overall,	PD	individuals	demonstrated	mean	increases	in	the	COM/BOS	variables,	along	with	decreases	in	step	count	and	a	return	to	normal	average	walking	velocity.	These	long-term	FOT	results	suggests	that	adding	texture	under	the	plantar	foot	sole	had	a	role	in	increasing	somatosensory	activity,	and	further	facilitating	motor	response.	This	is	an	interesting	consideration	for	future	textured	top	cover	research.	In	EMG	analysis,	the	average	muscle	activity	of	the	ipsilateral	tibialis	anterior	consistently	increased.	Greater	muscle	activity	is	suggestive	of	a	greater	need	to	decelerate	ankle	dorsiflexion,	implying	that	long-term	use	of	orthotics	may	help	PD	individual’s	reach	a	more	typical	heel-to-toe	walking	pattern.	Secondly,	the	average	muscle	activity	of	the	contralateral	tibialis	anterior,	during	the	swing	phase	of	gait,	
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has	returned	its	activity	to	baseline	(week	0-FO).	The	medial	gastrocnemius	activity	remained	activated.	Once	again,	it	is	hypothesized	that	this	increased	activity	occurred	at	toe-off.	This	behavior	is	consistent	with	the	observed	increase	in	walking	velocity;	however,	a	closer	breakdown	of	timing	in	the	stance	phase	is	required	to	make	definitive	conclusions.	A	consideration	of	muscular	co-contraction	and	the	activity	of	agonist	vs.	antagonist	muscle	activity	merits	closer	analysis.		The	textured	orthotics	weight	and	volume	within	participant’s	footwear	are	important	considerations	when	evaluating	these	long-term	FOT	results.	The	difference	in	weight	between	the	Sole	orthotic	with	and	without	texture	was	131.4g.	Without	the	comparison	of	different	weighted	orthotics,	we	cannot	attribute	EMG	results	solely	to	long-term	FOT	exposure.	Larger	changes	in	EMG	activity	are	expected	during	the	swing	phase	of	gait	(as	the	limb	is	required	to	lift	greater	weight	off	the	ground),	however	muscular	fatigue	could	equally	occur	with	prolonged	FOT	wear.	Secondly,	the	textured	orthotics	filled	greater	volume	within	participant’s	footwear	compared	to	the	FO	condition.	Experimental	studies	and	footwear	reviews	have	evaluated	various	footwear	features	in	hopes	to	optimize	balance	in	older	adults.	The	literature	suggests	that	harder	midsole	materials	and	low	heel	collars	improves	dynamic	stability	(Branthwaite,	Chockalingam,	Greenhalgh,	et	al.,	2013;	Hijmans,	Geertzen,	Dijkstra,	&	Postema,	2007;	Perry,	Radtke,	&	Goodwin,	2007).	The	FOT	condition	had	a	harder	durometer	than	the	footwear	only	condition	(F),	however	greater	material	compliance	than	the	FO	condition.	Maximizing	forefoot	volume	within	a	shoe’s	toe	box	decreases	the	likelihood	of	unwanted	forefoot	pressure	(Branthwaite,	Chockalingam,	&	Greenhalgh,	2013).	When	comparing	previous	literature	to	the	thickness	and	weight	of	the	textured	orthotics,	further	research	into	the	textured	top	cover	selection	is	required	to	maximize	balance	improvements.			
Additional	Observations	The	step	turn	strategy	was	adopted	consistently	across	all	experimental	conditions.	Minimal	conclusions	can	be	made	regarding	stepping	strategy,	as	this	appeared	to	be	the	preferred	turning	behavior	
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prior	to	both	orthotic	interventions.	As	the	step	turn	is	considered	more	stable	than	the	spin	turn,	it	is	not	surprising	that	Parkinson’s	individuals	self-select	this	turning	behavior.	Interestingly,	the	step	turn	was	adopted	regardless	of	braking	foot	side	and/or	turn	direction.	With	the	majority	of	participants	using	their	ipsilateral	limb	as	the	braking	foot,	these	results	suggest	an	adaptation	in	walking	behavior	occurred	in	the	ambulation	preceding	the	braking	step.	When	turning	in	their	non-dominant	direction,	stride	length	or	walking	velocity	adapted	to	ensure	their	ipsilateral	limb	was	the	final	forward	facing	step	prior	to	initiating	the	turning	movement.	It	is	unclear	if	this	behavior	was	a	conscious	compensatory	change	or	a	neuromuscular	adaptation	to	the	preferred	braking	limb.			
Final	Remarks	When	initially	placing	foot	orthotics	(non-textured	or	textured)	under	PD	participant’s	feet,	it	appeared	the	body	felt	a	small	threat	to	its	balance	system.	Dynamic	stability	experienced	a	slight	disturbance;	however,	posed	no	detrimental	threats	to	turning	performance	behavior.	Rather	than	interpreting	these	results	negatively,	I	would	encourage	an	evaluation	of	the	neurological	system’s	response	to	balance	equilibrium.	A	potential	explanation	for	this	disturbance	is	the	nervous	system	signaling	the	need	for	a	balance	adaptation,	as	a	method	of	returning	the	body	to	its	more	comfortable	state	of	equilibrium.	Changes	in	muscle	activity	are	required	to	regulate	the	relationship	between	the	COM	and	BOS	(Maki	&	McIlroy,	1996).	These	results	suggest	that	the	acute	wear	of	orthotics,	with	and	without	texture,	triggers	a	neuromuscular	compensatory	reaction,	whereby	the	body	is	required	to	adjust	its	state	of	equilibrium.	Muscular	adaptation	appears	complete	during	the	long-term	FO	condition,	and	adding	texture	to	the	orthotics	appeared	to	increase	the	sensory	information	available	to	the	motor	system,	facilitating	the	central	nervous	system’s	ability	to	adapt	to	postural	changes.	See	Figure	22.		
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Figure	18:	A	graphical	interpretation	of	the	neuromuscular	changes	across	orthotic	conditions.	
	Consequently,	there	appeared	to	be	no	negative	effects	from	both	acute	orthotic	considerations;	an	important	finding	for	rehabilitations	professionals.	The	small	balance	fluctuations	in	the	acute	stages	of	orthotic	wear	can	be	communicated	to	patients	when	initially	dispensing	orthotics.	Prolonged	orthotic	wear	appeared	to	regulate	these	fluctuations.	To	further	understand	these	results,	a	final	statistical	analysis	was	run	between	baseline,	week	0-F	and	long-term	textured	orthotics,	week	5-FOT	(see	Appendix	K	for	complete	result	table).	The	FOT	condition	appeared	to	significantly	increase	the	COM/BOS	ML	range	and	significantly	decrease	step	count.	This	is	suggestive	of	greater	COM/BOS	between-condition	variability,	and	improved	walking	confidence	when	completing	the	turns.	Statistical	significance	is	observed	across	all	ipsilateral	musculature.	Increased	activity	is	observed	in	the	tibialis	anterior	and	medial	gastrocnemius	muscles,	with	a	decreased	activity	in	the	peroneus	longus.	The	addition	of	texture	to	the	orthotics	appeared	to	increase	sensory	input,	consequently	increasing	motor	output	availability.		 	
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CHAPTER	5:	CONCLUSIONS		
	 The	balance	impairments	of	individuals	with	Parkinson’s	disease	are	a	large	contributing	factor	to	increased	fall	risks.	The	somatosensory	system’s	role	in	balance	control,	and	manipulations	at	the	plantar	sole	of	the	foot,	has	proven	effective	in	facilitating	sensory	response.	These	study	results	suggest	that	orthotics	and	added	texture	may	increase	sensory	augmentation,	and	provide	a	potential	treatment	option	for	PD.	This	is	the	first	study	to	combine	orthotics	and	added	texture	towards	the	improvement	of	balance	parameters,	in	either	non-pathological	or	pathological	populations.			 The	use	of	non-textured	foot	orthotics	appeared	to	impair	stability	short-term;	however,	improve	long-term	stability.	Similar	patterns	were	observed	with	the	addition	of	texture,	with	greater	stability	improvements	in	the	textured	condition.	Regardless	of	non-significant	findings	among	some	balance	variables,	these	results	increase	our	clinical	understanding	of	the	underlying	adaptation	process	to	acute	and	long-term	orthotic	wear.	Improvements	in	turning	performance	were	noted	by	a	decreased	step	count	and	increased	walking	velocity.	Progressive	improvements	were	observed	across	conditions,	suggesting	larger	improvements	are	associated	with	prolonged	orthotic	(non-textured	and	textured)	wear.	Both	orthotic	conditions	altered	the	average	magnitude	of	key	lower	limb	muscles	during	single	stance.	Isolating	muscular	activity	to	distinct	phases	within	single	stance,	will	further	clarify	specific	muscular	behavior	during	ambulation.				 Clinically,	the	addition	of	texture	to	orthotics	may	be	a	way	to	facilitate	the	sensory	system	to	increase	motor	output	in	PD	individuals,	while	retaining	similar	balance	and	performance	benefits	as	non-textured	orthotics.	It	is	important	to	note	that	this	interpretation	cannot	be	generalized	to	all	orthotic	scenarios;	however,	can	be	applied	to	PD	turning	behavior.	Secondly,	the	differentiation	between	statistical	significance	versus	clinical	significance	should	be	highlighted.	Statistical	significance	is	not	observed	across	all	COM/BOS	variables,	however	a	2cm	difference	within	this	vulnerable	population	is	an	improvement	in	the	right	direction.	For	rehabilitation	professionals,	these	results	provide	initial	evidence	of	using	orthotics,	with	and	without	a	textured	top	cover,	as	a	cost-effective	treatment	option	for	PD	patients.	Non-textured	
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and	textured	orthotics	appear	to	have	improved	gait	parameters	and	dynamic	balance,	which	can	hopefully	translate	into	decreased	fear	of	falling	and	improve	PD	individual’s	quality	of	life.	
Limitations		 This	research	study	leaves	a	few	questions	unanswered.	Does	an	individual	require	an	initial	accommodation	period	to	non-textured	orthotics,	prior	to	adding	a	textured	top	cover?	This	study	demonstrated	an	important	accommodation	period,	whereby	the	body	required	time	to	adapt	to	the	changes	under	the	plantar	sole	of	the	foot.	The	textured	orthotics	were	dispensed	following	this	non-textured	orthotic	accommodation	period.	If	textured	orthotics	were	dispensed	without	prior	foot	orthotic	experience,	would	this	accommodation	period	increase?	I	would	exercise	caution	in	the	immediate	dispensing	of	textured	orthotics	in	these	conditions,	as	it	remains	unclear	if	the	threat	to	balance	disturbances	would	be	large	enough	to	increase	fall	risks.	 		 The	results	of	this	study	are	limited	to	idiopathic	Parkinson’s	patients.	Further	research	is	required	for	individuals	diagnosed	with	early	onset	PD	and	to	generalize	these	results	to	healthy	older	adults.	EMG	muscle	activity	is	only	being	recorded	for	three	muscles:	the	tibialis	anterior,	peroneus	longus,	and	gastrocnemius.	Previous	research	has	revealed	a	decrease	in	muscular	activity	to	these	muscles	under	diminished	cutaneous	sensation	(Eils	et	al.,	2004),	and	consequently,	were	intentionally	selected	in	this	study.	Further	research	could	evaluate	the	effects	of	orthotics,	with	and	without	a	textured	top	cover,	on	other	lower	limb	muscles.		 The	role	of	footwear	merits	discussion,	as	participants	wore	their	own	walking	shoes	in	the	study.	Variations	in	participant’s	footwear	are	unavoidable	and	important	to	highlight	as	a	study	limitation.	Footwear	has	shown	to	play	a	role	in	increasing	somatosensory	response	in	older	adults,	by	improving	lateral	stability,	thus	decreasing	fall	risks	within	this	demographic	(Hatton,	Rome,	Dixon,	Martin,	&	McKeon,	2013).	Secondly,	participants	were	asked	to	wear	footwear	during	95%	of	their	weight-bearing	activities.	In	other	words,	footwear	was	worn	in	and	out	of	the	house,	not	a	typical	behavior	for	all	study	participants.	If	the	supportive	footwear	increased	self-perceptions	of	support	and	walking	self-efficacy,	these	factors	
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alone	could	have	decreased	fear	of	falling.	Consequently,	within	this	study,	it	is	difficult	to	isolate	the	influence	of	orthotics	alone,	and	footwear	must	be	taken	into	consideration	when	interpreting	results.	
Future	Research		 This	research	study	opens	the	door	to	additional	research	questions.	As	mentioned	throughout	this	thesis,	the	EMG	activity	within	individual	phases	of	single	stance	is	an	important	next	step	in	understanding	muscular	behavior.	The	turning	tasks	were	a	planned	behavior,	whereby	participants	balance	system	had	the	ability	to	pre-program	and	adapt	to	the	upcoming	turning	task.	Future	research	can	consider	the	effects	of	neurological	control	on	preplanned	tasks	versus	those	that	pose	a	larger	threat	to	the	disturbance	of	the	balance	system.	Variables	of	interest	were	isolated	to	the	braking	foot,	the	final	forward	facing	step	prior	to	initiating	the	turn.	Additional	research	is	required	during	different	analysis	windows,	more	specifically,	the	stance	phases	of	each	step	completing	the	turn.			 Additional	research	is	required	in	orthotics	and	textured	top	covers.	The	optimal	combination	of	orthotic	+	textured	top	cover	remains	undetermined.	It	is	unclear	if	larger	benefits	would	be	observed	between	custom	orthotics	and	over-the-counter	devices.	Furthermore,	different	top	cover	materials,	textured	designs,	and	weight	of	materials,	all	merit	further	exploration.	Lastly,	the	benefits	of	textured	orthotic	are	worth	exploring	in	other	neurological	disorders	and	healthy	populations.			 	
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APPENDICES	
	
Appendix	A:	The	Somatosensory	System	Somatosensory	receptors,	located	throughout	the	body,	provide	the	afferent	feedback	to	the	central	nervous	system	required	for	the	performance	of	human	movement.	More	specifically,	sensory	receptors	transform	stimuli	into	electrical	energy,	and	transmit	this	sensory	information	to	the	supraspinal	structures	and	cerebral	cortex.	There	are	four	types	of	receptors	responsible	for	somatic	sensation	response:	1)	cutaneous	and	subcutaneous	mechanoreceptors;	2)	thermoreceptors;	3)	nociceptors,	and	4)	muscle	and	skeletal	mechanoreceptors.	Each	receptor	type	transforms	energy	to	the	central	nervous	system	via	one	sensory	modality.	Each	modality	has	a	specific	pathway	dedicated	to	their	receiving	stimulus.	In	balance	control,	proprioceptors	and	mechanoreceptors	are	most	important,	responding	to	muscle	length	and	force	changes,	joint	angle	changes,	and	skin	deformation	(Gardner	&	Johnson,	2013a).		The	mechanoreceptors	in	the	feet,	and	the	proprioceptors	located	in	our	muscles	and	joints	have	important	roles	in	the	response	to	postural	changes.	Proprioceptors	When	there	is	a	threat	to	the	body’s	state	of	equilibrium,	in	static	and	dynamic	movement,	muscle	spindles	and	golgi	tendon	organs	(GTO’s)	sense	the	threat	to	the	body’s	state	of	equilibrium,	and	activate	to	assist	in	the	control	of	balance	and	awareness	of	body	segments	relative	to	their	position	in	space.	Muscle	spindle	afferents	detect	both	the	speed	and	amplitude	of	voluntary	muscle	contractions,	along	with	passive	limb	movement	from	external	stimuli,	whereas	GTO’s	respond	to	muscle	contraction	force	(E.P.	&	Johnson,	2013).	These	specialized	receptors	play	a	large	role	in	the	neural	mechanisms	responsible	for	controlling	center	of	mass	motion.	When	the	body	experiences	an	unpredicted	disturbance	to	its	state	of	equilibrium,	automatic	postural	adjustments	and	muscle	activation	produce	direction-specific	forces	to	maintain	balance	control.	In	response	to	the	change	in	muscle	and	joint	properties,	length,	speed,	and	force,	spindles	
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and	GTO’s	signal	the	recruitment	of	antagonistic	muscles	and	suppress	the	stretch	reflex	of	others	(Macpherson	&	Horak,	2013).			Mechanoreceptors	There	are	four	types	of	mechanoreceptors	located	in	the	plantar	sole	of	the	foot,	each	responding	to	stimulus	based	on	their	morphology,	innervation	pattern,	and	depth	in	cutaneous	tissue.	These	mechanoreceptors	are	further	subdivided	according	to	their	firing	rate	(slow-adapting	and	fast-adapting	innervating	axons)	and	the	size	of	their	receptive	fields	(type	1	and	type	2).	A	receptive	field	is	defined	as	the	location	on	the	skin	surface	in	which	an	external	stimulus	can	activate	a	sensory	neuronal	response	(Gardner	&	Johnson,	2013b).		
Merkel	cells/SA1.	Merkel	cells	are	small	epithelial	cells,	clustered,	and	surrounding	sweat	ducts	in	superficial	glabrous	skin.	They	respond	to	deformation	and	pressure	on	the	skin.	They	are	sensitive	in	detecting	edges,	corners,	points	and	curve	stimulus,	providing	sensory	information	on	object	shape,	size,	and	texture	(Gardner	&	Johnson,	2013b).	They	are	slow-adapting	receptors,	where	firing	rate	is	highest	at	initial	stimulus	detection.	With	the	application	of	continuous	pressure,	slow-adapting	mechanoreceptors	will	provide	continuous	neurological	response,	however,	when	the	stimulus	is	removed,	the	firing	terminates.	The	action	potential	firing	is	proportional	to	the	application	of	stimulus	pressure	(Gardner	&	Johnson,	2013a).		As	a	type	1	receptor,	Merkel	cells	have	small	and	localized	receptive	fields,	with	many	highly	sensitive	areas	(Gardner	&	Johnson,	2013b).	
Meissner	corpuscle/RA1.	Meissner	corpuscles	are	fluid	filled	globular	receptors,	enclosing	lamellar	cells,	and	located	within	the	papillary	ridges	of	superficial	skin.	These	receptors	are	highly	sensitive	to	lateral	motion	stimulus,	and	have	similar	receptive	fields	are	SA1	mechanoreceptors	(Gardner	&	Johnson,	2013b).	Meissner	corpuscles	are	fast-adapting	receptors,	where	action	potential	response	is	only	present	at	the	onset	and	termination	of	the	stimulus.		Consequently,	RA1	neurons	inform	the	somatosensory	system	when	a	stimulus	touches	the	skin	and	once	the	stimulus	is	removed.	There	is	no	firing	during	continual	pressure	(Gardner	&	Johnson,	2013a).			
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Ruffini	endings/SA2.	Ruffini	endings	are	located	deep	in	the	dermal	tissue	of	the	skin.	These	receptors	are	elongated	in	shape	and	surround	collagen	fibrils.		Type	2	receptors	are	larger	than	type	1,	have	broader	receptive	fields,	and	only	one	area	of	high	sensitivity.	This	mechanoreceptor	activation	is	greatest	when	a	stimulus	is	placed	directly	over	these	area	of	high	sensitivity	(Gardner	&	Johnson,	2013a).	Ruffini	endings	respond	to	skin	stretch,	and	as	a	slow-adapting	receptor,	will	provide	continual	action	potential	response	to	continual	pressure.		
Pacinian	corpuscle/RA2.	The	Pacinian	corpuscle	is	the	most	sensitive	receptor	in	the	somatosensory	system,	responding	to	vibratory	stimulation.	They	are	located	in	subcutaneous	tissue	and	are	formed	of	layered	connective	tissue	separated	by	fluid-filled	space	(Gardner	&	Johnson,	2013b).	They	are	rapid-adapting	type	2	receptors.			
	
		 	
			
Appendix	B:	Recruitment	Poster	VOLUNTEERS	NEEDED							PARKINSON’S	DISEASE	STUDY		The	purpose	of	this	study	is	to	increase	clinical	knowledge	of	the	relationship	between	increased	plantarsensory	information	and	orthotics	in	a	Parkinsonian	gait.	Research	findings	can	increase	clinical	treatment	options	goaled	at	improving	balance,	functional	mobility	and	decreasing	fall	risks	in	the	Parkinson’s	community.			This	study	requires	the	participation	of	individuals	(55-75	yrs	of	age)	diagnosed	with	idiopathic	Parkinson’s	disease.	Each	volunteer	will	be	asked	to	participate	in	a	pedorthic	clinical	assessment	and	perform	various	walking	and	balance	tasks	in	the	biomechanics	lab.	The	total	time	commitment	is	approximately	8	hours,	
spread	over	4	different	assessment/testing	days.	The	study	will	take	5	weeks	to	complete.			During	the	testing	sessions,	participants	will	have	orthotics	placed	in	their	footwear,	and	sensors	placed	on	their	clothing	and	skin.	Participants	will	be	compensated	with	paid	parking,	and	two	pairs	of	orthotics	for	their	participation.		For	further	information	or	to	volunteer,	please	e-mail:	Parkinson’s	Study	at	biomch@wlu.ca	Or	leave	a	message	at	884-0710	ext	2370.		This	project	has	been	reviewed	and	approved	by	the	University	Research	Ethics	Board	(REB#5082),	and	registered	as	a	clinical	trial	(Clinicaltrial.gov	Identifier	No:	NCT02809391).		
Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370	Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		Parkinson’s	Study	 (biomch@wlu.ca)	Or	leave	a	message	at	884-0710	x2370		
			
Appendix	C:	Pre-Screening	Questionnaire	
		
SCREENING	QUESTIONNAIRE	
	
	
Participant	#	_______________	 	 	
	
Date:	(MM/DD/YYYY):		 	 	 	 	 	,		 	 	 	 	 	,		 	 	 	 	 	
	
Name:	 	 	 	 	 	 	
	
Address:		 	 	 	 	 	
	
	 		 	 	 	 	 	
	
City,	Province:		 	 	 	 	 ,		 	 	 	 	 	Postal	Code		 	 	 	 	 	
	
Tel	#:	 (	 	 	 	 	 )-	 	 	 	 	 	Best	time	to	call:		 	 	 	 	 	
	
Email	address:		 	 	 	 	 	
	
Preferred	method	of	communication:		 	 	 	 	 	
	
	
This	information	will	be	kept	separate	from	the	remainder	of	this	document
			
SCREENING	QUESTIONNAIRE	
	
Participant	#	_____________	
	 	
Date:	(MM/DD/YYYY):		 	 	 	 	 	,		 	 	 	 	 	,		 	 	 	 	 	
	
	
VOLUNTEER	EXCLUSION	CRITERIA	
	
	
Age:	 	 	 	 	 	 	yrs.		 Height:		 	 	 	 	 	cm	 Weight:		 	 	 	 	 	kg	 Shoe	Size:		 	 	 	 	 	
	
Gender:	 M	 	 F	 	
	
	 	
Do	you	use	an	assistive	device	for	mobility	purposes?			 	 	 	select	 	
	 	 	 	 	 	 	 	 	 	
How	dependent	are	you	upon	your	assistive	device?	
	 I	always	use	it		 	 	 I	use	it	sometimes		 		 I	hardly	use	it		 	 	
	 	
	
Can	you	walk	10m	without	your	assistive	device?	 	 	 	 select	 	
	
Do	you	have	a	health	care	provider	helping	you	with	walking?	 	 select	
	
Do	you	have	any	conditions	that	limit	the	use	of	your	arms	or	legs?		 select	 	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 						little	or	 	 				a	great	
	 	 	 	 	 	 	 	 	 						none	 									moderate	 				deal	
If	yes,	how	much	does	the	condition	interfere	with	your	activities?		 			 																 																				 	
	
Please	describe:		 	 	 	 	 	
	
Have	you,	within	the	last	two	years,	or	currently	wear	orthotics?	 	 select	 	
	
	 	 	 	 	 	 	 	 	
Do	you	have	or	have	you	ever	had:	 	 	 																	 Please	check	all	that	applies	
	 a)	 paralysis	 	 	 	 	 	 	
	 b)	 epilepsy	 	 	 	 	 	 	 	
	 c)	 cerebral	palsy	 	 	 	 			 	 	
	 d)	 multiple	sclerosis	 	 	 	 	 	
	 e)	 stroke	 	 	 	 	 	 	 	
	 f)	 any	other	neurological	disorder			 	 	 	 	 	 	 	 	 	 	 	
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	 g)	 diabetes	 	
	 h)	 peripheral	neuropathy	 	 	
	 i)		 spina	bifida	 	 	 	 	 	 	
	 j)		 problems	with	your	vision,	not	corrected	by	glasses	 	
	 k)		 cataract	surgery	 	 	 	 	 	
	 l)		 deep	brain	stimulation	 	 	 	 	
	 m)	 an	inner	ear	disorder	 	 	 	 	 	
	 n)		 hearing	problems	 	 	 	 	 	
	 o)		 constant	ringing	in	your	ears	 	 	 	 	 	
	 p)	 ear	surgery	 	 	 	 	 	 	
	
Have	you	ever	had	any	serious	problems	with	your	memory?	 select	 	
	
Do	you	have	or	ever	had	recurrent	ear	infections?	 	 	 select	 	 	
	
	
Do	you	have	or	have	you	ever	had	:	
	 	 	 	 	 	 	 	 	 	 How	much	does	the	condition	
	 	 	 	 	 	 	 	 	 	 interfere	with	your	activities?	
	 	 	 	 	 	 	 	 	 				
	 	 	 	 	 	 	 	 Y/N	 						little	or	 	 				a	great	
	 	 	 	 	 	 	 	 	 						none	 									moderate	 				deal	
	
	 a)		 problems	with	your	heart	or	lungs	 	 select	 						 	 													 																			 	 	
	 b)	 high	blood	pressure	 	 	 	 select	 						 	 													 																			 	 	
	 c)	 cancer	 	 	 	 	 	 select	 						 	 													 																			 	 	
	 d)		 arthritis	 	 	 	 	 select	 						 	 													 																			 	 	
	 e)		 rheumatism	 	 	 	 	 select	 						 	 													 																			 	 	
	 f)		 back	problems		 	 	 	 select	 						 	 													 																			 	 	
	 g)		 a	joint	disorder	 	 	 	 select	 						 	 													 																			 	 	
	 h)		 a	muscle	disorder	 	 	 	 select	 						 	 													 																			 	 	
	 i)	 a	bone	disorder	 	 	 	 select	 						 	 													 																			 	 	
	 	
	
Have	you	ever	severely	injured	or	had	surgery	on	your	:	
	 	
a)	 head	 	 	 	 	 	 select	 						 	 													 																			 	 	 							
	 b)	 neck	 	 	 	 	 	 select	 						 	 													 																			 	 	
	 c)	 back	 	 	 	 	 	 select	 						 	 													 																			 	 	
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	 d)	 pelvis	 	 	 	 	 	 select	 						 	 													 																			 	 	
	 e)	 ankle,	knee,	or	hip	joints?	 	 	 select	 						 	 													 																			 	 	
	
	
Have	you	ever	broken	any	bones?	 	 	 	 select	 						 	 													 																			 	 	
	
	 Which	ones?	:	 	 	 	 	 	 	
	
	 	 	 	 	 	 	 	 	 	 How	much	does	the	condition	
	 	 	 	 	 	 	 	 	 	 interfere	with	your	activities?	
	 	 	 	 	 	 	 	 	 				
	 	 	 	 	 	 	 	 Y/N	 						little	or	 	 				a	great	
	 	 	 	 	 	 	 	 	 						none	 									moderate	 				deal	
	
Have	you	experienced	a	fall*	within	the	last	6	months?	 select	 						 	 													 																			 	
*A	fall	is	defined	as:	“an	event	which	results	in	a	person	coming	to	rest	inadvertently	on	the	ground	or	floor	or	other	lower	level”	
	
If	yes,	how	many	times?	Please	describe	how	you	fell:		 	 	 	 	 	
	
	 	 	 	 	 	 	 	 	 	 How	much	does	the	condition	
	 	 	 	 	 	 	 	 	 	 interfere	with	your	activities?	
	 	 	 	 	 	 	 	 	 				
	 	 	 	 	 	 	 	 Y/N	 						little	or	 	 				a	great	
	 	 	 	 	 	 	 	 	 						none	 									moderate	 				deal	
Have	you	had	any	recent	(specify)	
	 a)		 illnesses	 	 	 	 	 select	 						 	 													 																			 	
	 b)		 injuries		 	 	 	 	 select	 						 	 													 																			 	
	 c)		 operations	 	 	 	 	 select	 						 	 													 																			 	
	 d)	 gait	retraining	 	 	 	 	 select	 						 	 													 																			 	
	
	
	
Do	you	have	difficulties	performing	any	daily	activities?							select	 						 	 													 																			 	 	
	
Which	activities?:				 	 	 	 	 	
	
	
Are	you	currently	taking	any	medications	(prescription	or	over-the-counter),	or	other	drugs?	
	
	 Medication	 	 	 	 Ailment	 	 	 Frequency	of	use		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
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Appendix	D.	Informed	Consent		
INFORMED	CONSENT	STATEMENT		 WILFRID	LAURIER	UNIVERSITY	INFORMED	CONSENT	STATEMENT		
Orthotics	and	Parkinson's	Disease:	The	Acute	and	Long-term	Effects	of	Increased	Somatosensory	
Feedback			Principle	Investigator:	Kelly	Robb	Supervisor:	Dr.	Stephen	Perry,	Associate	Professor	and	Faculty	Researcher		We	welcome	your	participation	in	the	following	research	study.	The	purpose	of	this	study	is	to	increase	clinical	knowledge	of	the	relationship	between	increased	plantarsensory	information	and	orthotics	in	a	Parkinsonian	gait.	Research	findings	can	increase	clinical	treatment	options	goaled	at	improving	balance,	functional	mobility	and	decreasing	fall	risks	in	the	Parkinson's	community.		
INFORMATION		You	will	be	asked	to	participate	in	an	initial	screening	appointment.	During	this	appointment,	your	footwear	will	be	evaluated,	and	you	may	complete	two	questionnaires:	the	‘Unified	Parkinson’s	Disease	Rating	Scale	(UPDRS),	and	the	Montreal	Cognitive	Assessment	Tool	(MoCA).	These	questionnaires	evaluate	your	experiences	of	daily	living	and	cognitive	impairment.	UPDRS	results	do	not	effect	study	participation,	and	will	only	be	administered	if	required.	A	score	of	26	on	the	MoCA	questionnaire	is	required	for	study	participation.	A	pedorthic	assessment	will	follow.	Observations	will	be	made	while	you	stand	and	walk.	You	will	be	asked	to	participate	in	basic	physical	testing,	and	measurements	will	be	taken,	as	your	feet	are	moved	through	a	series	of	range	of	motion	exercises.	A	thin	monofilament	will	be	pressed	to	different	areas	on	the	bottom	of	your	foot.	This	will	measure	you	level	of	sensation,	and	should	not	cause	any	pain.	During	this	assessment,	you	can	choose	to	stop	anytime,	if	you	feel	uncomfortable,	or	experience	any	discomfort	or	pain.	Following	completion,	you	will	be	scheduled	for	3	testing	sessions:	one	booked	immediately,	the	2nd	in	4-weeks,	and	the	3rd	in	5-weeks	time.		Each	testing	session	will	be	approximately	2	hours	in	length.	In	the	first	session,	two	pairs	of	orthotics	will	be	customized	to	your	feet.	They	will	be	heated,	placed	in	your	shoes,	and	you	will	be	asked	to	walk	around	the	laboratory.	Four	different	assessments	will	be	performed	during	each	testing	session.	You	will	be	asked	to	perform	a	combination	of	sitting,	standing,	and	walking	tasks,	with	and	without	the	orthotics	provided.	Markers	will	be	placed	on	your	clothing	and	skin.	Between	each	testing	session,	you	will	be	provided	with	instructions	to	wear	one	pair	of	orthotics	until	our	next	session	together.	A	self-reported	diary	will	be	encouraged,	documenting	concerns,	level	of	comfort,	daily	orthotic	wear	and	report	of	any	falls.			Approximately	20-25	male	and	female	participants	diagnosed	with	idiopathic	Parkinson’s	disease	will	be	recruited	for	this	experiment.		
RISKS		Physical	risks	of	study	participation	include	loss	of	balance	and	tripping.	The	cable	required	for	EMG	recordings	can	pose	a	tripping	hazard.	You	will	be	asked	to	reach	past	your	comfortable	base	of	support,	step	over	obstacles,	stand	and	sit	from	a	chair,	and	turn	in	different	directions.	All	these	activities	can	increase	the	likelihood	of	you	loosing	balance	and	experiencing	a	fall.	There	is	also	a	potential	of	skin	irritation	from	the	tape	placed	on	your	skin,	which	adheres	the	sensors	and	EMG	electrodes	to	you.	At	the	
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screening	appointment,	minor	muscular	discomfort	is	possible	during	the	range	of	motion	and	physical	testing.	There	is	a	risk	of	you	experiencing	boredom,	frustration	and	anxiety	during	the	questionnaire	completion.	A	loss	of	confidence	is	possible,	during	or	following,	the	completion	of	the	MoCA	questionnaire.	As	domains	of	concentration,	memory	and	visuospatial	abilities	are	evaluated,	you	may	experience	disappointment	in	your	personal	performance.	Emotional	fatigue	and	anxiety	can	occur	during	the	testing	trials.			The	physical	risks	of	loosing	balance	and	experiencing	a	fall	will	be	minimized	with	the	help	of	your	research	assistants.	Assistants	will	walk	beside	you	during	the	testing	trials,	and	as	required,	respond	to	any	loss	of	balance	or	tripping.	Any	required	cables	on	the	ground	will	be	visibly	marked	and	highlighted	to	you.	Excess	cables/wires	will	be	carried.	If	you	have	ever	experienced	skin	irritation	from	tape,	an	alternate	method	of	electrode	adhesion	will	be	used.	If	unknown,	and	skin	irritation	does	occur,	the	skin	will	be	immediately	cleaned.	During	the	screening	appointment,	you	will	be	demonstrated	proper	form	for	all	physical	tests.	Manual	range	of	motion	testing	will	be	evaluated	in	slow,	gradual	movements	of	the	foot/ankle.			Verbal	encouragement	will	be	provided	to	you	during	and	following	the	MoCA	questionnaire,	and	we	ask	that	you	openly	communicate	any	questions	or	concerns	during	any	questionnaire.	To	limit	boredom,	all	the	testing	preparations	will	be	complete	prior	to	your	arrival	in	the	biomechanics	lab.	Ongoing	communication	will	take	place	between	the	you	and	your	caregiver.	Rest	periods	will	be	planned	between	each	testing	session,	and	available	to	you	upon	request.	To	decrease	testing	anxiety,	each	testing	trial	will	be	verbally	explained	to	you,	demonstrated	if	required,	and	all	questions	will	be	answered	prior	to	beginning.			
BENEFITS		This	proposed	study	provides	increased	knowledge	of	the	relationship	between	increased	plantarsensory	information	and	orthotics	in	a	Parkinsonian	gait.	Observing	gait	parameters	and	muscle	activation	changes,	in	orthotics	with	and	without	a	textured	top	cover,	provides	an	increased	understanding	of	conservative	treatment	options	available	to	the	Parkinson’s	population.	Research	findings	can	increase	clinical	treatment	options	goaled	at	improving	balance,	functional	mobility	and	fall	risks	in	the	Parkinson's	community.	Results	can	be	further	applied	to	individual	experiencing	sensory	deficits	and	older	adults	experiencing	frequent	falls.			
CONFIDENTIALITY			During	the	recruitment	process,	directly	identifying	information	will	be	collected.	Your	name	and	phone	number	are	required	for	scheduling	the	screening	appointment	and	testing	sessions.	Once	study	eligibility	is	confirmed,	your	identifying	information	will	be	replaced	by	a	code,	which	will	replace	your	true	identity	for	the	remainder	of	the	study.	Your	true	identity	will	only	be	known	by	your	caregiver,	Kelly	Robb	and	Dr.	Stephen	Perry.	In	the	event	of	study	publication,	findings	will	be	summarized	as	group	effects,	rather	than	individual	participant	results.	All	participants	shall	remain	anonymous	in	all	publications,	presentations,	posters…etc.		Your	personal	information	linked	to	your	participant	code	will	be	stored	in	a	locked	cabinet.	In	a	separate	cabinet,	all	coded	data	and	result	collection	will	be	stored.	In	the	event	that	research	assistants	are	involved	in	the	experimental	protocol,	data	collection,	or	analysis,	they	will	not	have	access	to	your	true	identity.	Electronic	data	and	video	recordings	will	be	stored	on	a	password	protected	computer.	All	data	will	be	stored	in	the	Biomechanics	Lab	(SR	119)	in	the	Laurier	Science	Research	Centre.	This	biomechanics	lab	has	
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controlled	access,	required	a	number	code	to	gain	access.	All	data	will	be	retained	for	five	years	following	all	necessary	analysis,	reports,	and	publication.		
	
IMAGES		Images	may	be	taken	of	your	feet	and	lower	legs	during	your	pedorthic	assessment	and	testing	sessions.	These	images	allow	for	supplementary	information	during	the	analysis	process.	No	directly	identifying	information	will	be	linked	to	these	images.	
	
VIDEOTAPING		In	an	effort	to	minimize	data	collection	errors,	certain	assessments	require	specific	foot	placement	on	the	force	plates	under	your	feet.	You	may	be	videotaped	below	the	shoulders,	allowing	the	availability	of	video	review	if	required.	These	videos	may	also	be	used	for	presentations	and	educational	conferences	following	the	completion	of	the	study.	All	videos	will	be	coded,	removing	all	personal	information,	and	ensuring	the	removal	of	all	distinguishable	features.	Videos	will	be	stored	in	a	locked	cabinet	in	the	Biomechanics	Lab	(SR	119)	in	the	Laurier	Science	Research	Centre.		
COMPENSATION			Financial	reimbursement	will	be	provided	for	all	parking	fees	while	attending	the	biomechanics	lab.	You	may	keep	all	socks	and	both	pairs	of	custom	orthotics	provided	to	you	during	the	study.		
CONTACT			Shall	you	have	any	questions	or	concerns,	throughout	the	recruitment	process,	screening	or	testing	sessions,	please	do	not	hesitate	to	contact	the	main	researcher,	Kelly	Robb,	at	robb8660@mylaurier.ca,	or	(519)	884-1970,	extension	3298.	This	project	has	been	reviewed	and	approved	by	the	University	Research	Ethics	Board	(REB#5082),	and	registered	as	a	clinical	trial	(Clinicaltrial.gov	Identifier	No:	NCT02809391).		If	you	feel	you	have	not	been	treated	according	to	the	descriptions	in	this	form,	or	your	rights	as	a	participant	in	research	have	been	violated	during	the	course	of	this	project,	you	may	contact	Wilfrid	Laurier’s	University	Research	Ethics	Board,	REB	contact:	Robert	Basso,	PhD	Chair	Research	Ethics	Board	rbasso@wlu.ca	519.884.0710		Extension	4994.		
PARTICIPATION			Participation	in	this	study	is	voluntary,	and	you	may	decline	participation,	without	penalty,	anytime	prior	to	the	start	of	the	study.	Shall	you	choose	to	participate,	you	may	choose	to	withdraw	from	the	study	at	any	time,	without	penalty	and	without	loss	of	benefits	to	which	you	are	otherwise	entitled.		In	instances	of	withdrawal,	every	attempt	will	be	made	to	remove	your	data	from	the	study.	All	confidential	information	will	be	destroyed.	You	have	the	right	to	omit	any	sections	of	questionnaires,	procedures,	and	testing	sessions	you	choose.									
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FEEDBACK	AND	PUBLICATION			The	outcome	of	this	study	may	result	in	potential	publications,	presentations,	and	reports.	Presentations	of	research	outcomes	may	be	made	at	scientific	symposiums,	meetings,	and	poster	presentations.		 Please	indicate	by	checking	the	box	if	you	would	like	to	be	contacted	in	the	future	with	results	of	this	study.			
CONSENT			I	have	read	and	understand	the	above	information.		I	have	received	a	copy	of	this	form.		I	agree	to	participate	in	this	study.		Participant's	signature____________________________________	 Date	_________________		Investigator's	signature__________________________________		 Date	_________________			
CAREGIVER’S		I	am	comfortable	with	having	my	caregiver	present	during	the	screening	appointment	and	testing	sessions.		Participant's	signature____________________________________	 Date	_________________		Caregiver’s	signature	_____________________________________	 Date	_________________		Investigator's	signature__________________________________		 Date	_________________			
CONSENT	TO	VIDEOTAPE	
	I	have	read	and	understand	the	details	surrounding	the	potential	of	images	being	taken	and	being	videotaped.	I	consent	to	having	any	images	or	video	footage	used	in	presentations	and	scientific	conferences.		Participant's	signature____________________________________	 Date	_________________		Investigator's	signature__________________________________		 Date	_________________	 	
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Appendix	E.	MoCA		
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Appendix	F.	Unified	Parkinson’s	Disease	Rating	Scale	(UPDRS)	
	
I.	MENTATION,	BEHAVIOR	AND	MOOD		
1.	Intellectual	Impairment		0	=	None.	1	=	Mild.	Consistent	forgetfulness	with	partial	recollection	of	events	and	no	other	difficulties.	2	=	Moderate	memory	loss,	with	disorientation	and	moderate	difficulty	handling	complex	problems.	Mild	but	definite	impairment	of	function	at	home	with	need	of	occasional	prompting.	3	=	Severe	memory	loss	with	disorientation	for	time	and	often	to	place.	Severe	impairment	in	handling	problems.	4	=	Severe	memory	loss	with	orientation	preserved	to	person	only.	Unable	to	make	judgments	or	solve	problems.	Requires	much	help	with	personal	care.	Cannot	be	left	alone	at	all.		
	
2.	Thought	Disorder	(Due	to	dementia	or	drug	intoxication)		0	=	None.	1	=	Vivid	dreaming.	2	=	"Benign"	hallucinations	with	insight	retained.		3	=	Occasional	to	frequent	hallucinations	or	delusions;	without	insight;	could	interfere	with	daily	activities.		4	=	Persistent	hallucinations,	delusions,	or	florrid	psychosis.	Not	able	to	care	for	self.		
	
3.	Depression		1	=	Periods	of	sadness	or	guilt	greater	than	normal,	never	sustained	for	days	or	weeks.	2	=	Sustained	depression	(1	week	or	more).	3	=	Sustained	depression	with	vegetative	symptoms	(insomnia,	anorexia,	weight	loss,	loss	of	interest).		4	=	Sustained	depression	with	vegetative	symptoms	and	suicidal	thoughts	or	intent.		
	
4.	Motivation/Initiative		0	=	Normal.	1	=	Less	assertive	than	usual;	more	passive.	2	=	Loss	of	initiative	or	disinterest	in	elective	(nonroutine)	activities.		3	=	Loss	of	initiative	or	disinterest	in	day	to	day	(routine)	activities.		4	=	Withdrawn,	complete	loss	of	motivation.		
	
II.	ACTIVITIES	OF	DAILY	LIVING	(for	both	"on"	and	"off")		
5.	Speech		0	=	Normal.	1	=	Mildly	affected.	No	difficulty	being	understood.	2	=	Moderately	affected.	Sometimes	asked	to	repeat	statements.		3	=	Severely	affected.	Frequently	asked	to	repeat	statements.	4	=	Unintelligible	most	of	the	time.		
	
6.	Salivation		0	=	Normal.	1	=	Slight	but	definite	excess	of	saliva	in	mouth;	may	have	nighttime	drooling.		2	=	Moderately	excessive	saliva;	may	have	minimal	drooling.	3	=	Marked	excess	of	saliva	with	some	drooling.	4	=	Marked	drooling,	requires	constant	tissue	or	handkerchief.		
	
7.	Swallowing		0	=	Normal.	1	=	Rare	choking.	2	=	Occasional	choking.	3	=	Requires	soft	food.	4	=	Requires	NG	tube	or	gastrotomy	feeding.		
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8.	Handwriting		0	=	Normal.	1	=	Slightly	slow	or	small.	2	=	Moderately	slow	or	small;	all	words	are	legible.		3	=	Severely	affected;	not	all	words	are	legible.	4	=	The	majority	of	words	are	not	legible.		
	
9.	Cutting	food	and	handling	utensils		0	=	Normal.	1	=	Somewhat	slow	and	clumsy,	but	no	help	needed.	2	=	Can	cut	most	foods,	although	clumsy	and	slow;	some	help	needed.		3	=	Food	must	be	cut	by	someone,	but	can	still	feed	slowly.	4	=	Needs	to	be	fed.		
	
10.	Dressing		0	=	Normal.	1	=	Somewhat	slow,	but	no	help	needed.	2	=	Occasional	assistance	with	buttoning,	getting	arms	in	sleeves.		3	=	Considerable	help	required,	but	can	do	some	things	alone.	4	=	Helpless.		
	
11.	Hygiene		0	=	Normal.	1	=	Somewhat	slow,	but	no	help	needed.	2	=	Needs	help	to	shower	or	bathe;	or	very	slow	in	hygienic	care.	3	=	Requires	assistance	for	washing,	brushing	teeth,	combing	hair,	going	to	bathroom.		4	=	Foley	catheter	or	other	mechanical	aids.		
	
12.	Turning	in	bed	and	adjusting	bed	clothes		0	=	Normal.	1	=	Somewhat	slow	and	clumsy,	but	no	help	needed.	2	=	Can	turn	alone	or	adjust	sheets,	but	with	great	difficulty.		3	=	Can	initiate,	but	not	turn	or	adjust	sheets	alone.	4	=	Helpless.		
	
13.	Falling	(unrelated	to	freezing)		0	=	None.	1	=	Rare	falling.	2	=	Occasionally	falls,	less	than	once	per	day.		3	=	Falls	an	average	of	once	daily.	4	=	Falls	more	than	once	daily.		
	
14.	Freezing	when	walking		0	=	None.	1	=	Rare	freezing	when	walking;	may	have	starthesitation.		2	=	Occasional	freezing	when	walking.	3	=	Frequent	freezing.	Occasionally	falls	from	freezing.	4	=	Frequent	falls	from	freezing.		
	
15.	Walking		0	=	Normal.	1	=	Mild	difficulty.	May	not	swing	arms	or	may	tend	to	drag	leg.		2	=	Moderate	difficulty,	but	requires	little	or	no	assistance.	3	=	Severe	disturbance	of	walking,	requiring	assistance.	4	=	Cannot	walk	at	all,	even	with	assistance.		
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16.	Tremor	(Symptomatic	complaint	of	tremor	in	any	part	of	body.)		0	=	Absent.	1	=	Slight	and	infrequently	present.	2	=	Moderate;	bothersome	to	patient.		3	=	Severe;	interferes	with	many	activities.		4	=	Marked;	interferes	with	most	activities.		
	
17.	Sensory	complaints	related	to	parkinsonism		0	=	None.	1	=	Occasionally	has	numbness,	tingling,	or	mild	aching.	2	=	Frequently	has	numbness,	tingling,	or	aching;	not	distressing.		3	=	Frequent	painful	sensations.	4	=	Excruciating	pain.		
	
III.	MOTOR	EXAMINATION		
18.	Speech		0	=	Normal.	1	=	Slight	loss	of	expression,	diction	and/or	volume.	2	=	Monotone,	slurred	but	understandable;	moderately	impaired.		3	=	Marked	impairment,	difficult	to	understand.	4	=	Unintelligible.		
	
19.	Facial	Expression		0	=	Normal.	1	=	Minimal	hypomimia,	could	be	normal	"Poker	Face".	2	=	Slight	but	definitely	abnormal	diminution	of	facial	expression	3	=	Moderate	hypomimia;	lips	parted	some	of	the	time.	4	=	Masked	or	fixed	facies	with	severe	or	complete	loss	of	facial	expression;	lips	parted	1/4	inch	or	more.		
	
20.	Tremor	at	rest	(head,	upper	and	lower	extremities)	0	=	Absent.	1	=	Slight	and	infrequently	present.	2	=	Mild	in	amplitude	and	persistent.	Or	moderate	in	amplitude,	but	only	intermittently	present.		3	=	Moderate	in	amplitude	and	present	most	of	the	time.		4	=	Marked	in	amplitude	and	present	most	of	the	time.		
	
21.	Action	or	Postural	Tremor	of	hands		0	=	Absent.	1	=	Slight;	present	with	action.	2	=	Moderate	in	amplitude,	present	with	action.	3	=	Moderate	in	amplitude	with	posture	holding	as	well	as	action.		4	=	Marked	in	amplitude;	interferes	with	feeding.		
	
22.	Rigidity	(Judged	on	passive	movement	of	major	joints	with	patient	relaxed	in	sitting	position.	Cogwheeling	to	be	ignored.)	0	=	Absent.	1	=	Slight	or	detectable	only	when	activated	by	mirror	or	other	movements.		2	=	Mild	to	moderate.	3	=	Marked,	but	full	range	of	motion	easily	achieved.		4	=	Severe,	range	of	motion	achieved	with	difficulty.		
	
23.	Finger	Taps	(Patient	taps	thumb	with	index	finger	in	rapid	succession.)	0	=	Normal.	1	=	Mild	slowing	and/or	reduction	in	amplitude.	
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2	=	Moderately	impaired.	Definite	and	early	fatiguing.	May	have	occasional	arrests	in	movement.	3	=	Severely	impaired.	Frequent	hesitation	in	initiating	movements	or	arrests	in	ongoing	movement.		4	=	Can	barely	perform	the	task.		
	
24.	Hand	Movements	(Patient	opens	and	closes	hands	in	rapid	succesion.)	0	=	Normal.	1	=	Mild	slowing	and/or	reduction	in	amplitude.	2	=	Moderately	impaired.	Definite	and	early	fatiguing.	May	have	occasional	arrests	in	movement.	3	=	Severely	impaired.	Frequent	hesitation	in	initiating	movements	or	arrests	in	ongoing	movement.		4	=	Can	barely	perform	the	task.		
	
25.	Rapid	Alternating	Movements	of	Hands	(Pronation-supination	movements	of	hands,	vertically	and	horizontally,	with	as	large	an	amplitude	as	possible,	both	hands	simultaneously.)	0	=	Normal.	1	=	Mild	slowing	and/or	reduction	in	amplitude.		2	=	Moderately	impaired.	Definite	and	early	fatiguing.	May	have	occasional	arrests	in	movement.	3	=	Severely	impaired.	Frequent	hesitation	in	initiating	movements	or	arrests	in	ongoing	movement.		4	=	Can	barely	perform	the	task.		
	
26.	Leg	Agility	(Patient	taps	heel	on	the	ground	in	rapid	succession	picking	up	entire	leg.	Amplitude	should	be	at	least	3	inches.)	0	=	Normal.	1	=	Mild	slowing	and/or	reduction	in	amplitude.		2	=	Moderately	impaired.	Definite	and	early	fatiguing.	May	have	occasional	arrests	in	movement.	3	=	Severely	impaired.	Frequent	hesitation	in	initiating	movements	or	arrests	in	ongoing	movement.		4	=	Can	barely	perform	the	task.		
	
27.	Arising	from	Chair	(Patient	attempts	to	rise	from	a	straightbacked	chair,	with	arms	folded	across	chest.)		0	=	Normal.	1	=	Slow;	or	may	need	more	than	one	attempt.	2	=	Pushes	self	up	from	arms	of	seat.		3	=	Tends	to	fall	back	and	may	have	to	try	more	than	one	time,	but	can	get	up	without	help.		4	=	Unable	to	arise	without	help.		
	
28.	Posture		0	=	Normal	erect.	1	=	Not	quite	erect,	slightly	stooped	posture;	could	be	normal	for	older	person.	2	=	Moderately	stooped	posture,	definitely	abnormal;	can	be	slightly	leaning	to	one	side.	3	=	Severely	stooped	posture	with	kyphosis;	can	be	moderately	leaning	to	one	side.	4	=	Marked	flexion	with	extreme	abnormality	of	posture.		
	
29.	Gait		0	=	Normal.	1	=	Walks	slowly,	may	shuffle	with	short	steps,	but	no	festination	(hastening	steps)	or	propulsion.	2	=	Walks	with	difficulty,	but	requires	little	or	no	assistance;	may	have	some	festination,	short	steps,	or	propulsion.		3	=	Severe	disturbance	of	gait,	requiring	assistance.	4	=	Cannot	walk	at	all,	even	with	assistance.		
	
30.	Postural	Stability	(Response	to	sudden,	strong	posterior	displacement	produced	by	pull	on	shoulders	while	patient	erect	with	eyes	open	and	feet	slightly	apart.	Patient	is	prepared.)	0	=	Normal.	1	=	Retropulsion,	but	recovers	unaided.		2	=	Absence	of	postural	response;	would	fall	if	not	caught	by	examiner.		3	=	Very	unstable,	tends	to	lose	balance	spontaneously.	4	=	Unable	to	stand	without	assistance.		
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31.	Body	Bradykinesia	and	Hypokinesia	(Combining	slowness,	hesitancy,	decreased	armswing,	small	amplitude,	and	poverty	of	movement	in	general.)	0	=	None.	1	=	Minimal	slowness,	giving	movement	a	deliberate	character;	could	be	normal	for	some	persons.	Possibly	reduced	amplitude.		2	=	Mild	degree	of	slowness	and	poverty	of	movement	which	is	definitely	abnormal.	Alternatively,	some	reduced	amplitude.	3	=	Moderate	slowness,	poverty	or	small	amplitude	of	movement.	4	=	Marked	slowness,	poverty	or	small	amplitude	of	movement.		
	
IV.	COMPLICATIONS	OF	THERAPY	(In	the	past	week)		
A.	DYSKINESIAS		
32.	Duration:	What	proportion	of	the	waking	day	are	dyskinesias	present?	(Historical	information.)		0	=	None	1	=	1-25%	of	day.	2	=	26-50%	of	day.		3	=	51-75%	of	day.		4	=	76-100%	of	day.		
	
33.	Disability:	How	disabling	are	the	dyskinesias?	(Historical	information;	may	be	modified	by	office	examination.)		0	=	Not	disabling.	1	=	Mildly	disabling.	2	=	Moderately	disabling.		3	=	Severely	disabling.	4	=	Completely	disabled.		
	
34.	Painful	Dyskinesias:	How	painful	are	the	dyskinesias?		0	=	No	painful	dyskinesias.		1	=	Slight.	2	=	Moderate.	3	=	Severe.		4	=	Marked.		
	
35.	Presence	of	Early	Morning	Dystonia	(Historical	information.)		0	=	No	1	=	Yes		
	
B.	CLINICAL	FLUCTUATIONS		
36.	Are	"off"	periods	predictable?		0	=	No		1	=	Yes		
	
37.	Are	"off"	periods	unpredictable?		0	=	No		1	=	Yes		
	
38.	Do	"off"	periods	come	on	suddenly,	within	a	few	seconds?		0	=	No		1	=	Yes		
	
39.	What	proportion	of	the	waking	day	is	the	patient	"off"	on	average?		
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0	=	None	1	=	1-25%	of	day.	2	=	26-50%	of	day.	3	=	51-75%	of	day.	4	=	76-100%	of	day.		
	
C.	OTHER	COMPLICATIONS		
40.	Does	the	patient	have	anorexia,	nausea,	or	vomiting?		0	=	No		1	=	Yes		
	
41.	Any	sleep	disturbances,	such	as	insomnia	or	hypersomnolence?		0	=	No		1	=	Yes		
	
42.	Does	the	patient	have	symptomatic	orthostasis?		(	Record	the	patient's	blood	pressure,	height	and	weight	on	the	scoring	form)		0	=	No	1	=	Yes		
	
V.	MODIFIED	HOEHN	AND	YAHR	STAGING		STAGE	0	=	No	signs	of	disease.	STAGE	1	=	Unilateral	disease.	STAGE	1.5	=	Unilateral	plus	axial	involvement.	STAGE	2	=	Bilateral	disease,	without	impairment	of	balance.	STAGE	2.5	=	Mild	bilateral	disease,	with	recovery	on	pull	test.	STAGE	3	=	Mild	to	moderate	bilateral	disease;	some	postural	instability;	physically	independent.		STAGE	4	=	Severe	disability;	still	able	to	walk	or	stand	unassisted.	STAGE	5	=	Wheelchair	bound	or	bedridden	unless	aided.		
	
VI.	SCHWAB	AND	ENGLAND	ACTIVITIES	OF	DAILY	LIVING	SCALE		100%	=	Completely	independent.	Able	to	do	all	chores	without	slowness,	difficulty	or	impairment.	Essentially	normal.	Unaware	of	any	difficulty.	90%	=	Completely	independent.	Able	to	do	all	chores	with	some	degree	of	slowness,	difficulty	and	impairment.	Might	take	twice	as	long.	Beginning	to	be	aware	of	difficulty.		80%	=	Completely	independent	in	most	chores.	Takes	twice	as	long.	Conscious	of	difficulty	and	slowness.	70%	=	Not	completely	independent.	More	difficulty	with	some	chores.	Three	to	four	times	as	long	in	some.	Must	spend	a	large	part	of	the	day	with	chores.	60%	=	Some	dependency.	Can	do	most	chores,	but	exceedingly	slowly	and	with	much	effort.	Errors;	some	impossible.	50%	=	More	dependent.	Help	with	half,	slower,	etc.	Difficulty	with	everything.	40%	=	Very	dependent.	Can	assist	with	all	chores,	but	few	alone.	30%	=	With	effort,	now	and	then	does	a	few	chores	alone	or	begins	alone.	Much	help	needed.	20%	=	Nothing	alone.	Can	be	a	slight	help	with	some	chores.	Severe	invalid.	10%	=	Totally	dependent,	helpless.	Complete	invalid.	0%	=	Vegetative	functions	such	as	swallowing,	bladder	and	bowel	functions	are	not	functioning.	Bedridden.			 	
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Appendix	G.	Pedorthic	Assessment	Form	
	
DATE:	 	__________________________________	
	 	
PARTICIPANT	NUMBER:		__________________________	 		
	
RELEVANT	MEDICAL	HISTORY:		_______________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
	 	
ADL’S:	______________________________		 	 OCCUPATION:		________________________________________	
	
OTHER	MEDICAL	CONDITIONS:		________________________________________________________________________________________________	
	 	 	 	 	 	 Diabetes	 	 RA	 	 Obesity		
PRESENT	FOOTWEAR:	______________________________							
	
WEAR	PATTERN:	 	 RIGHT				Upper:		___________________					Tread:		___________________	 		 	 	 	 LEFT							Upper:		___________________					Tread:		___________________			
STATIC	WEIGHT-BEARING	ASSESSMENT	
	
KNEE	ALIGNMENT:	Neutral	 	 	 	 	 TIBIAL	ALIGNMENT:	Rotation	Internal	/	External		L	/	R	 	 	 	 	 Straight		L	/	R	 	 	 		 	Varum		L	/	R				Valgum		L	/	R	 	 	 	 	 Varum			L:	mild	/	mod	/	severe	 R:	mild	/	mod	/	severe	Recurvatum		L	/	R	
	
FOOT	APPEARANCE:	 	 	 	 	 	 FOREFOOT	POSITION:	Normal			L	/	R			Cavus			L	/	R				Planus			L	/	R	 	 	 Neutral	L	/	R	 Pronated	L	/	R						Supinated			L	/	R	
L:	mild	/	mod	/	severe	 R:	mild	/	mod	/	severe	 	 	 L:	mild	/	mod	/	severe	 R:	mild	/	mod	/	severe	
	 	 	 	 	
MIDFOOT	POSITION:	 	 	 	 	 	 REARFOOT	POSTION:	Neutral	L	/	R	 Pronated	L	/	R						Supinated			L	/	R		 	 Neutral	L	/	R		 Varus		L	/	R	 Valgus		L	/	R	
L:	mild	/	mod	/	severe	 R:	mild	/	mod	/	severe	 	 	 L:	mild	/	mod	/	severe	 R:	mild	/	mod	/	severe		
PELVIC	ALIGNMENT:		__________________________________	
LLD:		yes	/	no						Discrepancy:		_____________________________		
MUSCLE	TESTS	AND	COMMENTS:	________________________________________________________________________	Squat:		___________________________________	 	 Heel	Raise:		___________________________________	CKC	STJ	ROM:	___________________________	 	 Single	Stance:	_________________________________	
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FOOT	POSTURE	INDEX	
	
GAIT	ASSESSMENT	
	
INITIAL	CONTACT:			 Rearfoot	 	 L:	Lateral	/	Central	/	Medial	 R:	Lateral	/	Central	/	Medial		 	 	 Midfoot		 L	/	R		 	 	 Forefoot	 	 L	/	R		
MIDSTANCE:	Pronation	 	 Early	onset		L	/		R	 Excessive	Magnitude		L	/		R		 Excessive	Varus				L	/		R		 												Supination	 L:	Mild	/	Mod	/	Severe	 R:	Mild	/	Mod	/	Severe		
TOE	OFF:		normal					failure	to	resupinate					/					early	heel	lift					/					weak	propulsion					/					abductory	twist					L	/		R		 	 	
SWING	PHASE:		normal		 limited	ankle	dorsiflexion		L	/	R	 	 Drop	Foot		L	/	R		Trendelenburg	 	 Shuffling	Gait	 	 Assistive	devices:	_______________________________________________		
ADDITIONAL	NOTES:	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
	 	 	 	 	 	 	 	
NONWEIGHT-BEARING	ASSESSMENT											
	
FOOT	STRUCTURE:	 	 FOREFOOT	ALIGNMENT:	 	 	 	Normal		L	/		R						Planus		L	/		R			Cavus			L	/		R	 	 	 Neutral		L	/	R	
L:	Mild	/	Mod	/	Severe	 R:	Mild	/	Mod	/	Severe	 	 	 Varus	L	/	R	 				Mild	/	Mod	/	Severe		 	 	 	 	 	 	 	 Valgus			L	/	R	 				Fixed	/	Flexible		 	 	 	 	 	 	 	 	
FOREFOOT	STRUCTURE:	 	 	 	 	 FIRST	RAY:	Straight		L	/	R	 	 	 	 	 	 	 Neutral		L	/	R	 	 Short		L	/	R	Hammer	L	/	R				2		3		4		5				Fixed	/	Flexible	 	 	 Plantarflexed		L	/	R						Fixed	/	Flexible	Claw						L	/	R				2		3		4		5				Fixed	/	Flexible	 	 	 	 Dorsiflexed				L	/		R					Fixed	/	Flexible	Mallet				L	/	R				2		3		4		5				Fixed	/	Flexible	 	 	 	 ROM:				 Normal		L	/	R	Morton’s	Foot	/	Toe		L	/	R	 	 	 	 	 	 	 Hypermobile			L	/	R	Dropped	metatarsal	arch		L	/	R	 	 	 	 	 	 Plantarflexion		L	/	R			Limited	/	Hypermobile	Prominent	MT	head(s)		2		3		4		5			L	/	R	 	 	 	 	 Dorsiflexion				L	/	R				Limited	/	Hypermobile		
	 FACTOR	 PLANE	 SCORE		 Left	
-2	to	+2	
Right	
-2	to	+2		
RF	
Talar	head	palpation	 Transverse	 	 	Curves	above	and	below	the	lateral	malleolus	 Frontal/Transverse	 	 	Inversion/Eversion	of	the	calcaneus	 Frontal	 	 		
FF	
Prominence	in	the	region	of	the	TNJ	 Transverse	 	 	Congruence	of	the	medial	longitudinal	arch	 Sagittal	 	 	Abd/adduction	forefoot	on	rearfoot	 Transverse	 	 		 TOTAL	 	 	 	
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FIRST	MTP	JOINT:	 	 	 	 	 	 SUBTALAR	JOINT:	Hallux	Valgus			L	/	R			Mild	/	Mod	/	Severe		 	 	 Neutral		L	/	R	Bunion				L	/	R			Mild	/	Mod	/	Severe	 	 	 	 Varus			L	/	R	 	 Valgus				L	/	R	Dorsal	osteophytes		L	/	R	 	 	 	 	 ROM:	 Normal			L	/	R	
ROM:			Normal		L	/	R	 	 	 	 	 	 	 Hypermobile:			inversion	/	eversion		 Limitus	/	FHL		L	/	R	 	 	 	 	 	 L:		Mild	/	Mod	/	Severe		R:		Mild	/	Mod	/	Severe		 Rigidus		L	/	R	 	 	 	 	 	 	 Limited:			inversion	/	eversion		 Hypermobile		L	/	R	 	 	 	 	 	 L:		Mild	/	Mod	/	Severe		R:		Mild	/	Mod	/	Severe		
ANKLE	ROM:	Dorsiflexion:			 Normal		L	/	R	 	 Plantarflexion:	 Normal		L	/	R		 	 Excessive		L	/	R	 	 	 	 Excessive		L	/	R		 	 Soft	tissue	equinus		L	/	R		 	 Limited		L	/	R		 	 Osseous	equinus		L	/	R		
ADDITIONAL	NOTES:	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________	
_______________________________________________________________________________________________________________________________________		
	
THE	FOOTWEAR	ASSESSMENT	FORM	 	 	 	
General	shoe	style/covering	 
❍ barefoot	 	 	 ❍ socks	only	 	 	 ❍ stockings	only	 	 ❍ backless	slipper	
❍ mule	 	 	 	 ❍ high	heel	 	 	 ❍ courtshoe	 	 ❍ boot	
❍ slipper	 	 	 ❍ sandal	 	 	 ❍ moccasin	 	 ❍ athletic	shoe	
❍ walking	shoe	 	 	 ❍ Oxford	shoe	 	 	 ❍ ugg	boot	 	 ❍ thong	
❍ surgical/bespoke	footwear	 
	
Heel	height	 
❍ 0–2.5	cm		 	 	 ❍ 2.6–5.0	cm		 	 	 ❍ >5.0	cm		 	 	 	
Fixation	 
❍ none		 	 ❍ laces		 	 ❍ straps/buckles			 ❍ Velcro		 ❍ zips	 
 
Heel	counter	stiffness	 
❍ minimal		 	 	 ❍ <45°		 	 	 	 ❍ <45°			
Longitudinal	sole	rigidity	 
❍ minimal		 	 	 ❍ <45°		 	 	 	 ❍ <45° 
 
Sole	flexion	point	 
❍ at	level	of	MTPJs		 	 ❍ before	MTPJs	 
	
Tread	pattern	 
❍ textured		 	 	 ❍ smooth	(i.e.	no	pattern)		 	 ❍ partly	worn	 	 ❍ fully	worn	
 
Sole	hardness	 
❍ soft		 	 	 	 ❍ firm		 	 	 	 ❍ hard	 	
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Appendix	H.	Functional	Gait	Assessment		
Requirements: A marked 6-m (20-ft) walkway that is marked with a 30.48-cm (12-in) width. 	
1. GAIT LEVEL SURFACE  
Instructions: Walk at your normal speed from here to the next mark (6 m [20 ft]). 
Grading: Mark the highest category that applies.  
(3) Normal—Walks 6 m (20 ft) in less than 5.5 seconds, no assistive devices, good speed, no evidence for imbalance, normal gait pattern, 
deviates no more than 15.24 cm (6 in) outside of the 30.48-cm (12-in) walkway width.  
(2) Mild impairment—Walks 6 m (20 ft) in less than 7 seconds but greater than 5.5 seconds, uses assistive device, slower speed, mild gait 
deviations, or deviates 15.24–25.4 cm (6–10 in) outside of the 30.48-cm (12-in) walkway width.  
(1) Moderate impairment—Walks 6 m (20 ft), slow speed, abnor- mal gait pattern, evidence for imbalance, or deviates 25.4– 38.1 cm 
(10–15 in) outside of the 30.48-cm (12-in) walkway width. Requires more than 7 seconds to ambulate 6 m (20 ft).  
(0) Severe impairment—Cannot walk 6 m (20 ft) without assistance, severe gait deviations or imbalance, deviates greater than 38.1 cm 
(15 in) outside of the 30.48-cm (12-in) walkway width or reaches and touches the wall.  
 
2. CHANGE IN GAIT SPEED  
Instructions: Begin walking at your normal pace (for 1.5 m [5 ft]). When I tell you “go,” walk as fast as you can (for 1.5 m [5 ft]). When I 
tell you “slow,” walk as slowly as you can (for 1.5 m [5 ft]). 
Grading: Mark the highest category that applies.  
(3) Normal—Able to smoothly change walking speed without loss of balance or gait deviation. Shows a significant difference in walking 
speeds between normal, fast, and slow speeds. Devi- ates no more than 15.24 cm (6 in) outside of the 30.48-cm (12-in) walkway width.  
(2) Mild impairment—Is able to change speed but demonstrates mild gait deviations, deviates 15.24 –25.4 cm (6 –10 in) outside of the 
30.48-cm (12-in) walkway width, or no gait deviations but unable to achieve a significant change in velocity, or uses an assistive device.  
(1) Moderate impairment—Makes only minor adjustments to walk- ing speed, or accomplishes a change in speed with significant gait 
deviations, deviates 25.4–38.1 cm (10–15 in) outside the 30.48-cm (12-in) walkway width, or changes speed but loses balance but is 
able to recover and continue walking.  
(0) Severe impairment—Cannot change speeds, deviates greater than 38.1 cm (15 in) outside 30.48-cm (12-in) walkway width, or loses 
balance and has to reach for wall or be caught.  
 
3. GAIT WITH HORIZONTAL HEAD TURNS  
Instructions: Walk from here to the next mark 6 m (20 ft) away. Begin walking at your normal pace. Keep walking straight; after 3 steps, 
turn your head to the right and keep walking straight while looking to the right. After 3 more steps, turn your head to the left and keep 
walking straight while looking left. Continue alternating looking right and left every 3 steps until you have completed 2 repetitions in each 
direction. Grading: Mark the highest category that applies.  
(3) Normal—Performs head turns smoothly with no change in gait. Deviates no more than 15.24 cm (6 in) outside 30.48-cm (12-in) 
walkway width.  
(2) Mild impairment—Performs head turns smoothly with slight change in gait velocity (eg, minor disruption to smooth gait path), deviates 
15.24–25.4 cm (6–10 in) outside 30.48-cm (12-in) walkway width, or uses an assistive device.  
(1) Moderate impairment—Performs head turns with moderate change in gait velocity, slows down, deviates 25.4–38.1 cm (10–15 in) 
outside 30.48-cm (12-in) walkway width but recov- ers, can continue to walk.  
(0) Severe impairment—Performs task with severe disruption of gait (eg, staggers 38.1 cm [15 in] outside 30.48-cm (12-in) walkway width, 
loses balance, stops, or reaches for wall).  
 
4. GAIT WITH VERTICAL HEAD TURNS  
Instructions: Walk from here to the next mark (6 m [20 ft]). Begin walking at your normal pace. Keep walking straight; after 3 steps, tip 
your head up and keep walking straight while looking up. After 3 more steps, tip your head down, keep walking straight while looking 
down. Continue alternating looking up and down every 3 steps until you have completed 2 repetitions in each direction.  
Grading: Mark the highest category that applies. 
(3) Normal—Performs head turns with no change in gait. Deviates  
no more than 15.24 cm (6 in) outside 30.48-cm (12-in) walkway  
width. 
(2) Mild impairment—Performs task with slight change in gait  
velocity (eg, minor disruption to smooth gait path), deviates 15.24 –25.4 cm (6 –10 in) outside 30.48-cm (12-in) walkway width or uses 
assistive device.  
(1) Moderate impairment—Performs task with moderate change in gait velocity, slows down, deviates 25.4 –38.1 cm (10 –15 in) outside 
30.48-cm (12-in) walkway width but recovers, can continue to walk.  
(0) Severe impairment—Performs task with severe disruption of gait (eg, staggers 38.1 cm [15 in] outside 30.48-cm (12-in) walkway width, 
loses balance, stops, reaches for wall).  
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5. GAIT AND PIVOT TURN  
Instructions: Begin with walking at your normal pace. When I tell you, “turn and stop,” turn as quickly as you can to face the opposite 
direction and stop. 
Grading: Mark the highest category that applies.  
(3) Normal—Pivot turns safely within 3 seconds and stops quickly with no loss of balance.  
(2) Mild impairment—Pivot turns safely in 3 seconds and stops with no loss of balance, or pivot turns safely within 3 seconds and stops with 
mild imbalance, requires small steps to catch balance.  
(1) Moderate impairment—Turns slowly, requires verbal cueing, or requires several small steps to catch balance following turn and stop.  
(0) Severe impairment—Cannot turn safely, requires assistance to turn and stop.  
 
6. STEP OVER OBSTACLE  
Instructions: Begin walking at your normal speed. When you come to the shoe box, step over it, not around it, and keep walking. 
Grading: Mark the highest category that applies.  
(3) Normal—Is able to step over 2 stacked shoe boxes taped together (22.86 cm [9 in] total height) without changing gait speed; no 
evidence of imbalance.  
(2) Mild impairment—Is able to step over one shoe box (11.43 cm [4.5 in] total height) without changing gait speed; no evidence of 
imbalance.  
(1) Moderate impairment—Is able to step over one shoe box (11.43 cm [4.5 in] total height) but must slow down and adjust steps to clear 
box safely. May require verbal cueing.  
(0) Severe impairment—Cannot perform without assistance.  
(Continued)  
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7. GAIT WITH NARROW BASE OF SUPPORT  
Instructions: Walk on the floor with arms folded across the chest, feet aligned heel to toe in tandem for a distance of 3.6 m [12 ft]. The 
number of steps taken in a straight line are counted for a maximum of 10 steps. Grading: Mark the highest category that applies.  
(3) Normal—Is able to ambulate for 10 steps heel to toe with no staggering.  
(2) Mild impairment—Ambulates 7–9 steps. 
(1) Moderate impairment—Ambulates 4 –7 steps. 
(0) Severe impairment—Ambulates less than 4 steps heel to toe or  
cannot perform without assistance.  
 
8. GAIT WITH EYES CLOSED  
Instructions: Walk at your normal speed from here to the next mark (6 m [20 ft]) with your eyes closed. 
Grading: Mark the highest category that applies.  
(3) Normal—Walks 6 m (20 ft), no assistive devices, good speed, no evidence of imbalance, normal gait pattern, deviates no more than 
15.24 cm (6 in) outside 30.48-cm (12-in) walkway width. Ambulates 6 m (20 ft) in less than 7 seconds.  
(2) Mild impairment—Walks 6 m (20 ft), uses assistive device, slower speed, mild gait deviations, deviates 15.24–25.4 cm (6–10 in) 
outside 30.48-cm (12-in) walkway width. Ambulates 6 m (20 ft) in less than 9 seconds but greater than 7 seconds.  
(1) Moderate impairment—Walks 6 m (20 ft), slow speed, abnor- mal gait pattern, evidence for imbalance, deviates 25.4–38.1 cm (10–
15 in) outside 30.48-cm (12-in) walkway width. Requires more than 9 seconds to ambulate 6 m (20 ft).  
(0) Severe impairment—Cannot walk 6 m (20 ft) without assistance, severe gait deviations or imbalance, deviates greater than 38.1 cm 
(15 in) outside 30.48-cm (12-in) walkway width or will not attempt task.  
 
9. AMBULATING BACKWARDS  
Instructions: Walk backwards until I tell you to stop. Grading: Mark the highest category that applies.  
(3) Normal—Walks 6 m (20 ft), no assistive devices, good speed, no evidence for imbalance, normal gait pattern, deviates no more than 
15.24 cm (6 in) outside 30.48-cm (12-in) walkway width.  
(2) Mild impairment—Walks 6 m (20 ft), uses assistive device, slower speed, mild gait deviations, deviates 15.24–25.4 cm (6–10 in) 
outside 30.48-cm (12-in) walkway width.  
(1) Moderate impairment—Walks 6 m (20 ft), slow speed, abnor- mal gait pattern, evidence for imbalance, deviates 25.4–38.1 cm (10–
15 in) outside 30.48-cm (12-in) walkway width.  
(0) Severe impairment—Cannot walk 6 m (20 ft) without assistance, severe gait deviations or imbalance, deviates greater than 38.1 cm 
(15 in) outside 30.48-cm (12-in) walkway width or will not attempt task.  
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10. STEPS  
Instructions: Walk up these stairs as you would at home (ie, using the rail if necessary). At the top turn around and walk down. 
Grading: Mark the highest category that applies.  
(3) Normal—Alternating feet, no rail. 
(2) Mild impairment—Alternating feet, must use rail. 
(1) Moderate impairment—Two feet to a stair; must use rail. (0) Severe impairment—Cannot do safely.  
 
TOTAL SCORE: ______ MAXIMUM SCORE 30  
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Appendix	I.	Data	Collection	Sheet	
	
	
	
	
	
	
	
	
	
	
	
	
DATA	COLLECTION	PACKAGE	
	
PARTICIPANT	NO:		___________	
	
DATE:	________________	
	
	
	
Testing	Protocol	Order:	1.	Monofilament	Testing	 	 	 	 	2.	EMG	normalization	3.	MVCs		Condition	1:	4.	Static	balance	5.	TUG	6.	FGA	7.	Walking		Condition	2:	8.	Static	balance	9.	TUG	10.	FGA	11.	Walking		*To	add	Condition	3	at	5-week	testing	day*								
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DATA	COLLECTION	SHEET			Participant	No:	________	 	 	 Date:	______________	 	 Time:	________		Shoes	worn	on	testing	day:	____________________________	
	
	
Sensory	Testing	(Monofilaments)	
Plantar Surface Location Smallest Filament Detected Notes 
1st MTP head   
5th MTP head   
Calcaneus   	
	
	
EMG	Normalization	
Muscle EMG GAIN 
RIGHT LEFT 
Tibialis Anterior   
Med. Gastroch   
Peroneus Longus   	*per.	Longus	–	“point	toe	down	and	outward”	
 
 Trace	feet	of	participant	on	force	plate	paper	
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(Condition	1	=	footwear	only)			(Condition	2	=	orthotic	only)			(Condition	3	=	
orthotic+texture)	
(OT	#	=	Optotrak	Trial	Number)	
	
Condition:	_______	
	
MVC’s	Data	Collection:	5	seconds	
Trials OT # Muscle Comments 
MVC_1  R - Tib. Ant.  
MVC_2  L – Tib. Ant.  
MVC_3  R – Med. Gastroc  
MVC_4  L – Med. Gastroc  
MVC_5  R – Per. Longus  
MVC_6  L – Per. Longus  
	
	
Static	Balance	–	Double	limb	support,	eyes	closed-	2	minutes	(120	seconds)	
Trials OT # Comments 
STAT.BAL_7   
	
	
TUG	Data	Collection:	20	seconds	
Trials OT # Completion Time Comments 
TUG_8    
TUG_9    
	
	
FGA	Data	Collection:	10	seconds	
Trials OT # FGA # Score Comments 
FGA_10  1   
FGA_11  2 “go”   
FGA_12  2 “slow”   
FGA_13  3   
FGA_14  4   
FGA_15  5   
FGA_16  6   
FGA_17  7   
FGA_18  8   
FGA_19  9   
FGA_20  10   
FGA total score:   	
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Walking	Trial	 Dominant	turn	direction	=	0	Non-dominant	turn	direction	=	1	
Data	Collection:	20	seconds	
Trials OT # Turn Direction Comments 
Walking_21  0  
Walking_22  0  
Walking_23  1  
Walking_24  0  
Walking_25  0  
Walking_26  0  
Walking_27  1  
Walking_28  0  
Walking_29  0  
Walking_30  1  
	
	
	
(Condition	1	=	footwear	only)			(Condition	2	=	orthotic	only)			(Condition	3	=	
orthotic+texture)	
(OT	#	=	Optotrak	Trial	Number)	
	
Condition:	_______	
	
	
Static	Balance	–	Double	limb	support,	eyes	closed-	2	minutes	(120	seconds)	
Trials OT # Comments 
STAT.BAL_31   	
TUG	Data	Collection:	20	seconds	
Trials OT # Completion Time Comments 
TUG_32    
TUG_33    
	
	
FGA	Data	Collection:	10	seconds	
Trials OT # FGA # Score Comments 
FGA_34  1   
FGA_35  2 “go”   
FGA_36  2 “slow”   
FGA_37  3   
FGA_38  4   
FGA_39  5   
FGA_40  6   
FGA_41  7   
FGA_42  8   
FGA_43  9   
FGA_44  10   
FGA total score:   
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Walking	Trial	 Dominant	turn	direction	=	0	Non-dominant	turn	direction	=	1	
Data	Collection:	20	seconds	
Trials OT # Turn Direction Comments 
Walking_45  0  
Walking_46  0  
Walking_47  1  
Walking_48  0  
Walking_49  0  
Walking_50  0  
Walking_51  1  
Walking_52  0  
Walking_53  0  
Walking_54  1  	
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Appendix	J.	Result	Tables	(Note:	F:	Footwear	only;	FO:	Non-textured	orthotics;	FOT:	Textured	orthotics;	GLMW1F:	general	linear	model	within	1	factor	ANOVA)	
	
Table	3:	Maximum	ML	COM/BOS	results	across	orthotic	conditions	
Maximum	ML	-	COM/BOS	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.1170	(0.0478)	 Type	I	SS:	F(1,	88)=0.21,	p=.6514	
ETA-Square:	0.35		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 0.1069	(0.0494)	
	Week	0	–	FO	 0.1069	(0.0494)	 Type	I	SS:	F(1,89)=7.46,	p=.0076	
ETA-Square:	0.33		
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 0.1298	(0.0538)		Week	4	–	FO	 0.1298	(0.0538)	 Type	I	SS:	F(1,98)=0.66,	p=.4182	
ETA-Square:	0.34		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.1239	(0.0510)		Week	4	–	FOT	 0.1239	(0.0510)	 Type	I	SS:	F(1,107)=0.84,	p=.3615	
ETA-Square:	0.37		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.1317	(0.0556)	
		
Table	4:	Minimum	ML	COM/BOS	results	across	orthotic	conditions	
Minimum	ML	-	COM/BOS	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.0823	(0.0426)	 Type	I	SS:	F(1,83)=0.77,	p=.3833	
ETA-Square:	0.35		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 0.0720	(0.0409)		Week	0	–	FO	 0.0720	(0.0409)	 Type	I	SS:	F(1,	87)=2.53,	p=.1151	
ETA-Square:	0.28		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 0.0857	(0.0492)		Week	4	–	FO	 0.0857	(0.0492)	 Type	I	SS:	F(1,	98)=0.13,	p=.7182	
ETA-Square:	0.25		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.0844	(0.0485)		Week	4	–	FOT	 0.0844	(0.0485)	 Type	I	SS:	F(1,	107)=0.19,	p=.6651	
ETA-Square:	0.25		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.0874	(0.0471)	
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Table	5:	ML	Range	COM/BOS	results	across	orthotic	conditions	
Range	ML	-	COM/BOS	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.0343	(0.0214)	 Type	I	SS:	F(1,83)=0.96,	p=0.3293	
ETA-Square:	0.14		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 0.0376	(0.0242)		Week	0	–	FO	 0.0376	(0.0242)	 Type	I	SS:	F(1,87)=4.67,	p=0.335	
ETA-Square:	0.14		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 0.0441	(0.0259)		Week	4	–	FO	 0.0441	(0.0259)	 Type	I	SS:	F(1,98)=0.65,	p=.4222	
ETA-Square:	0.34		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.0395	(0.0296)		Week	4	–	FOT	 0.0395	(0.0296)	 Type	I	SS:	F(1,107)=0.82,	p=.3672	
ETA-Square:	0.37		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.0443	(0.0296)	
			
Table	6:	Step	count	results	across	orthotic	conditions	
Step	Count	–	Performance	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 5.5167	(1.0813)	 Type	I	SS:	F(1,108)=4.86,	p=.0296	
ETA-Square:	0.54		
Tukey’s	HSD	Post	hoc	test:	significant	Week	0	–	FO	 5.2333	(0.8707)		Week	0	–	FO	 5.2333	(0.8707)	 Type	I	SS:	F(1,117)=0.32,	p=.5730	
ETA-Square:	0.51		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 5.2429	(1.3125)		Week	4	–	FO	 5.2429	(1.3125)	 Type	I	SS:	F(1,	126)=13.21,	p=.0004	
ETA-Square:	0.55		
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FOT	 4.6714	(0.7561)		Week	4	–	FOT	 4.6714	(0.7561)	 Type	I	SS:	F(1,126)=0.33,	p=.5647	
ETA-Square:	0.47		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 4.7286	(0.7787)	
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Table	7:	Step	length	results	across	orthotic	conditions	
Step	Length:	Performance	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.7662	(0.4850)	 Type	I	SS:	F(1,96)=1.20,	p=.2768	
ETA-Square:	0.55		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 0.7100	(0.3888)		Week	0	–	FO	 0.7100	(0.3888)	 Type	I	SS:	F(1,107)=1.07,	p=.3022	
ETA-Square:	0.40		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 0.7952	(0.3094)		Week	4	–	FO	 0.7952	(0.3094)	 Type	I	SS:	F(1,114)=0.26,	p=.6095	
ETA-Square:	0.30		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.8080	(0.3185)		Week	4	–	FOT	 0.8080	(0.3185)	 Type	I	SS:	F(1,118)=0.17,	p=.6816	
ETA-Square:	0.35		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.7773	(0.2693)	
	
	
Table	8:		Step	width	across	orthotic	condition	
Step	Width:	Performance	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.1637	(0.0719)	 Type	I	SS:	F(1,95)=0.16,	p=.6890	
ETA-Square:	0.14		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 0.1612	(0.0725)		Week	0	–	FO	 0.1612	(0.0725)	 Type	I	SS:	F(1,107)=0.01,	p=.9399	
ETA-Square:	0.18		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 0.1594	(0.1594)		Week	4	–	FO	 0.1594	(0.0640)	 Type	I	SS:	F(1,114)=0.03,	p=.8551	
ETA-Square:	0.17	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.1597	(0.0641)		Week	4	–	FOT	 0.1597	(0.0641)	 Type	I	SS:	F(1,118)=0.68,	p=.4119	
ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.1518	(0.0582)	
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Table	9:		Average	velocity	results	across	orthotic	conditions	
Average	Velocity:	Performance	Analysis	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 0.9443	(0.1682)	 Type	I	SS:	F(1,111)=16.91,	p<.0001	
ETA-Square:	0.48		
Tukey’s	HSD	Post	hoc	test:	significant	Week	0	–	FO	 0.8143	(0.2723)		Week	0	–	FO	 0.8143	(0.2723)	 Type	I	SS:	F(1,116)=12.20,	p=.0007	
ETA-Square:	0.66		
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 0.9180	(0.2196)		Week	4	–	FO	 0.9180	(0.2196)	 Type	I	SS:	F(1,119)=1.51,	p=.2209	
ETA-Square:	0.68		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 0.9512	(0.2074)		Week	4	–	FOT	 0.9512	(0.2074)	 Type	I	SS:	F(1,124)=1.28,	p=.2606	
ETA-Square:	0.59		
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 0.9524	(0.1858)	
	
	
Table	10:		Ipsilateral	tibialis	anterior	–	Normalized	EMG	results	across	orthotic	conditions	
Ipsilateral	Tibialis	Anterior	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 6.04	(5.60)	 Type	I	SS:	F(1,124)=0.56,	p=.4560	
ETA-Square:	0.20	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 4.75	(2.48)		Week	0	–	FO	 4.75	(2.48)	 Type	I	SS:	F(1,125)=17.42,	p<.0001	
ETA-Square:	0.42	
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 6.59	(3.40)		Week	4	–	FO	 6.59	(3.40)	 Type	I	SS:	F(1,126)=1.89,	p=.1716	
ETA-Square:	0.35	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 6.04	(3.54)		Week	4	–	FOT	 6.04	(3.54)	 Type	I	SS:	F(1,126)=2.00,	p=.1593	
ETA-Square:	0.30	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 6.84	(4.04)	
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Table	11:		Ipsilateral	medial	gastrocnemius	-	Normalized	EMG	results	across	orthotic	conditions	
Ipsilateral	Medial	Gastrocnemius	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 4.91	(2.24)	 Type	I	SS:	F(1,124)=5.75,	p=.0180	
ETA-Square:	0.39	
Tukey’s	HSD	Post	hoc	test:	significant	Week	0	–	FO	 5.96	(3.48)		Week	0	–	FO	 5.96	(3.48)	 Type	I	SS:	F(1,125)=14.52,	p=.0002	
ETA-Square:	0.41	
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 4.39	(2.04)		Week	4	–	FO	 4.39	(2.04)	 Type	I	SS:	F(1,126)=0.88,	p=.3494	
ETA-Square:	0.18	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 4.69	(2.04)		Week	4	–	FOT	 4.69	(2.04)	 Type	I	SS:	F(1,126)=11.67,	p=.0009	
ETA-Square:	0.18	
Tukey’s	HSD	Post	hoc	test:	significant	Week	5	-	FOT	 5.97	(2.72)	
		
Table	12:		Ipsilateral	peroneus	longus	-	Normalized	EMG	results	across	orthotic	conditions	
Ipsilateral	Peroneus	Longus	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 8.57	(4.92)	 Type	I	SS:	F(1,124)=4.13,	p=.0442	
ETA-Square:	0.20	
Tukey’s	HSD	Post	hoc	test:	significant	Week	0	–	FO	 7.13	(3.02)		Week	0	–	FO	 7.13	(3.02)	 Type	I	SS:	F(1,125)=10.33,	p=.0017	
ETA-Square:	0.26	
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 8.51	(3.07)		Week	4	–	FO	 8.51	(3.07)	 Type	I	SS:	F(1,126)=0.82,	p=.3679	
ETA-Square:	0.27	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 8.94	(3.29)		Week	4	–	FOT	 8.94	(3.29)	 Type	I	SS:	F(1,126)=14.37,	p=.0001	
ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	significant	Week	5	-	FOT	 7.23	(2.50)	
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Table	13:		Contralateral	tibialis	anterior	-	Normalized	EMG	results	across	orthotic	conditions	
Contralateral	Tibialis	Anterior	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 5.60	(5.30)	 Type	I	SS:	F(1,125)=6.03,	p=.0154	
ETA-Square:	0.60	
Tukey’s	HSD	Post	hoc	test:	significant	Week	0	–	FO	 6.44	(4.81)		Week	0	–	FO	 6.44	(4.81)	 Type	I	SS:	F(1,126)=5.74,	p=.0181	
ETA-Square:	0.52	
Tukey’s	HSD	Post	hoc	test:	significant	Week	4	–	FO	 6.99	(3.14)		Week	4	–	FO	 6.99	(3.14)	 Type	I	SS:	F(1,126)=0.46,	p=.4998	
ETA-Square:	0.50	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 6.69	(4.02)		Week	4	–	FOT	 6.69	(4.02)	 Type	I	SS:	F(1,126)=0.47,	p=.4920	
ETA-Square:	0.49	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 5.60	(5.30)	
		
Table	14:		Contralateral	medial	gastrocnemius	-	Normalized	EMG	results	across	orthotic	conditions	
Contralateral	Medial	Gastrocnemius	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 5.21	(3.51)	 Type	I	SS:	F(1,125)=0.19,	p=.6665	
ETA-Square:	0.40	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 5.39	(3.34)		Week	0	–	FO	 5.39	(3.34)	 Type	I	SS:	F(1,126)=0.73,	p=.3945	
ETA-Square:	0.35	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 5.04	(2.36)		Week	4	–	FO	 5.04	(2.36)	 Type	I	SS:	F(1,126)=0.35,	p=.5556	
ETA-Square:	0.22	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 5.26	(2.55)		Week	4	–	FOT	 5.26	(2.55)	 Type	I	SS:	F(1,126)=2.20,	p=.1410	
ETA-Square:	0.28	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 4.63	(3.11)	
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Table	15:		Contralateral	peroneus	longus	-	Normalized	EMG	results	across	orthotic	conditions	
Contralateral	Peroneus	Longus	-	Normalized	EMG	
Comparison	 Mean	(SD)	 GLMW1F	ANOVA	Results	
	Week	0	-	F	 7.53	(3.90)	 Type	I	SS:	F(1,125)=0.00,	p=.9570	
ETA-Square:	0.40	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	0	–	FO	 7.33	(3.47)		Week	0	–	FO	 7.33	(3.47)	 Type	I	SS:	F(1,126)=0.14,	p=.7087	
ETA-Square:	0.33	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FO	 7.50	(2.93)		Week	4	–	FO	 7.50	(2.93)	 Type	I	SS:	F(1,126)=0.19,	p=.6610	
ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	4	–	FOT	 7.35	(3.14)		Week	4	–	FOT	 7.35	(3.14)	 Type	I	SS:	F(1,126)=0.47,	p=.4921	
ETA-Square:	0.34	
Tukey’s	HSD	Post	hoc	test:	non-significant	Week	5	-	FOT	 8.04	(3.97)	
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Appendix	K:	Results	between	Week	0-F	and	Week	5-FOT		
Table	16:	Results	between	Week	0-F	and	Week	5-FOT	
	COM/BOS	ML	Maximum:		 Type	I	SS:	F(1,104)=4.18,	p=0.0434	ETA-Square:	0.41	
Tukey’s	HSD	Post	hoc	test:	non-significant	COM/BOS	ML	Minimum:		 Type	I	SS:	F(1,101)=0.28,	p=0.5979	ETA-Square:	0.35	
Tukey’s	HSD	Post	hoc	test:	non-significant	COM/BOS	ML	Range:		 Type	I	SS:	F(1,101)=7.71,	p=0.0066	ETA-Square:	0.36	
Tukey’s	HSD	Post	hoc	test:	significant		Step	Count:		 Type	I	SS:	F(1,117)=44.10,	p<.0001	ETA-Square:	0.67	
Tukey’s	HSD	Post	hoc	test:	significant	Step	Length:		 Type	I	SS:	F(1,97)=0.81,	p=0.3714	ETA-Square:	0.47	
Tukey’s	HSD	Post	hoc	test:	non-significant	Step	Width:		 Type	I	SS:	F(1,96)=0.04,	p=0.8363	ETA-Square:	0.47	
Tukey’s	HSD	Post	hoc	test:	non-significant	Average	Velocity:		 Type	I	SS:	F(1,116)=0.57,	p=0.4533	ETA-Square:	0.66	
Tukey’s	HSD	Post	hoc	test:	non-significant		Ipsilateral	Tibialis	Anterior:	 Type	I	SS:	F(1,125)=5.86,	p=0.0169	
ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	significant	Ipsilateral	Medial	Gastrocnemius:		 Type	I	SS:	F(1,125)=7.34,	p=0.0077	ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	significant	Ipsilateral	Peroneus	Longus:		 Type	I	SS:	F(1,125)=4.64,	p=0.0331	ETA-Square:	0.22	
Tukey’s	HSD	Post	hoc	test:	significant	Contralateral	Tibialis	Anterior:		 Type	I	SS:	F(1,125)=2.01,	p=0.1588	ETA-Square:	0.40	
Tukey’s	HSD	Post	hoc	test:	non-significant	Contralateral	Medial	Gastrocnemius:		 Type	I	SS:	F(1,125)=7.34,	p=0.0077	ETA-Square:	0.25	
Tukey’s	HSD	Post	hoc	test:	significant	Contralateral	Peroneus	Longus:		 Type	I	SS:	F(1,125)=0.71,	p=0.4023	ETA-Square:	0.35	
Tukey’s	HSD	Post	hoc	test:	non-significant				
